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SUMMARY
The aim of this work was the search for selective inhibitors of M. tuberculosis thymidine
monophosphate kinase (TMPKmt) as leads for the development of new anti-tuberculosis
agents. Based on the X-ray structure of TMPKmt, it was decided to establish a preliminary
structure-activity relationship by synthesising a series of nucleosides and nucleotides modi-
fied at the 2’-, 3’- and 5-positions of the dTMP-scaffold. These analogues were tested for
their affinities for TMPKmt. From this, a 2'-chlorine and a 2'-fluorine substituent emerged as
the most promising modifications of the dTMP scaffold. Furthermore, the affinities of a series
nucleosides and their corresponding nucleotides were compared. The deletion of the
phosphate moiety typically resulted in a modest, in many cases negligible affinity loss. In
view of the drug delivery problems of phosphorylated compounds, nucleosides seemed more
useful leads for further drug design.
The goal of the synthesis of a series 3'-C-branched-chain nucleosides and nucleotides
(3'-CH2N3, 3'-CH2NH2, 3'-CH2F, 3'-CH2OH) was to occupy a cavity in the enzyme near the
3'-position. Biological results and modeling confirmed this hypothesis. 3'-Azidomethyl-
3'-deoxy-thymidine (4.9), combining a low Ki-value (40 mM) with a high selectivity index for
the tuberculosis enzyme (K i TMPKh/ Ki TMPKmt = 26) emerged as the most promising lead
for further optimisation. Attempts were made to combine these favourable 3'-substitution
patterns with 2'-halogen substituents (6.9-6.14). However, introduction of the 2'-halogen led
to a drastic decrease in affinity compared to the corresponding 2'-deoxy-nucleosides.
Probably, the 2'-halogens compete with the 3'-substituents for the same binding pocket.
Furthermore, it was tried to supersede the good affinities of the 3'-C-branched-chain
nucleosides, by further exploration of the enzyme cavity near the 3'-position with alternative
nitrogen-containing substituents. However, attempted simultaneous reduction of the 6'-azido
function and the 2'-hydroxyl of compound 19 (chapter 6) failed. Instead three peculiar
nucleoside analogues (6.10, 6.11 and 6.12) were isolated that were tested for their affinities
for TMPKmt and TMPKh. Dinucleoside 6.12 unexpectedly showed a high affinity
(Ki = 37 mM) and selectivity for the tuberculosis enzyme, indicating an exceptional flexibility
of TMPKmt towards the orientation of the sugar ring. Also the bicyclic nucleosides 6.10 and
6.11 showed excellent affinities. With its Ki-value of 3.5 mM (exceeding the affinity of the
natural substrate) and its selectivity index of 200, 6.10 represents the highest affinity and most
selective inhibitor of TMPKmt found so far. The favourable affinities and selectivities of
these three inhibitors will form the basis for further drug design, considerably increasing the
variety of nucleoside analogues that may be envisaged for future synthesis.
Based on the encouraging affinity of anhydro-hexitol nucleotide 7.1, the effects of six-
membered sugar rings for the affinity for TMPKmt were further explored through the
synthesis of 1-[2,4-dideoxy-4-C-hydroxymethyl-a-L-lyxopyranosyl]thymine (7.4). This
nucleoside indeed showed the predicted equatorial orientation of the thymine ring (4C1).
Affinity results were however disappointing.
In conclusion, this work yielded some high affinity and selective inhibitors for TMPKmt that
open interesting perspectives in the search for new anti-tuberculosis agents. Based on their
high selectivity indices, especially dinucleoside 6.12 and bicyclic nucleosides 6.10 and 6.11
will be used as the starting point for the search of inhibitors with an optimal fitting in the
active pocket of TMPKmt.
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SAMENVATTING
Het doel van dit werk was de zoektocht naar selectieve inhibitoren voor M. tuberculosis
thymidine monofosfaat kinase (TMPKmt) als leads voor de ontwikkeling van nieuwe anti-
tuberculose geneesmiddelen. Op basis van de X-straal structuur van TMPKmt, werd besloten
een eerste structuur-activiteitsrelatie tot stand te brengen via de synthese van een reeks
nucleosiden en nucleotiden, gemodificeerd op de 2'-, 3'- en 5-posities van het dTMP skelet.
Deze verbindingen werden getest op hun affiniteit voor TMPKmt. Hieruit kwamen een
2'-chloor en een 2'-fluor substituent naar voor als de meest interessante modificaties. Verder
werden de affiniteiten van een reeks nucleosiden en hun overeenkomstige nucleotiden
vergeleken. Over het algemeen, veroorzaakte de verwijdering van de fosfaatgroep een
bescheiden, meestal zelfs verwaarloosbaar, affiniteitsverlies. Aangezien gefosforyleerde ver-
bindingen moeilijk door cellen opgenomen worden, zijn nucleosiden nuttigere leads voor
verdere geneesmiddelontwikkeling.
Met de synthese van een reeks 3'-C-vertakte-keten nucleosiden en nucleotiden (3'-CH2N3,
3'-CH2NH2, 3'-CH2F, 3'-CH2OH) werd gepoogd een holte dicht bij de 3'-positie in het enzym
op te vullen. Biologische resultaten en modeling bevestigden deze hypothese. 3'-Azido-
methyl-3'-deoxy-thymidine (4.9), dat een lage Ki-waarde (40 mM) combineert met een hoge
selectiviteitsindex voor het tuberculose enzym (Ki TMPKh/ Ki TMPKmt = 26) kwam naar
voor als de meest interessante lead voor verdere geneesmiddelontwikkeling. Pogingen werden
ondernomen om deze gunstige 3'-substitutiepatronen te combineren met 2'-halogeen
substituenten (6.9-6.14). Invoering van deze 2'-halogenen leidde echter tot een sterke
affiniteitsdaling in vergelijking met de overeenkomstige 2'-deoxy-nucleosiden. Waarschijnlijk
treden de 2'-halogenen in competitie met de 3'-substituenten voor de zelfde bindingsplaats.
Verder werd gepoogd de goede affiniteiten van de 3'-C-vertakte keten nucleosiden te
verbeteren via verdere verkenning van de holte in de buurt van de 3'-positie met andere
stikstof-bevattende substituenten. Een poging tot simultane reductie van de 6'-azidofunctie en
de 2'-hydroxylgroep van verbinding 19 (hoofdstuk 6) faalde. Niettemin werden hierdoor drie
bijzondere nucleoside analogen (6.10, 6.11 and 6.12) gevormd die getest werden op hun
affiniteiten voor TMPKmt en TMPKh.
Dinucleoside 6.12 vertoonde een onverwacht hoge affiniteit (Ki = 37 mM) en selectiviteit voor
het tuberculose enzym, wat wijst op een uitzonderlijke flexibiliteit van TMPKmt voor de
oriëntatie van de suikerring. Ook de bicyclische nucleosiden 6.10 en 6.11 vertoonden
uitmuntende affiniteiten: met zijn Ki-waarde van 3.5 mM (die de affiniteit van het natuurlijk
substraat overtreft) en een selectiviteitsindex van 200 is 6.10 de beste en meest selectieve
inhibitor voor TMPKmt die tot nu toe ontdekt is. De gunstige affiniteiten en selectiviteiten
van deze drie inhibitoren zullen de basis vormen voor verdere geneesmiddelontwikkeling. Zij
verhogen gevoelig de diversiteit van nucleoside analogen die voor verdere synthese in
aanmerking komt.
Op basis van de bemoedigende affiniteit van anhydro-hexitol nucleotide 7.1, werden de
effecten van zesring suikers op de affiniteit voor TMPKmt verder verkend via de synthese van
1-[2,4-dideoxy-4-C-hydroxymethyl-a-L-lyxopyranosyl]thymine (7.4). Dit nucleoside ver-
toonde inderdaad de voorspelde equatoriale orientatie van de thymine ring (4C1).
Affiniteitsresultaten van deze verbinding voor TMPKmt waren echter teleurstellend.
xWe mogen besluiten dat het beschreven onderzoek leidde tot de ontdekking van een aantal
hoge affiniteitsinhibitoren voor TMPKmt, wat interessante perspectieven opent voor de
zoektocht naar nieuwe anti-tuberculose geneesmiddelen. Op basis van hun hoge
selectiviteitindices zullen vooral het dinucleoside 6.12 en de bicyclische nucleosiden 6.10 en
6.11 gebruikt worden als uitgangspunt in de zoektocht naar inhibitoren die nog beter passen in
het actief centrum van TMPKmt.
xi
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51 Introduction
Tuberculosis (TB), an infectious disease that usually attacks the lungs, is frighteningly on the
rise. Once nearly vanquished by antibiotics, at least in the developed world, TB resurged in
the late 1980’s and now kills more than 2 million people a year – second only to AIDS among
infectious diseases. Thirty million people are at risk of dying from TB in the next 10 years,
most of them living in Africa (Figure 1).1
Mycobacterium tuberculosis, the causative agent of this disease is a slow-growing bacillus,
primarily transmitted via the respiratory route, mostly causing pulmonary TB. Estimates are
that one third of the world’s population is infected with this organism, but infection usually
does not lead to the active disease. Reactivation of this latent infection can be caused by
immuno-deficiency, HIV-infection, use of corticosteroids, aging, alcohol and drug abuse.
In HIV infected patients, TB has become the main cause of death. At the moment one out of
three HIV infected patients is co-infected with TB and 40% of them develops the active
disease, rendering the HIV-problem countries (most of them lying in Africa) also the regions
with the highest TB incidence in the world. Although it is a leading cause of HIV-related
morbidity and mortality, only little attention is paid to TB in HIV/AIDS programs so far.2
Next to HIV-infection, demographic factors, socio-economic trends and the neglected TB
control in many countries caused this vast epidemic. Efforts to stop the frightening trend are
hampered by the lack of financial means in developing countries, the appearance of multi-
drug resistant strains of M. tuberculosis and bad therapy compliance.
6Figure 1: TB incidence per 100.000 inhabitants
The current strategy in the battle against TB is DOTS (Directly Observed Treatment Short-
course). In DOTS, TB patients are subjected to standardised treatment regimens (generally
consisting of combinations of the most powerful anti-TB drugs) that, with direct observation
of drug intake, last 6-8 months. Such standardised treatment regimens reduce the duration of
illness, the risk of death and the appearance of resistant strains. In this way, one can indeed
prevent the development of resistance. However, for the unfortunate that are or will be
infected with the multi-drug-resistant bacteria or develop resistance after a previous drug
treatment (50-80% of previously treated cases), there’s a large need for more effective drugs
acting on novel targets. This has made the search for new targets and the development of new
antibiotic drugs a global emergency. 3 However, in spite of its abundance and the considerable
economic loss it causes, TB is one of the so-called neglected diseases. As the disease is gene-
rally spread in developing countries, the profitability of new anti-TB drug research is ques-
tionable, explaining the reluctant attitude of the pharmaceutical industry in this area.
The complete genome sequence of the best characterised strain of M. tuberculosis, H37Rv,
has been recently determined and analysed.4 The determination of its genome sequence was a
great aid to the cloning and overexpression of mycobacterial proteins, necessary for their
structure elucidation via crystallisation and X-ray analysis. In 2001 the structure of M. tuber-
culosis thymidine monophosphate kinase (TMPK) was elucidated by Li de la Sierra et al.5
The high resolution structure of TMPKmt and the difference in structure with the human
TMPK are a good starting point to devising novel inhibitory compounds using a structure-
based drug design approach. It may be worth mentioning here that one of the most successful
antiviral drugs against herpes simplex virus (aciclovir) targets thymidine kinase, a related
enzyme, which is responsible for the synthesis of both dTMP and dTDP in cells infected by
the virus.6,7
In this work the structure-based drug design of inhibitors for M. tuberculosis TMPK as
potential leads for new anti-mycobacterial drugs will be described.
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The genus of M. tuberculosis consists of aerobic rod-shaped organisms. Humans are the host
organisms for M. tuberculosis, cows for M. bovis. On their surface, mycobacteria have unique
lipid components called mycolic acids (see Figure 2). It is a group of complex branched-chain
hydroxy lipids that are bound to the peptidoglycan layer on their cell wall via phosphodiester
bonds. The mycobacteria use this layer for adhesion. Its hydrophobic character renders the
cells highly impermeable, making these resistant against dryness and disinfectants. Its
impermeability for nutrients causes the slow growth of these organisms (the generation time
of M. tuberculosis in synthetic medium or infected animals is 24 hours). This contributes to
the chronic nature of the disease, imposes lengthy treatment regimens and represents a
formidable obstacle for researchers.
2.1 PATHOLOGY
The interaction of the human host and M. tuberculosis is extremely complex. Partly, it is
determined by the virulence of the strain but probably more importantly by the specific and
non-specific resistance of the host. Cell-mediated immunity plays an important role in the
development of disease symptoms. It is convenient to distinguish between two kinds of
human tuberculosis infections: primary and postprimary (or reinfection).
The primary infection is the first infection that an individual acquires and usually results from
droplets containing viable bacteria from an individual with an active pulmonary infection.
8The bacteria that reach the lungs are ingested by macrophages but often survive because the
fusion between the phagosome and the lysosome is hindered. The bacteria multiplying in
macrophages cause a chemotactic response that brings additional macrophages into the area,
forming aggregates of macrophages, called tubercles in which M. tuberculosis continues to
multiply intracellularly. After a few weeks many of the macrophages die, releasing TB
bacteria and forming a liquid centre in the tubercle, which is surrounded by a mass of
macrophages and lymphocytes. The disease may become dormant after this stage.
Figure 2. Schematic drawing of the mycobacterial cell wall. 8
In a few individuals with low resistance, the bacteria are not effectively controlled. The centre
of the tubercle enlarges in the process of liquefaction, forming an air-filled tuberculous cavity
in which the bacilli multiply extracellularly. Liquefaction continues until the tubercle ruptu-
res, allowing bacilli to spill into a bronchiole and thus be disseminated throughout the respira-
tory system to other systems. This causes an acute pulmonary infection which can lead to an
extensive destruction of lung tissue, the spread of bacteria to other parts of the body and
death.
However, in most cases of tuberculosis, acute infection does not occur and the infection
remains localised and is usually inapparent.
The postprimary infection occurs when immunity wanes (e.g. HIV-infection, use of cortico-
steroids, alcoholism, lung emphysema, diabetes, malnutrition, stress, …). The mycobacteria
can multiply again in macrophages, the tubercle wall breaks down and the infection spreads to
different tissues. This causes symptoms like weight loss, night sweats, feverishness and a
cough that produces greenish sputum flecked with blood.
92.2 IMMUNOLOGY
The immunological response to M. tuberculosis is complex and multi-faceted (Figure 3). M.
tuberculosis succeeds in evading several toxic effects of this immune response, so that the
immune system is generally successful in sequestering, although not eliminating the
pathogen. M. tuberculosis then persists within a tubercle, composed of macrophages, T-cells
and B cells. In most cases of M. tuberculosis infection, the individual is asymptomatic and
non-infectious. This clinical latency often extends for the lifetime of the individual.
Breakdown of the immune response, can result in reactivation and replication of the bacilli,
with necrosis and damage to the lung tissue.
2.2.1 Macrophages
Interferon-gamma (IFN-g) was found to be the key endogenous activating agent that triggers
the anti-mycobacterial effects of murine macrophages. Tumor necrosis factor-alpha (TNF-a)
although ineffective alone, synergises with INF-g to induce the anti-mycobacterial effects of
the macrophages.
The macrophages contain complex vacuolar organelles, lysosomes, that contain potent
hydrolytic enzymes capable of degrading a whole range of macromolecules including those of
micro-organisms. These enzymes function optimally at acidic pH, a condition found in the
intralysosomal environment. They also produce reactive oxygen intermediates such as hydro-
gen peroxide and reactive nitrogen intermediates like nitric oxide, produced by inducible
nitric oxide synthase. The phagosomes can fuse with lysosomes and the phagocytosed micro-
organisms are subjected to degradation by intralysosomal acidic hydrolases and the reactive
oxygen- and nitrogen- intermediates. Prevention of this phagolysosomal fusion is a mecha-
nism by which M. tuberculosis survives within macrophages. Several theories to explain this
escape mechanism have been proposed. Probably several of those mechanisms contribute to
the prevention of the phagolysosmal fusion. 9
§ It has been reported that mycobacterial sulfatides, derivatives of multi acetylated trehalose
2-sulfate, a polyanionic glycolipid, would have the ability of inhibiting phagolysosomal
fusion.
§ Also, the large amounts of ammonia (regulated by mycobacterial urease and glutamine
synthetase) that M. tuberculosis generates could be responsible for this, but the precise
mechanism by which ammonia prevents phagolysosome fusion remains to be determined.
§ Exclusion of ATPase proton pumps from phagosomes containing living M. tuberculosis
provides another mechanism for the lack of acidification of mycobacterial phagosomes.
§ A TACO (tryptophan aspartate containing coat) protein is present in lymphoid and
myeloid cells and is associated with the cortical microtubule network in non infected
macrophages. Two hours after infection it gets relocalised to the mycobacterium
containing phagosomal membrane and it remains associated for a prolonged period of
time, which inhibits the phagolysosomal fusion.
On top of the evasion of the phagolysosomal fusion, mycobacteria are also capable of partly
evading the toxic effects of the reactive oxygen intermediates with oxygen radical scavengers
like phenoglycolipid I and lipoarabinomannan.9
10
Figure 3: Cellular interactions in acute and latent TB infection. (a) The acute stage of infection is
characterised by multiplying bacteria inside the phagosomes, which secrete or release proteins to
the surroundings. These proteins are processed by the endosomal pathway and presented mainly
by MHC class II molecules to CD4+ T-cells. The CD4+ T-cells secrete cytokines (e.g. IFN-g),
which activate the macrophage and lead to killing of the intracellular mycobacteria through the
production of reactive oxygen metabolites and phagosomal acidification. (b) During the chronic
or latent stages of infection, low numbers of dormant or slowly replicating bacteria release
antigens that enter both the MHC class I and the MHC class II pathway. CD8+ cells play an
important role in the control of infection mediated by their cytokine production and cytolytic
activity. In this phase of infection the CD4+ cells might serve more as bystanders promoting CD8
activity. 10
11
2.2.2 Cytokines
The immune response to all pathogens is at least in part dependent on cytokines, which
regulate all the cells of the immune system. M. tuberculosis is no exception and strongly
induces cytokines during infection. This response is crucial for the control of the infection but
may also contribute to the chronic infection and associated pathology.
§ Immunologic control of M. tuberculosis infection is based on a type I T-cell response.
Phagocytosis of M. tuberculosis bacilli by macrophages induces interleukine 12 (Il-12)
production, which in its turn activates the production of IFN-g by NK cells, CD4 and CD8
T-cells. IFN-g is a key cytokine in the control of M. tuberculosis infection. Although its
production alone is insufficient to control the infection, it is required for the protective
response against the pathogen. M. tuberculosis, however, is able to prevent macrophages
from responding adequately to IFN-g.
§ TNF-a plays multiple roles in immune and pathologic responses in tuberculosis. M.
tuberculosis induces TNF-a secretion by macrophages and T-cells. This cytokine is
required for control of acute M. tuberculosis infection. In synergy with IFN-g, it induces
nitric oxide synthase expression. It affects cell migration to tissues infected with M.
tuberculosis. TNF-a also influences expression of adhesion molecules as well as
chemokines and chemokine receptors and this is certain to affect formation of tubercles in
infected tissues. It is major factor in host-mediated destruction of lung tissues.
§ In contrast to TNF-a, Il-10 is generally considered to be primarily anti-inflammatory. This
cytokine, produced by macrophages and T-cells, possesses macrophage deactivating
properties, including down-regulation of Il-12 production, which, in its turn decreases
IFN-g production by T-cells. It directly inhibits CD4+ T-cell responses as well as the
antigen presenting cell (APC) function of cells infected with mycobacteria.
§ Il-6 also plays multiple roles in the inflammation process, hematopoiesis and the
differentiation of T-cells. It can be responsible for suppression of T-cell responses just as
the transforming growth factor-b  (TGF-b) does. The latter also participates in macrophage
deactivation by inhibiting IFN-g induced nitric oxide synthase production.9
2.2.3 T-cells
M. tuberculosis is a pathogen for which the protective response relies on cell mediated
immunity. This is primarily because the organism lives within cells, usually macrophages.
Thus T-cell effector mechanisms, rather than antibodies, are required to control or eliminate
the bacteria. Activated T-cells migrate to the site of infection and are interacting with APC’s.
The tubercles contain both CD4 and CD8 T-cells that likely participate in the continuous
battle to sequester the infection and prevent reactivation.
§ M. tuberculosis primarily resides in a vacuole within the macrophage and as reported
above MHC class II presentation triggers the action of the CD4+ T-cells. CD4+ T-cells
from infected subjects produce IFN-g in response to a wide variety of mycobacterial
antigens to activate macrophages, which can then control or eliminate intracellular
organisms. These macrophages can lyse infected cells. In humans, this happens via
secretion of perforin and granulysin. Perforin is required to form a pore but granulysin, a
cytotoxic granule protein is responsible for killing of the intracellular organism. These
12
CD4+ T-cells also play a role in maturing APC’s. M. tuberculosis infected macrophages
are diminished in their ability to present antigens to the CD4+ T-cells, which could
contribute to the inability of the host to eliminate persistent infection. M. tuberculosis
does this by down-regulation of cell surface expression of MHC class II molecules, which
results in fewer antigen presentation.
§ During the dormant stage of the infection, CD8+ cells play an important role in
sequestering the infection. They migrate to the lungs with kinetics similar to CD4+ T-cells
following M. tuberculosis infection. They lyse infected macrophages and produce IFN-g
that, in its turn activates macrophages.9
2.3 DIAGNOSIS
Because M. tuberculosis is a slow growing organism, diagnosis is difficult. A sputum smear
microscopic analysis, typical symptoms, responsiveness to certain antibiotics and X-ray
examinations can give an initial idea of M. tuberculosis infection. However, it takes weeks to
grow it out of sputum, for unambiguous confirmation of M. tuberculosis infection.
2.3.1 Tuberculin skin test
This test measures the hypersensitivity of an individual against the bacteria or their products,
caused by the primary infection. When tuberculin, a protein factor extracted from M.
tuberculosis, is injected intradermally into a hypersensitive individual, it elicits a localised
immune reaction (induration and swelling) within 1-3 days at the site of the injection. This
test doesn’t indicate the active disease but only that the individual has been exposed to the
organism at some time. Vaccination with the BCG vaccine can also result in a positive
tuberculin skin test.11
2.3.2 Sputum smear microscopy
M. tuberculosis gets visualised with a Zeehl-Neelsen stain. However, there is a 25% chance
for a false negative result; 25% of the smear negative patients appear to be culture positive.
2.3.3 Culture
Viable bacteria are found in the sputum of individuals with extensive lung tissue destruction.
The organism can be selectively isolated from sputum and other materials that are grossly
contaminated. Because of the high lipid content of its cell walls, M. tuberculosis is able to
resist alkali for a considerable amount of time. Therefore the sputum is first treated with 1N
NaOH for 30 minutes. Subsequently, it is neutralised and streaked onto an isolation medium.
Due to the slow growth of M. tuberculosis, visible colonies can only be observed after days to
weeks of incubation.
2.3.4 Symptoms
Tuberculosis infection causes symptoms like cough, feverishness, weight loss and sputum
production.
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2.3.5 Responsiveness to antibiotics
Smear negative patients can be treated with amoxicillin and/or erythromycin. Patients who do
not respond to either of these antibiotics have a 50-75% (depending on the chosen antibio-
tic(s)) chance of having TB anyway.
2.3.6 X-ray
Primary and reactivated tuberculosis have distinct radiographic patterns. When renewed
pulmonary infection occurs, it is usually a chronic infection that involves destruction of lung
tissue, followed by partial healing and slow spread of the lesions within the lungs. Those
spots of damaged tissue may be revealed by X-ray examination. However, intercurrent
pneumonia, pulmonary embolism or supervening carcinoma may be confounding factors.3
2.4 RESISTANCE
Unlike many drug resistant bacteria, TB does not acquire drug resistance through exchange of
plasmids. Instead, normal error rates of DNA replication in M. tuberculosis ensure that
spontaneous mutations arise that cause resistance in the absence of antibiotic exposure.
Spontaneous mutation to isoniazid resistance, for example, occurs in about 1 in 106 bacteria;
resistance rates for streptomycin and ethambutol are similar. About 1 in 108 bacteria is
rifampicin-resistant. If the bacterial load is large enough, treating a patient with a single drug
will lead to the suppression of susceptible bacteria and the selection for growth of a drug-
resistant strain. Avoidance of selection for resistance is, in part, the reason for treating TB
with multiple drugs. The probability of resistance arising when rifampicin and isoniazid are
used in combination is only 1 in 1014, sufficiently low to prevent resistance for either drug. 12
2.4.1 Drug resistant tuberculosis
In drug resistant TB, the bacteria are resistant to one or more anti-tuberculosis drugs.
§ In patients with some record of previous treatment, the bacterial resistance is called
acquired resistance. Interruption of the therapy by the patient, prescription of inadequate
chemotherapy, poor drug supply (especially in developing countries) may cause
resurgence of the infection. The resurgent organisms are often resistant to the original
treatment drug.
§ In patients without prior treatment with anti-tuberculosis drugs, the bacterial resistance is
called primary resistance. The occurrence of primary resistance is a consequence of the
level of acquired resistance in the community. The rate of primary resistance is lower than
the incidence of acquired one. It is also less severe than the acquired one. This resistance
is more often to one drug (streptomycin or isoniazid) than to two drugs. Resistance to
three drugs is exceptional. The level of resistance (measured by the minimum inhibitory
concentration of antibiotics) is lower in primary than in acquired resistance.
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2.4.2 Multi-drug resistant (MDR) tuberculosis
In MDR tuberculosis, bacteria are resistant to several anti-tuberculosis drugs and at least to
isoniazid and rifampicin. It is a consequence of inappropriate use of essential anti-tuberculosis
drugs. It is usually found in patients after failed treatment regimens and represents a
significant proportion of tuberculosis patients with acquired resistance. Only exceptionally it
is observed in new cases. Top priority is not the management, but the prevention of MDR
tuberculosis.
2.4.3 Cross-resistance
Patients showing resistance to one drug often also show resistance against other drugs from
that family or even drugs from other families. This should be taken into account when
choosing a drug regimen for a patient with multi-drug resistant TB.
2.5 CONTROL AND TREATMENT
2.5.1 Prevention
Since tuberculosis is highly contagious, patients with infectious tuberculosis must be
hospitalised in negative pressure rooms. People that have contact with the patients, have to
wear face masks with HEPA filters (high energy particulate air).
The efficiency of the bacille Calmette Guérin (BCG) vaccine, containing an enfeebled live
stem of M. bovis, is subject of controversy nowadays (see further).
2.5.2  Chemotherapy
The anti-tuberculosis drugs are divided into two categories: the essential drugs, used in
patients without drug resistance or drug resistance against some drugs (as long as it isn’t
against isoniazid and rifampicin) and the second line drugs that are used in case of multi-drug
resistant TB in combination with first-line drugs. These second line drugs are less effective,
have more side effects and are more expensive than the present standard essential drugs.
§ Essential drugs (Figure 4)
à Streptomycin: was the first drug used against tuberculosis. It inhibits the translation of
mRNA via interaction with the 30S ribosomal subunit. Mutations on the genes coding
for the ribosomal protein S12, confer streptomycin resistance. Resistance to
streptomycin has become less common since the wider use of ethambutol as fourth
drug in the WHO standard regimen. 13
à Isoniazid: the discovery of isoniazid (isonicotinic acid hydrazide) caused a revolution
in tuberculosis treatment. This agent is not only effective and free from toxicity, but
also inexpensive and readily absorbed when orally given. Isoniazid affects the
synthesis of mycolic acid by M. tuberculosis. It gets processed by mycobacterial
catalase-peroxidase (katG), which transforms the drug into a nucleophilic radical.
Reaction of this radical, with the cofactor NAD+, yields a potent inhibitor of enoyl-
15
ACP (acyl carrying protein) reductase. This enzyme is necessary for the mycolic acid
synthesis of the bacterial cell wall. The major class of mutations in isoniazid-resistant
M. tuberculosis map to a gene which encodes the catalase-peroxidase.14
à Rifampicin is an antibiotic drug that, by interacting with RNA-polymerase, blocks
RNA-transcription. It binds a pocket of RNA polymerase within the DNA/RNA
channel, but more than 12 Å away from the active site. It acts by directly blocking the
path of the elongating RNA when the transcript becomes 2 to 3 nucleotides in length.
Because it diffuses freely into tissues, living cells, and bacteria, it is extremely
effective against intracellular pathogens like M. tuberculosis. However, bacteria
develop resistance to rifampicin with high frequency. Mutations conferring rifampicin
resistance map almost exclusively to the rpoB gene that encodes the RNA polymerase
b  subunit.15
à Pyrazinamide: This drug has a special place in modern tuberculosis therapy, as it
appears to kill semi dormant tubercle bacilli that are not affected by other anti-
tuberculosis drugs. It has a bactericidal effect in an acid medium (bacilli inside
macrophages). So, in order to obtain a maximal bactericidal effect, it is best combined
with streptomycin or another aminoglycoside, effective against bacilli outside
macrophages. Pyrazinamide blocks fatty acid synthesis through inhibition of the
eukaryotic-like fatty acid synthetase I.16 Intracellularly, it is converted to pyrazinoic
acid by an amidase. Resistance to pyrazinamide is neither easily acquired nor proved
by susceptibility testing. It is correlated with the amidase activity of the M. tuberculo-
sis isolate in question: most pyrazinamide resistant isolates of M. tuberculosis have
decreased or no amidase activity and are presumably unable to convert pyrazinamide
into the active agent. However, this drug is toxic to retinal ganglion cells and ocular
toxicity has also been reported.17
à Ethambutol: The critical target for ethambutol lies in the pathway for the biosynthesis
of cell wall arabinogalactane (see Figure 2); it inhibits arabinosyl transferase, respon-
sible for the polymerisation of arabinose into the arabinan of arabinogalactane. Dis-
ruption of the biosynthesis of arabinogalactane would destroy the macromolecular
assembly of the mycolyl-arabinogalactan-peptidoglycan complex of the cell wall, per-
mitting drugs with intracellular targets (such as rifampicin) to enter the cell more easi-
ly. Ethambutol resistant M. tuberculosis strains carry mutations in one certain part of
the gene encoding for arabinosyl transferase. In the case of MDR-TB, if there is still a
reliable susceptibility, ethambutol might be valuable as a companion drug for preven-
ting the emergence of resistance to other active drugs.13,18
à Thioacetazone is a bacteriostatic agent, showing partial cross resistance with
ethionamide.19 Its mode of action has not been elucidated,20 although it has been
shown that thioacetazone forms copper complex salts that have been postulated to
represent the effective compound.21 The most frequently seen adverse effects include
gastrointestinal burden and central nervous system disorders.22
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Figure 4: First-line anti-tuberculosis drugs
§ Second line drugs (Figure 5)
à Aminoglycosides (e.g., kanamycin, amikacin and capreomycin) can be used in case of
resistance to streptomycin. These analogues also inhibit the translation of mRNA via
interaction with the 30S ribosomal subunit. The main adverse effects are ototoxicity
and reversible nephrotoxicity. Kanamycin-resistance is caused by mutations on the
gene coding for the 16S ribosomal RNA.13
à Thioamides (e.g., ethionamide and prothionamide). Thioamides show cross-resistance
with thioacetazone. Their adverse effects include nausea, psychotic reactions, hypo-
glycaemia and hepatitis. Ethionamide gets activated by an FAD-containing enzyme
which turns it in two steps into 2-ethyl-4-aminopyridine.23 Like isoniazid it blocks the
mycobacterial mycolic acid synthesis, but it binds enoyl-ACP reductase at a different
part of the active site.14
à Fluoroquinolones (e.g.,² ofloxacin and ciprofloxacin) have low bactericidal activity
and are useful in association with other drugs. They inhibit DNA gyrase, responsible
for supercoiling the bacterial DNA. Side effects are rare and consist of gastrointestinal
disturbance, dizziness, headache and mood changes. Missense mutations in the DNA
gyrase gene have been reported to be associated with increased levels of resistance to
fluoroquinolones.13
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à Cycloserine blocks the mycobacterial peptidoglycan synthesis by inhibition of D-alani-
ne racemase that catalyses the conversion of L-alanine into D-alanine. It has no cross-
resistance with the other anti-tuberculosis drugs, so it might be valuable to prevent
resistance to other active drugs but its high toxicity limits the use of cycloserine. Side
effects are dizziness, convulsions, headache and depression. 24
à Para-aminosalicylic acid is a bacteriostatic agent, valuable for preventing resistance to
other bactericidal drugs: it may prevent resistance to streptomycin and leads to a sub-
stantial enhancement of monotherapy with isoniazid. It has dose-related side effects
such as vomiting, diarrhea, hepatotoxicity, fever, hypocalcaemia and rash. 25
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Figure 5: Second-line anti-tuberculosis drugs
Depending on whether it is the first drug treatment of the patient, whether a treatment regimen
failed before and depending on the presence of drug-resistant TB, a different treatment regi-
men is chosen.
§ WHO standard first-line regimen: This regimen, consisting of a combination of four drugs
(isoniazid, rifampicin, pyrazinamide and ethambutol or streptomycin), is given during 6 to
8 months. This overcomes the risk of failure due to acquired resistance. Because primary
resistance is less severe than acquired resistance, it hardly affects the outcome of this
regimen.
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§ WHO standard retreatment regimen: This regimen is administered to patients, returning
after premature interruption of the first-line treatment and/or after relapse. It combines
four drugs during 8 months to reduce the risk of failure due to acquired resistance. It
consists of three drugs throughout the whole period (isoniazid, rifampicin, ethambutol),
supplemented by pyrazinamide during the first three months and streptomycin during the
first two months. Any bacteria remaining after 5 months are usually resistant to one or two
of the main bactericidal drugs (isoniazid and/or rifampicin). The vast majority of the
patients will be cured with this retreatment regimen, failures are generally due to the use
of an incorrect regimen and/or failure to ensure that the regimen is fully administered and
directly observed.
§ Treatment regimen for chronic cases: This regimen is administered to patients for whom
the WHO retreatment regimen failed. They usually received at least two courses of
chemotherapy, they are most of the time excreters of resistant bacilli and often of MDR
bacilli. Treatment of patients with MDR tuberculosis involves ‘second line’ spare drugs.
These are more expensive, less effective and have more side effects compared to the
standard drugs. They should only be distributed by a specialised unit, equipped with a
laboratory that is able to test for drug resistance in order to prevent incurable tuberculosis.
The treatment consists of a mix of essential drugs and second-line drugs. The initial
regimen should consist of 4 or 5 drugs to which the bacteria are likely to be fully
sensitive, i.e. drugs not previously used for that patient. For this, it is crucial to take cross-
resistance also into account. When the patient’s sputum has converted to negative, one or
more drugs are withdrawn, preferably weaker drugs which are causing side effects. In
order to prevent relapse, the treatment with this slimmed regimen is continued for at least
18 months after sputum conversion.
2.5.3 DOTS
The current strategy in the battle against TB is DOTS. DOTS combines five elements:
political commitment, microscopy services, drug supplies, monitoring systems and direct
observation of treatment. For the first, typically six, months of the disease (i.e. when the
bacterial load is the highest), combinations of several drugs are administered to the patients,
according to fixed patterns as presented by the WHO standard first-line regimen. This
therapy, when closely monitored, considerably decreases the duration of illness, risk of death
and the appearance of resistant strains. In all DOTS compliant countries the cure rates of
smear-positive tuberculosis are already over 80%. When implemented over a long period,
there will be a huge reduction in sources of infection and transmission.3
2.5.4 Surgery
For patients with bacilli resistant to all except 2 or 3 relatively weak drugs, surgery is
considered. However, for many of these patients the infection has evolved too extensively
and/or lung function has degraded too much for surgery to be possible. If the patient has a
large localised lesion with little other disease, reasonable lung function and only 2 or 3 weak
drugs available, surgery can be considered. To avoid serious and potentially fatal TB
complications, the operation is performed when the bacterial load is the lowest, i.e. after 2
months of treatment. After surgery, the same drug regimen is continued for at least 18
months.
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2.5.5 Vaccination
The current TB vaccine, M. bovis bacille Calmette-Guérin (BCG), was developed almost a
century ago. Although several clinical studies showed this vaccine to be inefficient, it is still
in widespread use. It was developed by attenuation of M. bovis, which is closely related to M.
tuberculosis (>90% DNA homology). However, recent data indicate that a large number of
mutations have taken place during the long in vitro propagation of this strain. It is known that
these mutations have resulted in the deletion of many open reading frames, encoding several
important T-cell antigens, thereby reducing the efficiency of the vaccine.
In experiments where animals were sensitised with environmental mycobacteria - which share
many antigens with BCG- the multiplication of the attenuated BCG vaccine was inhibited. As
such the protection provided by environmental mycobacteria partly masks the effect of BCG
vaccination. These aspects could explain the failure of multiple BCG vaccinations and need to
be taken into consideration when discussing the potential of substituting BCG with new
attenuated mycobacterial vaccines, also sharing numerous antigens with environmental
strains.26
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3 Current research in preventing and
curing TB
3.1 VACCINATION
Most current vaccines against bacterial and viral pathogens depend on long-lived humoral
responses that can be induced by many different vaccine formulations. However, TB vaccines
require the induction of a sustained cell-mediated immune response and for this purpose, the
best choice of antigens and adjuvants is still an open question.
An ideal vaccine has following requirements: it has to be safe, stable and inexpensive; it has
to provide worldwide protection against disease and infection, protect after single
administration and induce long-lasting immunological memory; it needs to be compatible
with childhood vaccines and should not compromise the tuberculin skin test.
So far none of the vaccine technologies tested, lives up to all of these ideal characteristics.26
3.1.1 Living mycobacterial vaccines
Living vaccines have the theoretical advantage that many antigens can act together to induce
maximum protection. They would also be expected to survive in the tissues for prolonged
periods of time, thereby ensuring that efficient immunological memory is induced and
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maintained. As development of molecular tools for manipulation of mycobacteria progresses,
the number of reports on successful attenuation of mycobacterial strains increases rapidly.
Selectable markers, such as antibiotic resistance genes, transposon mutagenesis and allelic
exchange have resulted in the generation of several auxotrophic mutants that have reduced
virulence owing to a lack of functional genes for the synthesis of nutritional growth
factors.27,28 Although several of these constructs are protective against subsequent infection
with tuberculosis, there seems to be a correlation between virulence and protection, and none
of the mutants tested so far has given higher levels of protection than BCG in the animal
models.
It has been suggested that BCG could be augmented with some of the many genes lost during
the in vitro attenuation of this strain. This idea is related to the argument that BCG might have
been attenuated to impotence,29 and one needs to reintroduce or overexpress some of the
genes lost or expressed in insufficient quantities. Along this line, efficient protection was
recently reported in the guinea pig model of pulmonary TB with a recombinant strain of BCG
that overexpresses the AG85 protein (the major antigen of M. tuberculosis in cell wall
biogenesis).30 Similarly, attempts have been made to improve the immunogenicity of BCG,
either by enhancing its CD8+ T-cell stimulating capacity through the introduction of listerio-
lysin31 or by the expression of Th1 cytokines.32 However, these different approaches are
always complicated by the potential risk of increasing the virulence of the vaccine strain.
3.1.2 Subunit and DNA vaccines
Both the subunit and DNA approach are based on the assumption that a few antigens are
sufficient to induce and maintain a protective immune response. In addition, both approaches
share the advantage of being stable and safe even in immunocompromised individuals. The
development of DNA and subunit vaccines has benefited tremendously from the sequencing
of the TB genome, and the accelerated identification of novel antigens has resulted in the
identification of defined antigens that are protective in animal models. To include antigens
that give rise to beneficial responses and exclude potential detrimental components is the
ultimate advantage provided by subunit or DNA vaccines. In the development of subunit
vaccines, the major focus has been on vaccines based on culture filtrates or secreted proteins
from the latter, such as components of the 30-33 kDa AG85 complex,  30 the 38 kDa
phosphate-binding protein33 and the low molecular mass antigen ESAT-6.34 The most
promising vaccines have promoted protection against subsequent TB challenge at levels close
to that provided by BCG, and one of the recent developments consists in combining these
single protective antigens into subunit vaccines based on di- or tri-fusion molecules.
The demonstration in animal models that DNA vaccines could induce humoral as well as
broad cellular responses with both CD4+ and CD8+ T-cells provided hope that they could
become the vaccine of choice for infections that require cellular responses. This approach has
been applied with success in several small animal models of infectious diseases and its
potential is convincingly demonstrated for the development of TB vaccines based on HSP60
and AG85,35 as well as other antigens recently evaluated. Most recently cocktails of different
genes have resulted in levels of protection close to that of BCG36. The most promising of
these vaccines still need further testing in animal models that mimic the human disease.
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3.2 DRUGS
In the search for more potent anti-tuberculosis drugs there are two principal choices: synthesis
of improved versions of existing drugs or discovery of new drugs with a novel mechanism of
action.
3.2.1 Improved versions of existing drugs
Existing drugs are adapted to improve their activity or pharmacokinetic properties, or to
circumvent the resistance mechanisms of M. tuberculosis.
§ An example of the first option is rifapentine (Priftin), the first anti-tuberculosis drug to be
approved in 25 years. Although the TB relapse rate for rifapentine is slightly higher (10%)
than that of rifampicin (5%), the FDA approved the new medication because it only has to
be taken once weekly during the last 4 months of treatment, as opposed to twice weekly
for rifampicin. Another derivative of rifampicin, currently in phase II clinical trials, is
rifalazil. In vitro studies have shown this analogue to be 10 to 100 times as potent as
rifampicin, and, more importantly, it has a longer half-life. This longer half-life and
increased potency could allow physicians to shorten the treatment period and lower the
frequency of doses, reducing the overall cost of therapy. Indeed, the administration of the
drugs and compliance surveillance are more expensive than the drugs themselves. 37
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§ Reneau et al. 38-39 performed a study to optimise the quinolone anti-bacterials against M.
tuberculosis by preparing a series of N-1 and C-7 substituted quinolones. A series of N-1
substituted anti-bacterials showed that increasing the lipophilic character of these
compounds by itself does not correlate with increased potency against mycobacteria and
none of the tested compounds was more effective against M. tuberculosis than the
fluoroquinolone-drug sparfloxacin. However, in a series of N-1, C-7 disubstituted
analogues, a cyclopropyl or a tert-butyl at the N-1 position in combination with a
substituted piperazine yielded more potent inhibitors of M. tuberculosis than sparfloxacin
(see Figure 4).
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§ Most cases of pyrazinamide resistance are due to low levels of pyrazinamidase activity,
necessary to convert pyrazinamide into the active agent, pyrazinoic acid. Pyrazinoic acid
esters that can be hydrolysed by an esterase, could equally well serve as prodrugs and
could circumvent the requirement for activation by an amidase. Modification of both the
pyrazine nucleus and the ester function proved to be successful. n-Propyl-, 2'-octyl- and
n-octylesters of 5-chloro pyrazinoic acid showed in vitro activities against M. tuberculosis
100-1000-fold greater than pyrazinamide.40 Recently several pyrazinoic acid ester
derivatives were designed as potential prodrugs through a self-immolative process. These
prodrugs generate an unstable intermediate that, following the activation process, will
provide the active drug in a number of steps. The advantage of self-immolation is that it
increases the diversity of prodrugs that can be activated by a certain enzyme. 4-Acetoxy-
benzyl pyrazionic acid and 4'-acetoxybenzyl-2-quinoxalinecarboxylate showed excellent
activities against TB (MIC values of 1-6.25 mg/mL). Enzymatic hydrolysis of the acetate
yields a hydroxyl group. The increased electron density in the aromatic system then leads
to the extrusion of pyrazinoic acid and a substituted quinone methide.41
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§ Inspired by the anti-tubercular drugs isoniazid and pyrazinamide, it was assumed that
precursors of isosteres of isonicotinic or pyrazinoic acid could possess anti-mycobacterial
activity. Pyrazines and pyridines substituted with N1 and N2 alkylated tetrazoles,
1,2,4-oxadiazole-5-ones, 1,2,4-oxadiazole-5-thiones and 1,3,4-oxathiazoline-2-ones were
synthesised. The 1,3,4-oxathiazoline-2-one derivatives were the most potent of the series,
showing to be 8 to 16 times as effective as pyrazinamide. Although the compounds were
not tested against pyrazinamide resistant strains of M. tuberculosis, it is expected that they
are effective against the latter. Indeed, most pyrazinamide resistance generally results
from lack of pyrazinamidase enzyme in the bacteria and the examined compounds do not
contain an amide bond that has to be hydrolysed for activity. 42-43
O
S
N O
N
X
O
S
N
O
N
X= CH, N
§ A series of isonicotinoyl hydrazone derivatives showed interesting anti-mycobacterial
activity against rifampicin-, pyrazinamide- and streptomycin resistant strains of M.
tuberculosis, but lower activities against isoniazid resistant strains. Sub-inhibitory
concentrations induced a significant increase in the anti-mycobacterial activities of
rifampicin, ethambutol and para-aminosalicylic acid.25,44
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§ Lee et al. 45 tried to find a better inhibitor of arabinosyltransferase than ethambutol. They
studied a large group (63238 compounds) of ethylenediamine derivatives via the use of
solide phase synthesis and found 26 compounds possessing MIC values lower than
ethambutol. They are all characterised by large hydrophobic groups. The most active
compound (MIC = 0.2 mg/mL), contained both an amantadyl and a geranyl group. It is
suggested that this potent activity is a result of the geranyl group mimicking the
polyprenol side chain of decaprenolphosphoarabinose in the active site of mycobacterial
arabinosyl transferase.
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3.2.2 Drugs with a novel mechanism of action
Drugs with a novel mechanism of action are more likely to be active against strains of M.
tuberculosis that are resistant to existing drugs. The ideal target for the design of novel anti-
TB agents would be a M. tuberculosis enzyme that isn't found in humans or differs
sufficiently from its human congener to allow selective blocking. The genome sequence of M.
tuberculosis H37Rv, which was recently determined and analysed, shows that a very large
portion of its coding capacity is devoted to the production of enzymes involved in lipogenesis,
lipolysis and synthesis of cell wall sugars.4 Lots of research is currently being directed against
biological targets, taking part in the mycobacterial cell wall synthesis. Below, an overview is
given of some of the most important recent achievements in that area of anti-tuberculosis drug
design.
§ 4,4'-Diisoamyloxy diphenyltiourea (ISO), a thiourea derivative successfully used in the
1960s to treat tuberculosis, recently showed to have considerable antimycobacterial
activity against multi-drug-resistant TB strains (MIC 1-10 mM), without showing toxicity
against macrophage cell cultures. This compound exerts its effect through inhibition of the
mycobacterial oleic- and mycolic-acid synthesis.46 Recently, membrane bound 9-stearoyl-
desaturase was proven to be the biological target of this compound.47 Several ISO
analogues with various side chains of allyl, alkoxy and alkylthio units showed even
superior activities against M. tuberculois (< 0.1mM for the propylthio- or butylthio- substi-
tuted diphenylthioureas).47
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§ While the synthesis of fatty acids occurs in all living organisms, mycobacteria possess
accessory fatty acid synthase enzymes with specialised substrate and product specificities
that are attractive targets for drug development. A new class of compounds designed to
inhibit the b-ketoacyl synthase reaction of fatty acid synthesis has been developed. Out of
more than thirty compounds, mimicking the transition state of the b-ketoacyl synthase
reaction48, the most active ones were 2-alkylsulphonylacetamides with an alkyl tail
between eight and ten carbons in length (lower MIC than ethambutol, rifampicin, strepto-
mycin and pyrazinamide, i.e. 1 mg/mL). The inhibitory activities were acutely sensitive to
variations in alkyl tail length, charge and relative position of the sulfone to the amide.
These compounds inhibit the growth of several species of mycobacteria, including both
isoniazid-resistant and multi-drug resistant strains of M. tuberculosis.49
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§ From a series of 6-arylpurines, carrying a variety of substituents at the 9-position, the
lowest minimum inhibitory concentration was found for 9-benzyl-2-chloro-6-(2-fu-
ryl)purine (0.78 mg/mL). Tests on its capacity to kill M. tuberculosis in monolayers of
mouse bone marrow macrophages showed that it is able to penetrate inside macrophages.
It exhibits low cytotoxicity and is active against several single drug-resistant strains of M.
tuberculosis. The mechanism by which these purines exhibit their anti-mycobacterial
activity is not known. However, the lack of cross-resistance with many known anti-
mycobacterial drugs suggests that these compounds do not share the same mode of
action. 50
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§ 3-Aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents,
having a new mechanism of action which involves very early inhibition of protein
synthesis. U-100593 and U-100766 demonstrate potent in vitro activity against M.
tuberculosis (MIC < 0.125 mM).51 A subclass with a thiomorpholine moiety showed
markedly potent in vitro activity against M. tuberculosis. A representative of this class,
U-100480, proved to be more active than isoniazid. Moreover it is also efficient against
M. tuberculosis strains which are resistant to the conventional anti-tuberculosis drugs,
without a sign of cross resistance.52
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§ Based on a series of N-hydroxyalkyl-1,2-benzisothiazol-3(2H)-ones (1), known to have
anti-mycobacterial properties, a series isosteric 2-mercapto-pyridine-3-(N-alkyl-carbothio-
amides) (2) was evaluated for its activity against M. tuberculosis. All compounds showed
anti-TB activity, especially the ethyl- and heptylamides proved to be more potent than
ethambutol (MIC values of 0.5 mM). These compounds show low toxicity but very rapid
elimination from the body after intravenous administration and poor absorption after oral
administration. 53
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4 Thymidine monophosphate kinase
4.1 MYCOBACTERIUM TUBERCULOSIS TMPK: AN ATTRACTIVE TARGET
Thymidine monophsophate kinase (TMPK, ATP:dTMP phosphotransferase, thymidylate
kinase) belongs to the large super family of nucleoside monophosphate kinases (NMPK's). It
catalyses the reversible phosphorylation of thymidine monophosphate (dTMP) to thymidine
diphosphate (dTDP) utilising ATP as its preferred phosphoryl donor.54
TMPKmt
dTMP + ATP              dTDP + ADP
The position of TMPK at the junction of the de novo and salvage pathways of the thymidine
triphosphate (dTTP) metabolism, as the last specific enzyme for dTTP synthesis, makes it an
interesting target for new drug design. With experiments using a cdc8 mutant of Saccharo-
myces cerevisiae, deficient in TMPK, Jong et al. proved that yeast TMPK (TMPKy) is
essential for DNA replication and thus for cellular growth. 55,56 Furthermore, the thymidylate
kinase activity of yeast shows to be a cell-cycle-regulated: enzyme activity is barely
detectable in non-proliferating tissues, whereas in growing tissues, thymidylate kinase activity
is increased considerably. A correlation between thymidylate kinase activity and the rate of
DNA synthesis during rapid growth has been documented.57
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Because studies using in vivo expression technology suggest that bacterial pathogenicity
depends on genes essential for bacterial growth and intracellular survival, 58 blocking
processes essential for the growth and replication of these organisms is believed to be an ideal
way to beat them.
This has successfully been demonstrated by aciclovir, one of the most successful drugs
against the herpes simplex virus. This drug is directed against thymidine kinase, which is
responsible for the synthesis of both dTMP and dTDP in cells infected by the virus. Once
selectively activated to its triphosphate form, it blocks the viral DNA synthesis through chain
termination.
Although the global folding of TMPKmt is similar to that of TMPKh, sequence comparison
showed only a 22% sequence identity between both enzymes, suggesting that selective
blocking of the bacterial DNA synthesis should be feasible.59 Moreover, AZTMP was already
identified as a selective competitive inhibitor of TMPKmt.59 TMPKmt represents the first
reported TMPK that does not phosphorylate AZTMP, a feature that could be exploited in the
search of selective inhibitors of TMPKmt.
4.2 STRUCTURE OF TMPKMT
TMPKmt has recently been crystallised by Li de la Sierra et al.60 The structural data used in
this work are based on a 1.95 Å resolution X-ray image of TMPKmt bound to its natural
substrate, dTMP, with a sulphate ion mimicking the b-phosphoryl of ATP.
4.2.1 Primary, secondary, tertiary and quaternary structure
TMPKmt has a molecular mass of 24 kDa and consists out of 214 amino acid residues. It is a
homodimer in solution (Figure 6). In each monomer, nine a-helices surround a five-stranded
b-sheet core. The interface of the dimer consists of three pairs of helices (a2, a3 and a6),
kept together through hydrophobic interactions and an ion pair Glu50-Arg127.60
 
Figure 6: Stereo plot of the functional TMPKmt dimer crystallised in sodium malonate. The
protein is shown in ribbon representation with helices shown in green and b-strands in red. The
dTMP substrate as well as the acetate molecule found in the ATP-binding site are shown in a ball
and stick representation. The magnesium ion found in the dTMP-binding site of one monomer
(monomer B, on the right side) is shown in magenta. The P-loop is depicted in yellow and
ordered parts of the LID are in dark blue.61
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The global folding of TMPKmt is similar to that of other TMPKs, despite the low similarity
of their amino acid sequences (26%, 25% and 22% sequence identity over about 200 aligned
residues with TMPKec, TMPKy and TMPKh respectively) (Figure 7).
Like other NMPK’s, TMPKmt undergoes large conformational changes upon substrate
binding. One can distinguish between:
§ the open conformation, observed without substrate
§ the partially closed conformation with a single substrate
§ the fully closed and active conformation, observed in the presence of both substrates
(dTMP and ATP).
In the X-ray structure described by Li de la Sierra et al.,60 the enzyme is in the fully closed
conformation even though the presence of ATP is mimicked by SO42-.
Three regions contain the essential residues for the function of this enzyme
§ The P-loop motif (consensus sequence Gly X1X2X3X4 Gly Lys X5)62 controls the
positioning of the phosphoryl groups of the phosphate donor. It binds and positions the a-
and b-phosphoryl groups of ATP through interactions between amide backbone
hydrogens and phosphate oxygen atoms. Unique to TMPKs is an interaction between the
P-loop and the phosphoryl acceptor dTMP. This is achieved through a hydrogen bond
between the 3’-hydroxyl group of dTMP and a carboxylic acid residue at position X2 of
the P-loop motif (Asp9 in TMPKmt). The exact function of this acidic amino acid is still
unclear but it seems to be crucial for the catalytic mechanism of TMPK as any mutation of
this residue in either the yeast, human or E. coli enzyme abolishes the phosphoryl transfer
activity. 63
§ The DR(Y/H/F) motif is a loop containing a strictly conserved arginine residue, acting as
a clip which favorably orients the phosphoryl donor and acceptor via an interaction with
the phosphate group of dTMP and the g-phosphate of ATP.
§ The LID region is a flexible stretch that closes upon the phosphoryl donor when it binds
the enzyme. This highly flexible stretch undergoes substantial conformational changes
when the ATP molecule is fixed onto the enzyme. Simultaneously there is a transition
from a coil to a helical conformation in the LID region when ATP gets bound.64
Phosphoryl groups of both substrates interact with arginine side chains of the LID region,
revealing their importance in catalysing phosphoryl transfer.60
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_______________P-loop_______________
1 10 20 30
mt . . . . . . . . M L I A I E G V D G A G K R T L V E K L S G A F R A A . . . . . . . . . G R S V A T L A
ec . . . . . M R S K Y I V I E G L E G A G K T T A R N V V V E T L E Q L G . . . . . . . . I R D M V F T R
h . . M A A R R G A L I V L E G V D R A G K S T Q S R K L V E A L . . . . . . . . . C A A G H R A E L L R
___________b1___________ _______________a1________________ ______b______
40 50 60 70
mt F P R Y G Q S V A A D I A A E A L H . . G E H G D L A S S V Y A M A T L F A L D R A G A . . . . . V H T
ec E P G G T Q L A E K L R S L V L D I K S V . . G D E V I T D K A E V L M F Y A A R V Q L V . . . . E T V
h F P N P D T T T G G L I L S Y L Q K K S . . . . . . D V E D H S V H L L F S A N R W E . . . . . Q V P L
_b2__ _____________________a2_________________________ ______________________a3____________________ _____________a4_______________
_DRY/H_
90 100 110 120 130
mt I Q G L C R G Y D V V I L D R Y V A S N A A Y S A A R L H E N A A G K A A A W V Q R I E F A R L G L P K
ec I K P A L A N G T W V I G D R H D L S T Q A Y Q G G G R G . . . I D Q H M L A T L R D A V L G D . . F R
h I K E K L S Q G V T L V V D R Y A F S G V A F T G A K . . . . . E N F S L D W C K Q P D V . . . G L P K
_______a4_______ _______b3______ ______________a5_______________ ________a6_________
_________LID region__________
140 150 160 170 180
mt P D W Q V L L A L . S A E L A G E R S R G R A Q R D P G R A R D N Y E R D A E L Q Q R T G . A V Y A E L
ec P D L T L Y L D V . T P E V G L K R A R A R G E L . . . . . . D R I E Q E S F D F F N R T R A R Y L E L
h P D L V L F L Q L . Q L A D A A K R G A F G H . . . . . . . . E R Y E . N G A F Q E R A L . R C F H Q L
_________b4________ __________________a7_________________________
190 200 210
mt A A Q G . . . W G G R W L V V G A D V D P G R L A A T L A P P D V P S . . . . . . . . . . . . . . . . .
ec A A Q D . . . . . K S I H T I D A T Q P L E A . V M D A I R T T V T H W V K E L D A . . . . . . . . . .
h M K D . . . . T T L N W K M V D A S K R L E A V H E E L R V L S E D A I R T A . T E K P L G E L W K . .
________b5________ ___________________a8___________________
Figure 7: Alignment of the amino acid sequences of TMPKmt, TMPKec and TMPKh. Identical residues in all three sequences are shown in yellow. In red are
amino acids common to TMPKmt and TMPKh and blue denotes commonalties between TMPKmt and TMPKec. Three positions occupied in TMPKmt by
specific amino acids (Arg14, Tyr39 and Asn100) are shown in pink.
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The phosphoryl transfer is catalysed by basic amino acids, mostly positively charged arginine
residues that stabilise the negatively charged transition state. Based on the position of those
arginines in the enzyme, TMPKs are categorised into two types:
§ Type I TMPKs (e.g. yeast and human) have, in addition to the invariant lysine (residue 19
in the human enzyme), a basic residue (arginine) around position 16 in their P-loop
sequence that can interact with the g-phosphate group of ATP and lack such a positively
charged residue in the LID region;
§ Type II TMPKs (e.g. E. coli) have a glycine residue at that place in the P-loop and one
additional basic residue in the LID region that interacts with ATP (Arg 153 in the E. coli
enzyme).
This sequence variability in the catalytic region of eukaryotic versus prokaryotic TMPKs is
associated with subtle but essential differences in phosphorylation mechanisms,65 suggesting
that inhibitors could be directed specifically against the enzyme of a pathogenic bacteria.
TMPKmt displays a configuration essentially representative of type II TMPKs, the LID
region (residues 147-159) comprising a series of basic residues (Arg149, Arg151, Arg153 and
Arg 156) and the P-loop (residues 7-14) having the usual glycine residue (Gly10) at position
X3. However, a peculiar additional basic residue, Arg14, is found at position X5 in the P-loop,
partly reminiscent of type I TMPKs, but unique among all TMPKs.
The observed magnesium ion is another unique feature of the TMPKmt structure: no magne-
sium atom was reported for the yeast or the E. coli enzyme.64,65 For the human enzyme, one
magnesium binding site has been reported but is located further away along the ATP-binding
site, between the b- and g-phosphate groups.63 Three water molecules, an oxygen atom from
the phosphoryl group and the carboxylate oxygen atoms of Asp9 and Glu166 coordinate the
magnesium ion in an octahedral configuration. Fioravanti et al.61 suggest this cation
neutralises the electrostatic repulsion between the anionic substrates and optimises their
proper alignment.
4.2.2 The dTMP-binding site
Examination of the X-ray structure of TMPKmt learns that the main bonding forces between
dTMP and the enzyme are:
§ a stacking interaction between the pyrimidine ring and Phe70;
§ a hydrogen bond between O4 of thymine and the Arg74 side-chain, which results in a
preference for thymine over cytosine;
§ a hydrogen bond between Asn100 and N3 of the thymine ring;
§ a hydrogen bond between the 3’-hydroxyl of dTMP and the terminal carboxyl of Asp9,
that in its turn interacts with the magnesium ion, responsible for positioning the phosphate
oxygen of dTMP;
§ hydrogen bonds and an ionic interaction between the 5’-O-phosphoryl and Tyr39, Phe36,
Arg95 and Mg2+ respectively;
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§ the presence of Tyr103 close to the 2’-position is believed to render the enzyme
catalytically selective for 2’-deoxy-nucleotides versus ribo-nucleotides (Figure 8).
Several subtle differences are observed when comparing TMPKmt to other TMPK’s. These
include:
§ the hydrogen bond between the N3 atom of the pyrimidine ring with the Asn100 side-
chain (changed to a glycine residue in both yeast and human, and to a threonine residue in
the E. coli enzyme);
§ the Tyr39 residue makes two polar contacts with dTMP: one with the phosphate oxygen
atom and the other with the oxygen atom at the 5’-position. Arginine and glycine residues
replace this tyrosine in the human and yeast enzymes respectively;
§ the 3’-hydroxyl group of the ribose moiety makes three polar contacts: one with a water
molecule involved in the Mg2+-coordination and two others with Asp9.60
These differences are potentially interesting starting points for finding selectivity for
TMPKmt versus TMPKh.
Figure 8: Image of the dTMP binding site of M. tuberculosis, complexed with dTMP, showing the
most important amino acids interacting with dTMP. dTMP is pictured in bold, the water
molecules as red spheres and the magnesium ion as a green sphere.
4.2.3 The ATP binding site
Despite the fact that TMPKmt was co-crystallised as a complex with dTMP and SO42-, in the
absence of ATP, the structural characteristics observed around the ATP binding site are
similar to those observed in complexes from yeast and E. coli enzymes where ATP was fixed,
indicating that the crystal structure represents the closed conformation. The LID region has
made the transition from a coil to a helical conformation, normally seen upon ATP binding.
Arg149 (part of the LID helix) and Thr15, which interacts via a stacking interaction with the
adenine ring of ATP, are in the correct position to accommodate the adenine ring of ATP, just
as observed in the closed conformation of the TMPKec.60
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TMPKmt has a broader substrate specificity for nucleoside triphosphates than other NMPK's.
The reaction rates with ATP or dATP as phosphate donors were similar. ITP, GTP, CTP and
UTP could also serve as efficient phosphate donors (order of efficacy: ITP > GTP > CTP >
UTP). Even dGTP, dCTP and dTTP act as phosphate donors, even though much less
efficiently (1% for dTTP, 8% for dCTP and 35% for dGTP compared to ATP).59
4.2.4 Catalysis
4.2.4.1 Kinetic parameters for dTMP and ATP
TMPKmt has a high resistance to thermal denaturation, associated with a lower catalytic
activity (the specific activity of TMPKmt is four- and six-fold lower compared to TMPKec
and TMPKy, respectively). The Km-values for dTMP and ATP lie in the same order of
magnitude in TMPKmt, TMPKy, TMPKec and TMPKh.59 (Table 1).
TMPK Km (ATP) (mM) Km (dTMP) (mM) Vm (ATP, dTMP)
a kcat (s
-1)
M. tuberculosis 0.1 4.5 13 4.5
E. coli 0.04 15 50 10.5
Yeast 0.19 9 84 35
Human 5 5 2 0.7
Table 1: Kinetic parameters for dTMP and ATP in TMPKmt,59 TMPKec64 and TMPKy59 and
TMPKh.59 .a Vm in mmole/min.mg of protein.
4.2.4.2 Structural changes of TMPKmt upon substrate binding
The structural changes of TMPKmt occurring upon binding of the substrates and subsequent
catalysis were investigated by protein crystallography. Structures were determined at different
pH values, in the presence and/or absence of sulphate ions, acetate ions and ATP, yielding
different snapshots along the reaction pathway (Figure 9).61
§ Structure 1 (apo-TMPKmt) shows a dTMP binding site completely ready to accommodate
dTMP, the LID region is in a highly disordered conformation.
§ Structure 2 (TMPKmt-dTMP) shows the native dTMP bound state of the enzyme, the
partially closed conformation. The switch from the open to the closed conformation is
triggered by the 3'-hydroxyl and the phosphoryl group of dTMP, attracting positively
charged residues from the LID region (Arg149, Arg151, Arg153, Arg156, Arg160 and
Arg162).
§ Structure 3 (TMPKmt-dTMP-Mg2+) shows that Mg2+ binds the enzyme transiently during
catalysis. Structural changes of the LID region result in the correct positioning of Glu166
in order to trap the magnesium ion. The binding of magnesium orders Asp9 in the correct
position to interact with Glu166, thereby establishing a link between the P-loop and the
LID region.
§ Structure 4 (TMPKmt-dTMP-Mg2+-SO42-) represents the closed conformation, the
sulphate ion mimicking the b-phosphate of ATP. Binding of ATP provides additional
contacts between the LID region and the P-loop, through Arg153 and Lys13. Glu166 now
coordinates the magnesium ion at in the correct position for catalysis.
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Figure 9: Snapshots along the reaction coordinate of TMPKmt. The five described structures
((1) apo-TMPKmt; (2) TMPKmt-dTMP; (3) TMPKmt-dTMP-Mg 2+; (4) TMPKmt-dTMP-Mg 2+-
SO4
2- and (5) TMPKmt-dTDP-Mg 2+-ADP) are shown from top to bottom. Nucleotides, sulphate
and acetate ions are shown in blue. The part of the main chain in the LID region that could be
modelled in the electron density is shown in ball-and-stick representation. The LID closes when
going from (1) to (4) and re-opens in (5). (b) A drawing of the TMPKmt active site. 61
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§ Structure 5 (TMPKmt-dTDP-Mg2+-ADP) resembles the state of the enzyme immediately
after phosphoryl transfer, with the LID region still fully closed. This structure is more
relaxed with Gu166 at a greater distance from Mg2+.
The scenario described above aligns with the induced-fit mechanism already suggested in
several NMPK's66,67,68,69 and with the idea of an ordered bi-bi-catalytic mechanism, in contrast
to the random bi-bi-mechanism proposed for these enzymes.70,71 The possibility of a
mechanism, involving ATP binding first, cannot be excluded from this study completely.
However, it has been shown that dTMP exhibits an affinity (Km = 4.5 mM) for the enzyme
more than 20 times stronger than ATP (Km=100 mM),59 suggesting that the pathway involving
dTMP binding first is largely favoured when both substrates are present in the same
concentration. Closure of the LID region upon ATP binding would sterically restrict the
access of dTMP to its binding site. A mechanism starting with ATP binding first would
probably require a secondary channel through which dTMP may enter the active site.
4.2.4.3 Possible catalytic residues
The magnesium ion provides a strong electrostatic potential, attracting the g-phosphate of
ATP sufficiently close to the a-phosphate of dTMP for phosphoryl transfer. It tightly
coordinates these phosphoryl groups, thereby acting as a clamp between the phosphoryl donor
and acceptor. The essential role of this ion in driving the catalysis suggests that structure-
based design of inhibitors for the enzyme should focus on possibilities to destabilise this
ion.61
In prokaryotic TMPKs, the arginine residues located in the LID region are responsible for
stabilisation of the negatively charged transition state with their positive charges. In the
eukaryotic enzymes, however, one of the key basic residues is located in the P-loop and not in
the LID region. In TMPKmt, apart from the side-chains of Arg153, Arg156 and Arg160 of the
LID region, the active site contains also an arginine residue (Arg14) in the P-loop, together
creating a highly positive electrostatic potential at the location where the triphosphate moiety
of the ATP molecule binds.
The phosphoryl group of dTMP makes direct polar contacts with three residues (Asp9, Tyr39
and Arg95) and solvent mediated contacts with six residues (Gly12, Lys13, Phe36, Arg153,
Asp163 and Glu166) of the enzyme. These tyrosine and arginine residues are also good
candidates in assisting the transfer of a phosphoryl group to dTMP.5
4.3 HUMAN TMPK
4.3.1 Structure and catalysis
Human TMPK (TMPKh) is a 24 kDa protein, consisting of 212 amino acid residues. It is a
homodimer with a similar fold as described for the TMPKmt, TMPKy and TMPKec. Each
monomer consists of a five-stranded parallel b-sheet core surrounded by nine a helices. The
highly hydrophobic dimer interface is generated by the stacking of three nearly parallel
helices from each monomer against the other. It is a type I TMPK with a basic residue in the
P-loop that can interact with the substrate.
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Figure 10: (a) The minimal scheme for a bi-bi-mechanism requires an expansion to account for
the conformational changes that occur after both substrates are bound and prior to product
release. States, I, II, III and IV are proposed on the basis of the different structural features
observed in different complexes of human TMPK (b), labeled A, B, C and D: (A) overlay of the
TMP–ADP (gray) and TMP–AppNHp (yellow) complexes; (B) TMP–AppNHp and TMP–ADP–
AlF3 (green); (C) TMP–ADP–AlF3 and Tp5A (blue; the b-phosphate group of Tp5A is modeled;
(D) Tp5A and TDP–ADP (red). Superposition of the different states reveals the possible
dynamics that occur during the phosphoryl transfer reaction. Note that the dTMP-ADP complex
shown in A does not represent a state on the reaction coordinate, but rather reveals the
conformational changes that occur upon the replacement of a diphosphate by a triphosphate at
the phosphoryl donor site.
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A special feature, only observed in the human TMPK structures are the additional conforma-
tional changes occurring within the globally closed conformation, which are dependent on the
nature of the bound substrates. This feature entails the rigid-body movement of three loop
regions: the P-loop, the LID region and the adenine-base binding loop. Several complexes of
TMPKh (TMPKh with dTMP and ADP, with dTMP and AppNHp, with TP5A, with ADP and
dTDP and with dTMP, ADP and AlF3) have been crystallised,63 representing different states
along the reaction coordinate and giving an image of the different conformations for these
regions (Figure 10).
§ P-loop open: is formed in the presence of dTMP and ADP
§ P-loop partially closed: when ADP is replaced by AppNHp or when the phosphoryl group
mimic AlF3 is soaked into a dTMP-ADP crystal
§ P-loop closed: is seen when the bisubstrate inhibitor TP5A is present or when dTDP and
ADP are present.
Although with each P-loop movement a concomitant shift in the position of the LID region
and the adenine-base binding loop is also observed, the terminology used above focuses on
the P-loop for reasons of clarity. However, at the moment we cannot be sure whether this
novel feature is unique to the human enzyme, or if it is common for all TMPK’s.
The P-loop moves as a rigid body, with the hinges being formed by two highly conserved
residues: Glu12, anchoring the P-loop via a bidentate interaction with Ser101 and Lys19,
interacting with the phosphate(s).
There is no information available about the free and singly bound enzyme. The dTMP and
AppNHp complex structure, represents the first step along the reaction coordinate of
phosphoryl transfer: the P-loop and LID region have already undergone a conformational
change from the open form to the P-loop partially closed state. However, in this state, the
dTMP phosphoryl group is not ideally positioned for nucleophilic attack on the g-phosphate
of ATP. Therefore, it is assumed that, before the chemical step can take place, the dTMP
phosphoryl group swings away from Arg45 towards Arg97 and the phosphate group of ATP,
thus shortening the distance to the donor nucleotide. Arg97 now acts as a clamp bringing the
donor and acceptor nucleotides together.
The structure of the AlF3 bound complex is a model for the transition state of the phosphoryl
transfer. The P-loop moves slightly further towards the monophosphate and in this state, the
oxygen of the dTMP phosphoryl group is optimally positioned for attack on the g-phosphate
of ATP. It makes only one interaction with Arg97, leaving the attacking oxygen atom free for
nucleophilic attack on the g-phosphate of ATP.
The TP5A complex structure is interpreted to represent the enzyme conformation just after the
reaction has taken place. Probably this state is only observed because of the restraints
imposed by using the covalently linked phosphate chain TP5A. Without this constraint, the
phosphate groups of dTDP and the sidechain of Arg97 rotate to the stable product
conformation represented by the complex with dTDP and ADP. As in the TP5A complex, also
in this case the enzyme adopts the fully closed conformation. The diphosphate moiety of
dTDP rotates with respect to the phosphate position when dTMP is bound. As a result, the
b-phosphoryl group of dTDP does not interact with the catalytic magnesium ion, but rather
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forms two hydrogen bonds to Arg97, thereby forcing it in a new position so that it cannot act
as a clamp anymore.
The magnesium ion, present in human TMPK, coordinates the b  and g-phosphates of ATP. By
withdrawing negative charge from the reactive phosphate, the magnesium ion promotes
nucleophilic attack on the phosphorus atom.72 Instead of a magnesium ion at this position, in
TMPKmt a coordination by the guanidinium-group of Arg14 is seen. Superposition of the
human and the tuberculosis TMPK suggests that the two enzymes have evolved slightly
differently by swapping the roles played by the two key positive charges in the active site (the
metal ion and one arginine residue). Whereas an NTP-bound Mg2+ is required in TMPKh,
Arg14 takes this role in TMPKmt. Conversely, a dTMP-bound Mg2+ is required for catalysis
in TMPKmt whereas in TMPKh Arg45 interacts with the dTMP phosphate group. The roles
of Arg97 (TMPKh) and Arg95 (TMPKmt), which superimpose very well in the two
structures, are likely to be similar in the two enzymes, acting as a clamp during catalysis.61
4.3.2 The low catalytic efficiency of human TMPK
The P-loops of all eukaryotic TMPK’s contain an arginine residue that follows the strictly
conserved carboxylic acid residue Asp15. A catalytic role was assigned to this residue
because mutating this arginine to glycine in yeast, reduced the activity 200-fold. In all of the
human TMPK complex structures, however, this arginine is observed in an extended
conformation that precludes interaction with the phosphates. This result is consistent with
mutagenesis experiments that show no appreciable decrease in catalytic rate upon mutating
this residue to glycine. Interestingly the rate observed for the human enzyme (0.7 s-1) is
similar to that of the yeast enzyme lacking this residue (35 s-1 for wild type, 0.2 s-1 for the
Asp15®Gly mutant).63
Of the two arginines (Arg15 and Arg97) that could potentially interact with the transferred
phosphoryl group to stabilise the transition state only the latter is also seen to show this
interaction with the g-phosphate of ATP. Possibly in vivo an additional factor interacts with
TMPKh and can induce the P-loop arginine to make the interaction mentioned above. It
seems likely that this and also the extra conformational changes within the globally closed
conformation limit the overall catalysis rate of human TMPK, which, in its isolated state, is
several orders of magnitude less efficient than AMPK, UMPK or even the highly homologous
yeast TMPK. Therefore, the question arises as to whether a mechanism or factor is present in
the cell for acceleration of this surprisingly slow reaction. Such a factor or mechanism would
add another level of control to the activity of the protein, in addition to that of cell-cycle-
dependent transcriptional control. 63
4.3.3 The role of human TMPK in activating AZT
The HIV-prodrug 3’-azido-3’-deoxy-thymidine (AZT) is converted by cellular enzymes to its
active form 3'-azido-3'-deoxy-thymidine triphosphate (AZTTP). The most important antiviral
effect of AZT is a consequence of efficient AZTTP incorporation into a growing DNA chain
by HIV reverse transcriptase, but to a much lesser extent by human DNA polymerases,
resulting in viral DNA chain termination in HIV infected cells. A prerequisite for AZT to be a
potent drug is that all phosphorylation steps to the triphosphate are catalysed efficiently by the
cellular enzymes. AZTMP, however, the substrate of TMPKh, accumulates in millimolar
concentrations in cells treated with AZT, implicating TMPK to be the rate limiting kinase in
AZT activation. Lavie et al.73 crystallised AZTMP with TMPKh. The location of dTMP and
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AZTMP in the enzyme is almost identical, which is in agreement with the kinetic data which
show a very similar Km value for dTMP and AZTMP. The enzyme-AZTMP interactions are
identical to those made with dTMP, including those with the 3’ substituent: the azido group
and the side chain of Asp14 lie in close proximity. These identical interactions are made
possible by a rigid body movement of the entire P-loop by about 0.5 Å away from the azido
group. Arg15 of the P-loop, involved in fixing the a- and b-phosphates of ATP, appears to
play an important catalytic role but is mispositioned because of steric hindrance between the
azido group of AZTMP and the carboxylic acid side chain of Asp14. So, as it is the P-loop
which binds the phosphoryl donor, its position determines the relative orientation of the donor
(ATP) and acceptor (dTMP or AZTMP) and the relative position of Arg15. Consequently, the
0.5 Å shift of the P-loop does not affect binding, as reflected in the unchanged Km values, but
rather increases the activation energy for the phosphoryl transfer step, thus lowering the rate
(200 fold in comparison to dTMP). This low phosphorylation rate of AZT by TMPK does not
only result in insufficient concentrations of the active AZTTP, but also in the accumulation of
toxic AZTMP.
TMPKec has no arginine in its P-loop motif, but rather several arginine residues in its LID
region. One or more of these arginines are predicted to assume the catalytic role assigned to
the P-loop arginine of the yeast and human enzyme. Therefore, TMPKec is less affected by
the presence of the azido group of AZTMP. Insertion of the LID domain of the bacterial
TMPK into the human enzyme (and mutation of Arg15 to Gly15 to avoid a steric clash
between this arginine and the LID region arginine) resulted in a pronounced acceptance of
AZTMP such that it gets phosphorylated even faster than TMP.74
Because AZTMP behaves as a competitive inhibitor (Ki-value of 10mM) of TMPKmt, in
contrast to the human enzyme, this feature could be exploited in the search of selective
inhibitors of TMPKmt.
4.4 HERPES TK (TKHSV)
TKhsv1 (thymidine kinase of herpes simplex virus 1) is an example of a kinase of a pathogen
whose differences with the human isozyme lead to the discovery of a series of antiviral drugs
such as aciclovir and ganciclovir.
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In contrast to the human isozyme, TKhsv not only catalyses the transfer of the g-phosphate
from ATP to the 5’-hydroxyl of deoxythymidine (dT) to form dTMP, but also phosphorylates
dTMP to dTDP. The catalysed phosphorylations of dT and dTMP have slow rates, with kcat
numbers around 5 s-1. Both reactions occur successively and the phosphoryl acceptor remains
in the binding site during the two phosphorylation steps. A superposition of the dT and dTMP
complex structures shows only small differences. The largest one occurs around position 222,
where the phosphate of dTMP pushes the backbone 1.5 Å outwards.75
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Because it has a much broader substrate specificity than the human enzyme, TKhsv
selectively helps activating antiviral drugs like aciclovir and ganciclovir to their triphosphates,
which cause chain termination of the growing DNA chains in herpes viruses.76
This broad substrate specificity of TKhsv can be rationalised the fact that thymine, even
though it is bound tightly, doesn’t fill up its binding pocket completely. In complex
TK:ADP:dTMP, thymine leaves a non-polar 35 Å void close to its C5 position. In TK:ADP:5-
iodo-dUMP, the large iodine replaces the smaller methyl group without steric hindrance and
still leaves a void of 17 Å.77,64
Selectivity is ensured through the inability of the host-cell TK to phophorylate these drugs to
an appreciable extent. These compounds can also be used in gene therapy for cancer, to
achieve selective toxicity after introduction of the viral TK gene in tumor cells. TKhsv itself
is not a direct target for antiviral therapy because the enzyme is not required for virus
replication in proliferating cells. However, viral TK activity may be required for reactivation
of the virus from latency in nerve cells so that TK inhibitors have potential use in treatment of
recurrent herpes infections.75
TMPKmt, in contrast to TKhsv, is essential for the DNA replication and survival of M.
tuberculosis. Therefore, selective inhibitors of TMPKmt hold great promise as anti-
tuberculosis drugs. In spite of the similarities between the tuberculosis and the herpes
enzyme, aciclovir and ganciclovir could never be accommodated by TMPKmt, since the 35 Å
void close to the C5 position is not present in the tuberculosis enzyme. The inhibition of
TMPKmt (in contrast to TMPKh) by AZTMP, however, indicates that the 3'-position holds
great promise for differentiating between the human and the tuberculosis enzyme.
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5 Initial Structure Activity Relationship
At the moment we became involved in this project, kinetic data for various base- and sugar-
modified dTMP analogues were already available.
5.1 BASE-MODIFICATIONS
The 5-methyl was replaced by several halogen atoms.59 All these compounds are substrates
for TMPKmt, the best one being 5-Br-dUMP with a slight increase in Km and Vm compared to
dTMP (Km = 30 mM). Substitution by a iodine (5-I-dUMP) or a fluorine (5-F-dUMP) drasti-
cally decreases the affinity for the enzyme. X-ray crystallography showed that 5I-dUMP
binds to the phosphate acceptor binding site in a very similar fashion as dTMP.
Removal of the methyl group (dUMP) affects the affinity even more (50-fold increase in
Km-value and 44% decrease in reaction rate).
Furthermore, different substitution patterns at position 2 of the pyrimidine ring were probed
and from this 5-methyl-iso-dCMP emerged as a competitive inhibitor with a Ki of 130 mM.
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5.2 SUGAR MODIFICATIONS
Substitution of the 3'-hydroxyl by an azido group (AZTMP), yielded an inhibitor with a
Ki-value of 10mM. Surprisingly, TMPKmt is the first reported TMPK (in contrast to TMPK’s
from eukaryotes and other prokaryotes) to be a competitively inhibited by AZTMP. AZTMP
is a substrate for TMPKec and TMPKy, with only a 2-fold reduction of kcat for the bacterial
enzyme and 200-fold for the yeast enzyme. In TMPKmt, the presence of an azido group
abolishes catalysis without changing the affinity. A plausible explanation for the inhibitory
effect of AZTMP could be a direct interaction between the magnesium ion and the azido
group of AZTMP. Modeling showed a distance of only 2 Å between the last nitrogen atom of
the azido group and the ion. This would displace one of the ligands of the magnesium ion and
significantly perturb the geometry of the active site. Since this ion is involved in the
positioning of several key chemical groups for the reaction, i. e. one of the phosphate oxygen
atoms and Asp9, this displacement of the magnesium ion is believed to cause the observed
inhibition of the phosphoryl transfer.59, 5
5.3 SIX-MEMBERED SUGAR RINGS
1',5'-Anhydro-2',3'-dideoxy-5'-O-phosphoryl-2'-(thymin-1-yl)-D-arabino-hexitol was tested
for its affinity for the enzyme to probe the effect of a six-membered sugar ring. It turned out
to be an inhibitor of TMPKmt with a Ki-value of 31 mM, which indicates that six-membered
sugar rings can be accepted by the substrate binding cavity.
NMP Km
 (µM) Vm
a Ki (mM)
dTMP 4.5 10.60
dUMP 2100 3.50
5-Br-dUMP 33 9.82
5-I-dUMP 140 7.46
5-F-dUMP 420 4.66
AZTMP 10
OH
O
OPO3
N N
NH2
O
2- 130
O
OPO3
OH
N
NH
O
O
2-
31
Table 2: Kinetic parameters of base and sugar modified nucleotides for TMPKmt; a Vm in
(mmole/min.mg of protein)
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6 Modeling and rational drug design
Accidental discoveries always played an important role in science, especially in the search for
new drugs. Up to the eighties, drugs were discovered, rather than developed. Meanwhile, new
scientific developments, especially in the areas of biological sciences, molecular modelling
and spectroscopy, have brought irreversible changes in the organic chemistry and drug
discovery culture. Since the fast evolving elucidation of protein structures, a new way of drug
design was introduced: structure-based ('rational') drug design. Using computer modeling and
target structures obtained through X-ray or NMR, new ligands with a higher chance of being
active can be synthesised. The structural information is used for explaining the basis of
effective inhibition and improving the potency and specificity of new lead compounds. The
complementary methods of computer-aided molecular design and combinatorial chemistry are
now routinely employed in both the lead identification and the development phases of drug
design. Examples of therapeutically used drugs developed in this way are captopril, an anti-
hypertensive Angiotensin-converting enzyme inhibitor (the first drug derived from a struc-
tural model of a protein), dorzolamide, a carbo-anhydrase inhibitor for the treatment of
glaucoma and the HIV protease inhibitors Saquinavir, Indinavir, Ritonavir, and Nelfinavir. In
the absence of a protein 3 dimensional (3D) structure, the 3D structures of certain ligands can
also be used for rational design. This approach, called pharmacophore-based drug design, has
been successfully applied the design of specifically acting integrin-receptor antagonists.78
Although it considerably increases the chance of finding effective drugs, there are some
problems that rational drug design cannot overcome today;
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§ Our incomplete understanding of intermolecular interactions which may e.g. result in
unexpected binding modes of newly synthesised compounds to the target protein. In order
to increase the predictability of these models, the force fields currently used need further
optimisation and gas-phase calculations should be replaced by calculations in an aqueous
environment. Furthermore, not only the enthalpy component of the free energy should be
considered but also the entropy component, which still remains a challenge today.
§ The potential drug may not reach the target in vivo;
§ Metabolic processes may transform the potential drug into an ineffective compound;
§ New compounds may be toxic, teratogenic, mutagenic or carcinogenic.
In this work, most of the changes of the dTMP-scaffold were chosen, inspired by the X-ray
structure of TMPK with dTMP and aimed to establish novel interactions with certain amino
acids. Modeling was mainly used to explain the affinities of the best binding ligands. For
those compounds, docking in GOLD was performed, using the AMBER force field. Although
the enzyme stays rigid in these experiments, they are a fast and easy way to get an idea of the
most likely binding modes of the nucleoside analogues. Finally, based on this most favourable
binding way, an energy minimisation was performed, allowing the ligand and the amino acids
in the active pocket to move towards the minimum energy conformation. The interactions
observed in the resulting model were then used as the basis for further inhibitor design.
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7 Objectives
TMPKmt emerged as an interesting target for the design of selective inhibitors as potential
leads for the development of a new class of anti-tuberculosis agents. Based on the X-ray
structure of TMPKmt and the known affinities of a few compounds for the enzyme,59 it was
decided to establish a preliminary SAR by synthesising a series of nucleotides modified at the
2’-, 3’- and 5-positions of the dTMP-scaffold and testing them on their affinity for TMPKmt
(Figure 11).
7.1 5-MODIFIACTIONS
Because a 5-bromine (5Br-dUMP) is well accepted by the enzyme, we envisaged some larger
substituents at the 5-position. The introduction of a furanyl or a thienyl substituent was aimed
to form a stacking interaction with Phe36. A 5-CH2OH, on the other hand, could interact with
the side chain of Arg74 (Chapter 3).
7.2 2'-MODIFICATIONS
Near the 2’-position lies Tyr103, believed to be responsible for discrimination between ribo-
and deoxy-nucleotides. By introducing a 2’-hydroxyl function on the a- or b-face of the sugar
ring, the interactions with Tyr103 were investigated. An a-directed 2'-amine could indicate if
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this positively charged substituent is capable of interacting with Tyr103 via a cation-p
interaction. 79 To sort out the influence of the size and electronegativity of 2’-substituents on
the affinity for TMPKmt, the 2’-hydroxyl function of thymidine was replaced by a fluorine.
1H-NMR studies have demonstrated a relation between the electronegativity and the size of
the 2'-substituents and the sugar puckering in a series of 2’-substituted-2’-deoxy-adenosines.80
In these studies, introduction of a fluorine increases the percentage of sugar that exhibits the
2’-exo-3’-endo-conformation, while a 2’-chloro-substitution favours the 2’-endo-3’-exo-
conformation. The latter puckering is the one adopted by the furanose of dTMP when bound
to TMPKmt. It could be expected that nucleotide-analogues that exhibit a similar S-type
conformation will have a higher affinity for TMPK, than those that have to be forced into that
configuration by the enzyme (Chapter 2).
7.3 3'-MODIFICATIONS
Due to the unique behaviour of AZTMP towards TMPKmt in comparison to other TMPKs,
particularly the 3'-position was considered to have potential for finding good and selective
inhibitors. Because AZTMP interacts through its azido group with Asp9, we intended to
establish an ionic interaction with Asp9 by introducing a 3'-amino group. A 3'-fluorine, on the
other hand, could show the effect of an electronegative substituent at that position (Chapter
3).
In the X-ray structure, a cavity near the 3'-position was observed with the potential of
accommodating larger substituents. Li de la Sierra et al.5 suggested that the azido group of
AZTMP moves the magnesium ion away from the active site, thereby abolishing catalysis.
We explored the feasibility to have a similar effect produced by a series of 3’-C-branched-
chain nucleotides (the 3’-C-azidomethyl, 3’-C-aminomethyl, 3’-C-fluoromethyl and 3’-C-hy-
droxymethyl derivatives of dTMP) (Chapter 4).
7.4 5'-MODIFICATIONS
Initially, we focused on the synthesis of phosphorylated analogues of dTMP. Indeed, one can
expect that the loss of the ionic interaction between the phosphate moiety and the enzyme will
cause an unacceptable affinity drop. Furthermore, the phosphoryl group is believed to be
important to correctly position dTMP in its binding site. By conserving the phosphate moiety
in (closely) related analogues, their binding mode is believed to mimick that of dTMP, which
renders prediction of the interactions with the enzyme easier. However, due to their inability
to enter cells, monophosphate derivatives cannot be delivered as such. Generally, nucleosides
cross the cell membrane barrier in a non-phosphorylated form and are then converted to the
corresponding nucleotides by intracellular kinases. In this particular case, where TMPK is the
drug target, a thymidine analogue could be activated by thymidine kinase (TK), which
converts the analogue into the corresponding mono-phosphorylated compound. However, a
search of the M. tuberculosis genome4 did not identify any gene coding for TK. This result
aligns with other biochemical studies indicating a lack of TK activity in mycobacteria.81
These problems make it a challenge to find a 5'-substituent, undergoing high affinity
interactions with the enzyme and not hampering the cellular uptake. As a starting point
towards this, we will not only test nucleotides but also their corresponding nucleosides to
probe the effect of the loss of the phosphoryl group on the affinity (Chapter 5).
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7.5 SIX-MEMBERED RING NUCLEOSIDES
1',5'-Anhydro-2',3'-dideoxy-5'-O-phosphoryl-2'-(thymin-1-yl)-D-arabino-hexitol proved to be
an inhibitor of TMPKmt with a Ki-value of 31 mM, indicating that six-membered sugar rings
can be accepted by the substrate binding cavity. In this nucleotide the base is oriented axially
(1C4 conformation), in contrast to dTMP, were thymine is in a more equatorial-like position.
When co-crystallised with a similar enzyme, HSV-1 TK, the sugar ring of 1',5'-anhydro-2',3'-
dideoxy-5'-O-phosphoryl-2'-(thymin-1-yl)-D-arabino-hexitol is forced in the 4C1 (base
equatorially) conformation. 82 Because this conformational change demands energy, 1-[2,4-di-
deoxy-4-C-hydroxymethyl-a-L-lyxopyranosyl]thymine, carrying thymine in an equatorial
position, seemed a very promising dTMP mimic (Chapter 7).
7.6 BIOLOGICAL EVALUATION
Via a reported spectrometric assay, 83 all compounds mentioned above were tested for their
inhibitory activity for TMPKmt and those showing the most promising activity were also
evaluated for their affinity for TMPKh.
In this spectrometric assay, the formation of nucleoside diphosphates (NDPs) is coupled to
reactions catalyzed by pyruvate kinase (PK) and lactate dehydrogenase (LDH) in the presence
of phosphoenolpyruvate (PEP) and NADH, using NADH as indicator. Each mole of
transferred phosphoryl group generates two moles NDP (sum of ADP and NDP) and
consequently two moles of NADH are oxidised to NAD+.
ADP + NDP
ATP + NTP + 2 pyruvate
2 lactate + 2 NAD+
NMPK
PK
LDH
ATP + NMP
ADP + NDP + 2 PEP
2 pyruvate + 2(NADH + H+)
Because the reactivity of various NDPs towards PK can vary a lot, the coupling system may
become rate limiting, which leads to underestimation of the phosphorylation rate. Adding
NDP-kinase (NDPK), that has a broad specificity for the phosphoryl donors and acceptors,
can circumvent this problem.
ATP + NMP
NDP + ATP
2 ADP + PEP
2 pyruvate + 2(NADH + H+)
ADP + NDP
NTP + ADP
2 ATP  + 2 pyruvate
2 lactate + 2 NAD+
TMPK
NDPK
PK
LDH
From the spectrometrically measured decrease in NADH, the phosphorylation rate can be
calculated. In case the synthesised compounds were no substrates, their inhibitory capacity
was determined. At a fixed concentration of dTMP, the decrease in phosphorylation rate was
measured, allowing to calculate the Ki-value.
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Modeling of the best binding inhibitors was then used to explain their interactions with the
enzyme and to plan the synthesis of novel ligands with potentially higher affinity.
7.7  FURTHER OPTIMISATION OF THE 3'-C-BRANCHED-CHAIN NUCLEOSIDES
Based on the above mentioned biological results and modelling, the intended purpose was to
synthesise a series of 3'-C-branched-chain nucleosides, containing larger nitrogen-containing
substituents at the 6'-position. The synthesis of a series of 2'-halogeno-3'-C-branched-chain
nucleosides was another object in view (Chapter 6-).
7.8 GENERAL OBJECTIVE
In summary, the objective of this Ph.D. study comprehends the design and synthesis of a
series thymidine and thymidine-5'-O-monophosphate analogues as selective inhibitors of
TMPKmt.
OH
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O3PO
N NH
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S O
CH2OH
N NH
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O
O
O
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Figure 11: Aimed changes of the dTMP scaffold
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A number of 2’- and 3’-modified thymidine 5’-O-monophosphate analogues were synthesised
as potential leads for new anti-mycobacterial drugs. Evaluation of their affinity for
Mycobacterium tuberculosis thymidine monophosphate kinase showed that a 2’-halogeno-
substituent and a 3’-azido function are the most favourable leads for further development of
potent inhibitors of this enzyme.
Tuberculosis (TB) is frighteningly on the rise. Once nearly vanquished by antibiotics, at least
in the developed world, tuberculosis resurged in the late 1980’s and now kills more than two
million people a year – second only to AIDS among infectious diseases.1
Mycobacterium tuberculosis, the causative agent of this disease, is primarily transmitted via
the respiratory route and mostly causes pulmonary tuberculosis. Estimates are that one third
of the world’s population is infected with this organism, but infection does not usually lead to
the active disease. Reactivation of this latent infection can be caused by immunodeficiency,
HIV-infection, use of corticosteroids, aging, alcohol and drug abuse.
TB has re-emerged as a serious public health threat worldwide because of a significant
increase in multiple-drug-resistant TB and synergism between HIV and M. tuberculosis
infection. Resolution of the current TB epidemic will require prevention of new TB infections
as well as improved methods for treating existing ones. All this has made the search for new
targets and the development of new antibiotic drugs a global emergency.
M. tuberculosis thymidine monophosphate kinase (TMPKmt), which phosphorylates dTMP to
dTDP, is believed to be an attractive potential target for chemotherapeutic intervention
because: (i) the enzyme lies at the junction of the de novo and salvage pathways for thymidine
triphosphate (dTTP) and is the last specific enzyme for its synthesis,2 (ii) in vivo studies with
the cdc8 mutant in Saccharomyces cerevisiae have demonstrated that it is essential for DNA
synthesis,3,4 and (iii) sequence comparison of TMPKmt with the human enzyme reveals only
a 22% sequence identity which should make the design of selective inhibitors possible.5
This enzyme has recently been crystallised by Li de la Sierra et al.5 Examination of its X-ray
structure (Figure 1) reveals that the main bonding forces between dTMP and the enzyme are:
(i) a stacking interaction between the pyrimidine ring and Phe70, (ii) a hydrogen bond
between O4 of thymine and the Arg74 side-chain which results in a preference for thymine
over cytosine, (iii) a hydrogen bond between Asn100 and N3 of the thymine ring, (iv) a
hydrogen bond between the 3’-hydroxyl of dTMP and the terminal carboxyl of Asp9, that in
its turn interacts with the magnesium ion that is responsible for positioning the phosphate
oxygen of TMP, and (v) hydrogen bonds and an ionic interaction between the 5’-O-phospho-
ryl group and Tyr39, Phe36, Arg95 and Mg2+ respectively.5
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The presence of Tyr103 close to the 2’-position is believed to render the enzyme catalytically
selective for 2’-deoxynucleotides versus ribo nucleotides.
Figure 1: Simplified image of the dTMP binding site of M. tuberculosis , complexed with dTMP and
SO4
2-, showing the most important amino acids interacting with dTMP. dTMP is pictured in bold, the
water molecules as red spheres and the magnesium ion as a green sphere. A sulphate ion is located at
the place normally occupied by the b -phosphate of ATP.
Considering these interactions and the available Ki and Km values of some nucleotides for
TMPKmt,6 we decided to make a series of nucleotides with modifications at the 2’- and
3’-positions of the dTMP scaffold in order to establish a preliminar structure activity
relationship (SAR), that should be directive for the further design of inhibitors of TMPKmt.
3’-Azido-3’-deoxythymidine 5’-O-monophosphate (AZTMP) was the best known inhibitor so
far with a Ki value of 10 mM.6 Remarkably, the presence of the 3’-azido group totally
abolishes its conversion by TMPKmt without significantly altering the affinity in comparison
to dTMP. We assume that the azide moiety interacts directly with Asp9 and displaces the
magnesium ion, which seriously disturbs the geometry of the active site.5 To probe the effect
of an amino group at the 3’-position, AZTMP was reduced to 3’-amino-3’-deoxythymidine
5’-O-monophosphate (1). The corresponding ribo-analogue 8, was synthesised to examine the
capability of Tyr103 to discriminate between ribo- and deoxy nucleotides. Introduction of an
amino group at the 2’-position in 9, on the other hand, could indicate if the positively charged
nitrogen is able to interact with Tyr103 by a cation-p  interaction.
To sort out the influence of the size and the electronegativity of 2’- and 3’-groups on the
affinity for TMPKmt, a fluorine (13) and a chlorine (12) were introduced at C-2’, and the
3’-hydroxyl was replaced by a fluorine (20). 1H-NMR studies have demonstrated a relation
between the electronegativity and the size of the substituents and the sugar puckering in a
series of 2’-substituted-2’-deoxyadenosines.7 Introduction of a fluorine increased the
percentage of sugar that exhibits the 2’-exo-3’-endo conformation, while a 2’-chloro
substitution favoured the 2’-endo-3’-exo conformation. The latter puckering is the one
adopted by the sugar part of dTMP when bound to TMPKmt. It could be expected that
nucleotide analogues that exhibit a similar S-type conformation would have a higher affinity
for TMPKmt, than those that have to be forced into that configuration by the enzyme.
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The synthetic methods used to prepare the desired dTMP analogues are outlined into Schemes
1 and 2. All phosphorylation steps were performed using the procedure of Yoshikawa et al.,8
i.e. treatment with POCl3 (3 eq.) in (MeO)3PO. The obtained compounds were purified by
column chromatography (iPrOH/ NH4OH/H2O : 77.5/15/2.5®60/30/5), followed by HPLC
(C-18, CH3CN/MeOH/0.05% HCOOH in H2O : 45/45/10, 3 mL/min).
1-(3’-Azido-3’-deoxy-b-D-ribofuranosyl)thymine (4) was prepared by Vorbrüggen coupling9
of sugar synthon 210 with 5-methyl-2,4-bis [(trimethylsilyl)oxy]pyrimidine followed by
alkaline deprotection, while its 2’-azido isomer 5 was obtained via opening of 2,2’-anhydro-
thymidine (3) with NaN3 in DMF according to the method of Verheyden. 11 Azidonucleosides
4 and 5 were converted to the corresponding amino nucleoside monophosphates 8 and 9 by
sequential 5’-O-phosphorylation and reduction of the azido group with Ph3P and NH4OH.12
Compound 3 also served as synthon for the preparation of 2’-chlorothymidine13 (10) and
2’-fluorothymidine (11). For the synthesis of the latter, 3 was treated with 3,4-dihydropyran in
DMF, followed by saponification to yield its 3’,5’-bisprotected arabinosyl derivative.
Fluorination with DAST, followed by deprotection with p-toluenesulfonic acid in MeOH,
afforded 11.14 Nucleosides 10 and 11 were converted to their monophosphates 12 and 13 in
53% and 55 % yield, respectively (Scheme 1).
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Scheme 1: Synthetic pathways of nucleotides 8, 9, 12 and 13. Reagents and conditions: (a) 5-methyl-
2,4-bis[(trimethylsilyl)oxy]pyrimidine, (CH3)3SiOSO2CF3, Cl2(CH2)2; (b) NH3, MeOH; (c) NaN3,
DMF; (d) HCl, dioxane; (e) 3,4-dihydropyran, p-toluenesulfonic acid, DMF; (f) 1N NaOH, MeOH; (g)
DAST, CH2Cl2, pyridine; (h) p-toluenesulfonic acid, MeOH; (i) POCl3, (MeO)3PO; (j) Ph3P, NH4OH,
pyridine.
3’-Deoxy-3’-fluorothymidine (19) was synthesised from 5’-O-tritylthymidine (14), using the
method of von Janta-Lipinski. 15 In our hands, treatment of the intermediate 3’-mesyl ester of
14 with NaOH in ethanol resulted in the formation of four reaction products: the desired SN2
product 18 (17% yield), as well as the 5’-O-tritylethers of 3’-O-ethylthymidine (16, 26 %),
3’-deoxy-2’,3’-didehydrothymidine (15, 12 %) and 2,3’-anhydrothymidine (17, 33 %). 18
was then converted into 19 via treatment with DAST16 and subsequent detritylation, and
phosphorylation of 19 to give 20 (Scheme 2).
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Scheme 2: Synthetic pathway of nucleotide 20. Reagents and conditions: (a) MsCl, pyridine; (b)
NaOH, EtOH; (c) DAST, CH2Cl2, pyridine; (d) CH3COOH, H2O, 90°C; (e) POCl3, (MeO)3PO.
All compounds were tested with the reported spectrophotometric assay. 17 The results are
given in Table 1.
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Compounds R1 R2 R3 Km (µM) Vm
a Ki (µM)
dTMP CH3 H OH 4.5 10.6
dUMP6 H H OH 2100 3.5
5F-dUMP6 F H OH 420 4.7
5Br-dUMP6 Br H OH 33 9.8
5I-dUMP6 I H OH 140 7.5
AZTMP6 CH3 H N3 10
1 CH3 H NH2 235
8 CH3 OH NH2 45
9 CH3 NH2 OH 120
12 CH3 Cl OH 19
13 CH3 F OH 43
D4T-MP CH3 dehydro dehydro 140 0.16
20 CH3 H F 30 0.11
Table 1: Kinetic parameters of TMPKmt with various nucleoside monophosphates.
a Vm in mmole/min.mg of protein
The Ki value of 1 increases 20-fold compared to AZTMP. This strongly suggests that the
3’-amino group doesn’t succeed in interacting with Asp9 in contrast to AZTMP. To our
surprise the ribo-analogue 8 shows good affinity (45 mM) for TMPKmt. A modeling
experiment was suggestive for an interaction between the 3’-amino group and the carboxyl
function of Asp9. According to the model, Tyr103, believed to discriminate between deoxy-
and ribo nucleotides, remained further away from the C-2’ compared to the X-ray structure of
TMPKmt with dTMP. Analogue 8 represents a first example of a ribo-nucleotide with good
affinity for TMPKmt. The higher Ki value of 2’-amino dTMP (9) suggests that the positively
charged nitrogen is not capable of interacting favourably with Tyr103 or Asp9. The
monophosphate of d4T (D4TMP) behaves as substrate for TMPKmt, although its Km-value is
30 times larger than that of the natural substrate.
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The introduction of halogens at the 2’-position appears to be better tolerated than a hydroxyl
group at that position. 12 exhibits appreciable affinity with a Ki value of 19 mM. Changing the
chlorine of 12 for a fluorine (13) leads to a 2-fold affinity drop. A modeling experiment of 12
(results not shown) showed that introduction of the chlorine affects the relative position of the
sugar ring. As a result, the 2’-chlorine occupies the pocket where normally the 3’-hydroxyl
group resides. Indeed, the 3’-analogues indicate that this particular domain can accommodate
larger substituents. The somewhat lower affinity of the 2’-fluoro nucleotide could be due to
the fact that the smaller and more electronegative fluorine is not able to fill up that cavity,
perhaps as a result of a different preferential sugar pucker.
Replacement of the 3’-OH of dTMP by a 3’-F in 20 affords an analogue that behaves as a
substrate with a Km of 30 mM.
In conclusion, only a few dTMP analogues, i.e. the 5-halogeno derivatives, d4T-MP, dUMP
and 3’-deoxy-3’-fluorothymidine 5’-O-monophosphate (20), remain substrates for TMPKmt,
while other modifications lead up to competitive inhibitors. The introduction of a bromine,
the best known 5-modification so far, doesn’t drastically lower the affinity in comparison to
dTMP.
Among the tested analogues in the ribo configuration (8, 9, 12, 13), the best inhibition is
obtained by the introduction of a 2’-chlorine and the replacement of the 3’-OH by an azido
group. From these results it seems interesting to combine a 2’-chlorine and 3’-azido group
and to explore other substitution patterns at the 3’-position. Because modeling experiments
show that there’s a lot of space at the 3’-position, introduction of larger nitrogen containing
compounds that could interact with Asp9 will be the basis for further development of more
potent ligands.
Experimental section
NMR spectra were obtained with Varian Mercury 300 and 500 spectrometers. Chemical shifts
are given in ppm (d) relative to residual solvent peak of DMSO-d6 (2.5 ppm). All signals
assigned to amino and hydroxyl groups were exchangeable with D2O. Mass spectra and exact
mass measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight
(Q/oaTOF) tandem mass spectrometer (qTof 2, Micromass, Manchester, UK) equipped with a
standard electrospray ionisation (ESI) interface. Samples were infused in a 2-propanol:water
(1:1) mixture at 3 µL/min. Precoated Merck silica gel F254 plates were used for TLC and spots
were examined under UV light at 254 nm and revealed by sulfuric acid-anisaldehyde spray.
Column chromatography was performed on Uetikon silica (0.2-0.06 mm). Anhydrous
solvents were purchased from Acros Organics.
General procedure for the selective phosphorylation of the 5’-hydroxylgroup
A solution of the nucleoside (0.42 mmol) in trimethyl phosphate (4 mL) was cooled to 0° C,
POCl3 (0.25 mL, 2.70 mmol) was added dropwise and the mixture was stirred for 5 h at 0° C
and for 30 min at room temperature. The mixture was poured into ice-water (10 mL),
neutralised with concentrated NH4OH and evaporated to dryness. The resulting residue was
purified by column chromatography (iPrOH-NH4OH-H2O 77.5:15:2.5®60:30:5). Further
purification of the white powder by HPLC (C-18, CH3CN-MeOH-0.05% HCOOH in H2O
45:45:10, 3 mL/min) and lyophilisation of the fractions containing the formed nucleotide,
provided it as a white powder.
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1-(3-Amino-3-deoxy-5-O-phosphoryl-b -D-ribofuranosyl)thymine (8)
1-(3-Azido-3-deoxy-b-D-ribofuranosyl)thymine18 was phosphorylated according to the gene-
ral procedure described above in a 48 % yield. The obtained nucleotide 6 (145 mg,
0.40 mmol) and triphenylphosphine (230 mg, 1.22 mmol) were then dissolved in pyridine
(6 mL) and stirred at room temperature. After 1h, concentrated NH4OH (4 mL) was added and
the solution was allowed to stir for an additional 6.5 h. Pyridine was removed under reduced
pressure, water (20 mL) was added and the unreacted triphenylphosphine and triphenylphos-
phine oxide were removed by filtration. The filtrate was extracted with toluene and the water
layer was evaporated under reduced pressure to give a syrup. The syrup was purified via
column chromatography (iPrOH-NH4OH-H2O 77.5:15:2.5®60:30:5). Further purification of
the white powder by HPLC (C-18, CH3CN-MeOH-0.05% HCOOH in H2O 45:45:10,
3 mL/min) and lyophilisation of the fractions containing the formed nucleotide, yielded 8
(101 mg, 71 %) as a white powder. 1H-NMR: (300 MHz, D2O) d 1.75 (3 H, d, 5-CH3), 3.82
(1H, t, H-3’), 3.93 (2H, dd, H-5’), 4.27 (1H, dt, H-4’), 4.49 (1H, dd, J = 3.6 and 6.3 Hz, H-2’),
5.77 (1H, dd, J = 3.6 Hz, H-1’), 7.58 (1H, d, J = 1.2 Hz, H-6); 13C-NMR: (125 MHz, D2O)
d 14.21 (5-CH3), 54.20 (C-3’), 65.72 (C-5’, 2JC, P = 3.9 Hz), 75.10 (C-2’), 82.84 (C-4’,
3JC, P = 6.8 Hz), 95.35 (C-1’), 114.29 (C-5), 140.19 (C-6), 154.30 (C-2), 169.19 (C-4);
31P-NMR: (500 MHz, D2O) d 3.40; HRMS (ESI-MS) for C10H17N3O8P [M+H]+: found
338.0745; calcd, 338.0753.
1-(2-Amino-2-deoxy-5-O-phosphoryl-b -D-ribofuranosyl)thymine (9)
2’-Azido-2’-deoxythymidine11 (5) was phosphorylated according to the general procedure
described above in a 56 % yield. The obtained nucleotide 7 (201 mg, 0.51 mmol) and
triphenylphosphine (410 mg, 1.56 mmol) were dissolved in pyridine (8 mL) and stirred at
room temperature. After 1h, concentrated NH4OH (5 mL) was added and the solution was
allowed to stir for an additional 4 h. Pyridine was removed at reduced pressure, water (20 mL)
was added and the unreacted triphenylphosphine and triphenylphosphine oxide were removed
by filtration. The filtrate was extracted with toluene and the water layer was evaporated under
reduced pressure to give a syrup. The resulting syrup was purified by column chromatography
(iPrOH-NH4OH-H2O 77.5:15:2.5®60:30:5). Further purification of the white powder by
HPLC (C-18, CH3CN-MeOH-0.05% HCOOH in H2O 45:45:10, 3 mL/min) and lyophilisation
of the fractions containing the formed nucleotide yielded 9 (101 mg, 71 %) as a white powder.
1H-NMR: (300 MHz, D2O) d 1.77 (3 H, s, 5-CH3), 3.84 (3H, m, H-2’ and H-5’), 4.20 and
4.39 (2H, br s and app. d, H3’ and H-4’), 6.06 (1H, d, J = 8.4 Hz, H-1’), 7.68 (1H, s, H-6);
13C-NMR: (125 MHz, D2O) d 14.28 (5-CH3), 58.88 (C-2’), 66.81 (C-5’, 2JC, P = 3.9 Hz),
73.32 (C-3’), 88.43 (C-4’, 3JC, P = 7.8 Hz), 88.88 (C-1’), 114.93 (C-5), 139.54 (C-6), 154.81
(C-2), 169.08 (C-4); 31P-NMR: (500 MHz, D2O) d 2.83; HRMS (ESI-MS) for C10H17N3O8P
[M+H]+: found 338.0750; calcd, 338.0753.
1-(2’-Chloro-2’-deoxy-b -D-ribofuranosyl)thymine (10)13
An ice-cooled suspension of 2,2'-anhydrothymidine13 (340 mg, 1.41 mmol) in dry dioxane
(20 mL) was saturated with anhydrous hydrogen chloride. The mixture was heated in a glass
cylinder at 75-80° C for 24 h. After cooling, the yellow solution was concentrated and the
obtained residue purified by column chromatography (CH2Cl2-MeOH 99:1®97:3), yielding
10 (195 mg, 50%) as a white foam. 1H-NMR: (300 MHz, DMSO-d6) d 1.78 (3 H, s, 5-CH3),
3.57-3.70 (2H, m, H-5’), 3.93 (1H, app. q, H-4’), 4.21 (1H, dd, H-3’), 4.55 (1H, t, H-2’), 5.23
(1H, t, J = 5.1 Hz, 5’-OH), 5.84 (1H, d, J = 5.5 Hz, 3’-OH), 6.03 (1H, d, J = 6.3 Hz, H-1’),
7.78 (1H, d, J = 1.1 Hz, 6-H); HRMS (ESI-MS) for C10H13ClN2O5Na [M+Na]+: found
299.0443; calcd, 299.0410.
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1-(2’-Chloro-2’-deoxy-5’-O-phosphoryl-b -D-ribofuranosyl)thymine (12)
10 (116 mg, 0.42 mmol) was phosphorylated according to the general procedure described
above yielding 12 (78.94 mg, 53 %) as a white powder. 1H-NMR: (300 MHz, D2O ) d 1.93
(3 H, s, 5-CH3), 4.00-4.22 (2H, m, H-5’), 4.39 (1H, m, H-4’), 4.54 (1H, t, H-3’), 4.66 (1H, t,
H-2’), 6.20 (1H, d, J = 6.0 Hz, H-1’), 7.82 (1H, d, J = 1.0 Hz, H-6); 31P-NMR: (500 MHz,
D2O) d 0.88 ppm; HRMS (ESI-MS) for C10H14ClN2O8PNa [M+Na]+: found 379.0112; calcd,
379.0112.
1-(2’-Deoxy-2’-fluoro-b -D-ribofuranosyl)thymine (11)14
To a suspension of 2,2'-anhydrothymidine13 (880 mg, 3.46 mmol) in DMF (15 mL) and
3,4-dihydro-2H-pyran (8.8 mL, 96.45 mmol) was added p-toluenesulfonic acid (683 mg,
3.59 mmol) at 0° C for 4 h, at which time a clear solution was obtained. This was neutralised
with Et3N (1.5 mL) and concentrated. The residue was dissolved in EtOAc, washed with
saturated NaHCO3 and dried over MgSO4. Removal of the solvent gave a residue which was
triturated with hexane. The solid cake was collected and washed with hexane to give 1-[2,2'-
anhydro-3-O-5-O-di(tetrahydro-2H-pyran-2-yl)-b-D-arabinofuranosyl]thymine as a white so-
lid. This was dissolved in MeOH (11 mL) and 1 N NaOH (11 mL) and was stirred at room
temperature for 2 h. The solution was then neutralised with diluted acetic acid. The mixture
was evaporated to dryness and the residue was purified by column chromatography (EtOAc)
to give 1-[3-O-5-O-di(tetrahydro-2H-pyran-2-yl)-b-D-arabinofuranosyl]thymine (750 mg,
51 %) as a white solid. To a stirred mixture of the aforementioned nucleoside (750 mg,
1.76 mmol) in CH2Cl2 (10 mL) and pyridine (2 mL), cooled at -60°C under a nitrogen atmo-
sphere, was added DAST (0.72 mL, 5.46 mmol). The resulting mixture was slowly warmed to
room temperature and then refluxed for 4 h. The reaction was quenched with aqueous
saturated NaHCO3 and ice-water, extracted with CH2Cl2 (3 x 10 mL) and dried (MgSO4).
Removal of the solvent yielded crude 1-(2-deoxy-3,5-O-di(tetrahydro-2H-pyran-2-yl)-2-
fluoro-b-D-ribofuranosyl)thymine as a dark-brown syrup. This was dissolved in MeOH
(10 mL) and treated with p-toluenesulfonic acid (420 mg, 2.21 mmol) at room temperature for
3 h. The mixture was then neutralised with Et3N (7 mL) and evaporated under reduced
pressure. The obtained residue was purified by column chromatography (CH2Cl2-MeOH, 97:3
® 95:5) to yield 11(270 mg, 59 %) as a white foam.1H-NMR: (300 MHz, DMSO-d6) d 1.76
(3 H, s, 5-CH3), 3.57-3.79 (2H, m, H-5’), 3.86 (1H, m, H-4’), 4.17 (1H, m, J3’-H, F = 20.2 Hz,
3’-H), 5.03 (1H, ddd, JH-2’, F = 53.2 Hz, 2’-H), 5.24 (1H, t, J = 4.8 Hz, 5’-OH), 5.61 (1H, d,
J = 6.3 Hz, 3’-OH), 5.91 (1H, dd, JH-1’, H-2’ = 2.3 Hz, JH-1’, F = 17.6 Hz, H-1’), 7.62 (1H, d,
J = 1.2 Hz, 6-H); 19F-NMR: (300 MHz, D2O) d -203.08; HRMS (ESI-MS) for
C10H13FN2O5Na [M+Na]+: found 283.0733; calcd, 283.0706.
1-(2’-Deoxy-2’-fluoro-5’-O-phosphoryl-b -D-ribofuranosyl)thymine (13)
11 was phosphorylated according to the general procedure affording 13 (65.16 mg, 48 %) as a
white powder. 1H-NMR: (300 MHz, D2O) d 1.92 (3 H, s, 5-CH3), 4.07 (1H, m, H-5'A), 4.23
(1H, m, H-5'B), 4.27 (1H, app. d, H-4’), 4.49 (1H, ddd, JH-3,’ F = 19.9 Hz, H-3’), 5.14-5.25
(1H, ddd, JH-2’, F = 52,5 Hz, H-2’), 6.06 (1H, dd, JH-1’, H-2’= 7.9 Hz, JH-1’, F = 18.1 Hz, H-1’),
7.76 (1H, d, JH-6, 5-CH3 = 1.2 Hz, H-6) ppm; 13C-NMR: (125 MHz, D2O) d 14.19 (5-CH3),
65.60 (C-5’, 2JC, P = 3.9 Hz), 70.52 (C-3’, 2JC, F = 15.6 Hz), 84.30 ( C-4’, 3JC, P = 9.8 Hz),
90.76 (C-1’, 2JC, F = 35.1Hz), 95.91 (C-2’, 1JC, F = 185.6 Hz), 114.17 (C-5), 140.08 (C-6);
19F-NMR: (300 MHz, D2O) d -203.63 ppm; 31P-NMR: (500 MHz, D2O) d 1.22; HRMS
(ESI-MS) for C10H14FN2O8P [M+H]+: found 341.0576; calcd, 341.0549.
67
1-(2’-Deoxy-5’-O-trityl-b -D-threo-pentofuranosyl)thymine (18)
To an ice-cooled solution of 1415 (1.45 g, 3.39 mmol) in pyridine (15 mL), was added
methanesulfonyl chloride (0.70 mL, 8.75 mmol). The reaction mixture was kept overnight at
room temperature. Water (0.5 mL) was added and the solution was poured into vigorously
stirring ice-water (540 mL). The resulting amorphous precipitate was collected by filtration,
washed with water and coevaporated with EtOH to yield pure 1-(2’-deoxy-3’-O-metha-
nesulfonyl-5’-O-trityl-b-D-erythro-pentofuranosyl)thymine, which was immediately used in
the next step without further purification. It was dissolved in EtOH (25 mL) and heated at
reflux. Sodium hydroxide (156 mg, 3.9 mmol) was added, and refluxing was continued for
1.5 h. After cooling to room temperature, the reaction mixture was concentrated to 10 mL and
poured into water (250 mL). The turbid solution was extracted with CHCl3 (2 x 150 mL). The
combined organic layers were dried over MgSO4, filtered and evaporated. The resulting
residue was purified by column chromatography (CHCl3-MeOH-Et3N, 99:1:0.1) yielding 18
(279 mg, 17 %) as a foam. Apart from the expected 18, three other products were formed.
These were isolated and characterised as 1-(2’-deoxy-3'-O-ethtyl-5’-O-trityl-b-D-threo-
pentofuranosyl)thymine (16) (452 mg, 26 %), 3'-deoxy-2',3'-didehydro-5'-O-tritylthymidine
(15) (189 mg, 12 %) and 2,3'-anhydro-5'-O-tritylthymidine (17) (522 mg, 33 %). 18 1H-NMR:
(300 MHz, DMSO-d6) d 1.66 (3 H, s, 5-CH3), 1.86 (1H, app d, H-2’), 2.54 (1H, m, H-2’),
3.19-3.34 (2H, m, H-5’), 4.11 (1H, m, H-4’), 4.22 (1H, m, H-3’), 5.22 (1H, br. s, 3’-OH), 6.14
(1H, app. d, J = 8.0 Hz, H-1’), 7.25-7.45 (15 H, m, CPh3), 7.61 (1H, br. s, 6-H); MS (ES,
iPrOH/H2O): m/z (%) 507.1 ([M+Na]+, 100); 17 1H-NMR: (300 MHz, DMSO-d6) d 1.79 (3H,
s, 5-CH3), 2.43-2.61 (2H, m, H-2’), 3.09-3.16 (2H, m, H-5’), 4.47 (1H, m, H-4’), 5.33 (1H, br.
s, H-3’), 5.90 (1H, d, J = 3.3 Hz, H-1’), 7.20-7.40 (15H, m, CPh3), 7.64 (1H, s, H-6) ppm;
MS(ES, iPrOH/H2O): m/z (%) 467.2 ([M+H]+, 100); 15 1H-NMR: (300 MHz, DMSO-d6)
d 1.24 (3H, s, 5-CH3), 3.19 (2H, m, H-5’), 4.97 (1H, br. s, H-4’), 6.03 and 6.54 (2H, 2d, H-2’
and H-3’), 6.85 (1H, t, J = 1.6 Hz, H-1’), 7.24-7.38 (15H, m, Ph3C); MS(ES, iPrOH/H2O):
m/z (%) 489.1 ([M+Na]+, 100); 16 1H-NMR: (300 MHz, DMSO-d6) d 1.33 (3H, t,
J = 7.06 Hz, OCH2CH3), 1.67 (3H, s, 5-CH3), 1.95 (1H, d), 2.57 (1H, m, H-2’A and H-2’B),
3.20-3.44 (4H, m, H-3’, H-4’ and H-5’), 4.36 (2H, q, CH2CH3), 6.10 (1H, dd, J = 1.6 and
7.9 Hz, H-1’), 7.25-7.36 (15H, m, Ph3C), 7.44 (1H, s, 6-H); MS(ES, iPrOH/H2O): m/z (%)
513.2 ([M+H]+, 100). Treatment of 17 (460 mg, 0.95 mmol) with a mixture of NaOH 1 N
(7 mL), MeOH (12 mL) and dioxane (15 mL) at room temperature during 2 h, followed by
neutralisation with diluted acetic acid, evaporation en column chromatography (EtOAc,
100 %) yielded 18 (377 mg, 82 %).
3'-Deoxy-3'-fluorothymidine (19)
A solution of 18 (480 mg, 0.99 mmol) in dichloromethane (10 mL) was treated with DAST
(0.23 mL, 1.73 mmol) and the reaction mixture was stirred at room temperature for 3h. The
mixture was diluted with chloroform (30 mL) and extracted with saturated aqueous NaHCO3
(40 mL). The organic layer was dried over MgSO4, evaporated and the obtained residue was
purified by column chromatography (CHCl3-MeOH-Et3N 99:1:0.1) yielding 3'-deoxy-3'-fluo-
ro-5'-O-tritylthymidine (130 mg, 27 %) as a white foam. This foam (120 mg, 0.25 mmol) was
treated with aqueous acetic acid (80%, 10 mL) and was heated at 90° C for 15 min. After
cooling, the solvent was removed under reduced pressure, and the residue purified by column
chromatography (CH2Cl2-MeOH, 98:2) yielding 19 (24.11 mg, 40 %) as a white foam.
1H-NMR: (300 MHz, DMSO-d6) d 1.78 (3 H, s, 5-CH3), 2.21-2.45 (2H, m, H-2’), 2.55-2.67
(1H, m, H-5’), 4.13 and 4.17 (1H, dt, JH-4’, F = 27.8 Hz, H-4’), 5.23 (1H, under signal 3’-H,
5’-OH), 5.24 and 5.36 (1H, app. dd, JH-3’, F = 53.9 Hz, H-3’), 6.22 (1H, dd, JH-1’, H-2’ = 5.5 Hz
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and 9.3 Hz, H-1’), 7.72 (1H, br. s, 6-H); HRMS (ESI-MS) for C10H13FN2O4Na [M+Na]+:
found 267.0770; calcd, 267.0757.
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Abstract
The chemical synthesis of new compounds designed as inhibitors of M. tuberculosis thymidine
monophosphate kinase (TMPK) is reported. The synthesis concerns dTMP analogues
modified at the 5-position of the thymine ring, as well as a novel compound with a six-
membered sugar ring. The binding properties of the analogues are compared with the known
inhibitor AZTMP, which is postulated here to work by excluding the dTMP-bound magne-
sium-ion. The crystallographic structure of the complex of one of the compounds, 5-CH2OH-
dUMP, with TMPK has been determined at 2.0 Å. It reveals a major conformation for the
hydroxyl group in contact with a water molecule and a minor conformation pointing towards
Ser99. Looking for a role for Ser99, we have identified an unusual catalytic triad, or a proton
wire, made of strictly conserved residues (including Glu6, Ser99, Arg95 and Asp9), that
probably serves to protonate the transferred PO32- group. The crystallographic structure of
the commercially available bisubstrate analog Ap5T bound to TMPK is also reported at
2.45 Å and reveals an alternative binding pocket for the adenine moiety of the molecule,
compared with what is observed either in the E. coli or the yeast enzyme structures. This
alternative binding pocket opens a way for the design of a new family of specific inhibitors.
Introduction
The incidence of tuberculosis (TB) has been increasing during the last twenty years; it is now
the first cause of mortality among infectious diseases in the world.1 The combination of four
active drugs (rifampicin, isoniazid, pyrazinamide and ethambutol or streptomycin) is currently
used in Mycobacterium tuberculosis treatment but this has led to the appearance of resistant
bacterial strains.2 These resistant strains are alarming for two reasons. First, as there are only
few effective drugs available, infection with drug-resistant strains could give rise to a
potentially untreatable form of the disease. Second, although only 5% of immunocompetent
people infected with M. tuberculosis succumb to the disease, it is nevertheless highly conta-
gious.3 Therefore, a large effort is necessary to identify potential new targets and inhibitors.
An attractive potential target is thymidylate kinase (EC. 2.7.4.9; ATP: dTMP phosphotransfe-
rase; TMPK)1, an essential enzyme that catalyses an obligatory step in the synthesis of
thymidine triphosphate (dTTP) either from thymidine via thymidine kinase (salvage pathway)
or from dUMP via thymidylate synthase in all living cells.4 This enzyme phosphorylates
thymidine monophosphate (dTMP) into thymidine diphosphate (dTDP), using ATP as the
preferred phosphoryl donor.
In the case of the herpes simplex virus (HSV), the most successful antiviral drug (acyclovir)
available on the market is directed against thymidine kinase (TK). Acyclovir is phosphoryla-
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ted by several viral or host kinases into acyclovir triphosphate, which terminates DNA
synthesis when incorporated into the viral DNA. 5,6 The comparative X-ray structures of diffe-
rent enzyme/ligands complexes of HSV-1 thymidine kinase7,8,9,10 revealed a number of inte-
resting structural features and paved the way for rational structure-based drug design of
antiviral compounds.11,12 A similar approach might lead to potent anti-tuberculosis agents.
TMPK from M. tuberculosis is a homodimer with 214 amino acids per monomer.13 The X-ray
three-dimensional structure has been recently solved at 1.95 Å resolution14,15 as a complex
with dTMP, thereby making it possible to initiate structure-based drug design studies. The
global folding of the protein is similar to that of the other TMPKs and NMPKs despite the
low similarity of their amino-acid sequences. The TMPK backbone is characterised by nine
solvent-exposed a-helices surrounding a central b-sheet made of five b-strands, typical of the
so-called Rossmann-fold.16,17,18,19,20 However, the dimerisation mode of the M. tuberculosis
enzyme differs from that reported in the yeast, human and E. coli enzymes.15
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Figure 1: Chemical structure of synthesised dTMP analogues.
The active site of M. tuberculosis TMPK complexed with dTMP differs from the other known
TMPKs in the following ways.15 It is in a fully closed conformation, with the ATP binding
site being already preformed and the LID region well ordered into an a-helical conformation,
even though the second substrate ATP (or non-hydrolysable ATP) is absent from the
structure. In the dTMP binding site, the protein-dTMP interaction shows three specific
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features when compared to yeast, human or E. coli enzyme structures. The first feature
involves both a magnesium ion and Tyr39; they interact with two opposite non-bridging
oxygens of the phosphate moiety of dTMP. The second feature involves Asn100 in contact
with atom N3 of the base moiety.15 The third feature, perhaps more amenable to the design of
new inhibitors, is the interaction of the 3’-OH atom of dTMP with both the side chain of Asp9
and a water molecule, W9, which is a ligand of the Mg++ ion. In addition, there is a high
concentration of positively charged side chains both from the LID region and from the P-loop,
with arginine residues 14, 95, 149, and 160 as well as Lys13.15 Examination of the structure
therefore suggested the following targets for species-specific inhibitors.
Target 1. The 3’-OH and 2’-OH groups of the ribose ring could be systematically replaced
with different chemical groups; this has been recently reported.21
Target 2. The 5-position of the thymine ring is another possibility, which has also been
considered in the past for HSV thymidine kinase inhibitors.11,12 Preliminary results of
compounds modified at this position have already been reported.13 Here we report results on
other compounds, with the aim of adding an extra hydrogen bond with water molecule W12
detected in the three-dimensional structure. W12 is located close to Pro37 (which is in a cis
conformation) and forms hydrogen bonds with residues building up the thymidine binding
cavity, such as Phe70, Asp73 and Arg74.
Target 3. The 2-position of the thymine ring could also be explored and preliminary but
encouraging results have been reported for one compound modified at this position.13 The aim
here is to replace the inserted (space filling) water molecules W2 and W3 which, if removed,
give rise to a well defined cavity that can be readily materialised with computer programs
such as VOIDOO.22
In this study we have synthesised five dTMP analogues (1-5, Figure 1), modified at the
thymine moiety and focused on target 2. In addition, one member of a new class of nucleotide
analogues has been tested,23,24 namely a 1-5 anhydrohexitol analog 6 of dTMP, where the
3’-OH and/or of the 5’-O-phosphate positions are expected to depend on the sugar conforma-
tion. The inhibitiory effect of these dTMP analogues has been measured in vitro by a novel
direct specific enzymatic activity test using HPLC and compared to the reference compound
AZTMP, which is a good inhibitor.13
All compounds have been subjected to co-crystallisation experiments as well as soaking
experiments for exchange with dTMP in dTMP-TMPK crystals (M. tuberculosis TMPK does
not crystallise in the absence of dTMP). We solved the structure of one promising enzyme-
inhibitor complex by X-ray diffraction and have determined the rearrangement of side chains
in the active site and the concomitant modification of the water molecules network around the
thymine moiety of the dTMP substrate. In addition, we have co-crystallised and solved the
structure of the complex between TMPK and the bisubstrate analogue Ap5T.
Altogether, considerable new insight into the possible mechanism of phosphoryl transfer has
been gained, as described at the end of the discussion.
Experimental procedures
Protein and reagents
The M. tuberculosis TMPK was overexpressed in E. coli and purified as described previous-
ly.13 The protein was stored at -20 °C in aliquots of 100 µL at 4 mg/ml in a buffer containing
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20 mM Tris-HCl pH 7.5, 0.5 mM dithiothreitol and 1 mM EDTA, conditions at which it is
stable over several months. Ap5T was purchased from Jena Bioscience (Germany). All other
reagents used were purchased from Sigmaâ (St. Louis), including the reference inhibitor
AZTMP. All solutions were made with pyrolyzed water.
Inhibitors synthesis
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Scheme 1: Reagents and conditions: (a) 5-benzyloxymethyl-2,4-bis[(trimethylsilyl)oxy]pyrimidine,
CH3CN; (b) NH3, MeOH; (c) POCl3, (MeO)3PO.
Several methods have already been reported for the synthesis of 5-hydroxymethyl-2’-deoxy-
uridine. We found that hydroxymethylation of 2’-deoxyuridine with formaldehyde under
acidic25 or basic 26 catalysis gave only low yields. Therefore, we decided to couple 5-benzyl-
oxymethyluracil with an appropriate sugar. In Ref. 27, the base is coupled with 1,2,3,5-tetra-
acetylribose.27 Since this method requires subsequent 2’-deoxygenation, we chose to
glycosylate the silylated base with 2-deoxy-3,5-O-di-toluoyl-a-D-eryhtro-pentafuranosylchlo-
ride.28 Unfortunately racemisation of the sugar prior to coupling led to a hardly separable
mixture of the a- and b-anomers of the protected nucleoside. After alkaline removal of the
acyl groups, however, the anomeric mixture could be separated via column chromatography
to give the a- en b-anomers 10 and 11 as white foams. Both isomers were then
phosphorylated. We noticed that the 5-O-benzyl group got partly removed during this step.
Thus phosphorylation of the b-nucleoside gave three compounds: 2’-deoxy-5-hydroxymethyl-
5’-O-phosphoryluridine (1), its benzyl-protected analogue (2) and 2’-deoxy-5-hydroxy-
methyluridine (12). Phosphorylation of the a-nucleoside gave the corresponding benzylated
and non-benzylated nucleotides 13 and 3 (Scheme 1).
2’-Deoxy-5-(furan-2-yl)uridine (15) and 2’-deoxy-5-(thien-2-yl)uridine (16) were synthesised
according to a published procedure from unprotected 2’-deoxy-5-iodouridine (14).29 Phospho-
rylation of these two nucleosides yielded the two desired 5-hetero-aryl substituted nucleotides
4 and 5 (Scheme 2).
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Scheme 2: Reagents and conditions: (a) 2-(tributylstannyl)furan, (Ph3P)2Pd(II)Cl2, dioxane or 2-(tri-
butylstannyl)thiophene, Pd(OAc)2, Ph3P, Et3N, dioxane, (b) POCl3, (MeO)3PO
Synthesis
General
NMR spectra were obtained with a Varian Mercury 300 or 500 spectrometer using the solvent
signal of DMSO-d6 as a secondary reference. All signals assigned to amino and hydroxyl
groups were exchangeable with D2O. Mass spectra and exact mass measurements were
performed on a quadrupole/orthogonal-acceleration time-of-flight tandem mass spectrometer
(qTof 2, Micromass, Manchester, UK) equipped with a standard electrospray ionisation
interface (ESI). Samples were infused in a 2-propanol:water (1:1) mixture at 3 µL/min. If
necessary, nucleoside 5-O-monophosphates were ultimately purified using a Gilson HPLC
system with a Gilson 322 pump, a UV/VIS-156 detector on a C18 column (10 µM; Altech;
Altima; 250 ´ 22 mm). Precoated Merck silica gel F254 plates were used for TLC and spots
were examined with UV light at 254 nm and sulfuric acid-anisaldehyde spray or
phosphomolybdic acid (0.5% in EtOH) solution. Column chromatography was performed on
Uetikon 560 silica (0.2-0.06 mm) and Amersham Biosciences DEAE SephadexTM A-25.
5-Benzyloxymethyl-1-[2-deoxy-3,5-O-di-(toluoyl)-b -D-erythro-pentafuranosyl]thymine
(8) and 5-benzyloxymethyl-1-[2-deoxy-3-5-O-di-(toluoyl)-a -D-erythro-pentafurano-
syl]thymine (9)
5-Benzyloxymethyluracil (680 mg, 2.93 mmol) was suspended in a mixture of
hexamethyldisilazane (62 mL), trimethylsilyl chloride (0.5 mL, 3.94 mmol) and pyridine
(5 mL). The mixture was refluxed overnight. The resulting solution was evaporated and
coevaporated with toluene. The obtained residue was suspended in anhydrous CH3CN
(3.5 mL) and 2-deoxy-3,5-O-di-(toluoyl)-a-D-erythro-pentofuranosyl chloride (1 g,
2.58 mmol) was added. The reaction mixture was stirred 3 h at room temperature. CH2Cl2
(25 mL) was added and the organic layer was washed with a 7 % solution of NaHCO3
(25 mL). The water layer was washed twice with CH2Cl2 (25 mL). The combined organic
layers were dried over MgSO4 and evaporated. The residue was purified by column
chromatography (silica, CH2Cl2-MeOH, 98:2) to give a mixture of a- and b- anomers
(0.932 g, 62 %). The anomers were partly separated by a combination of precipitation (ether-
MeOH, 13:8) and column chromatography (silica, CH2Cl2-MeOH, 100:0®99:1®98:2). The
two mixtures, enriched in either anomer, were used without further purification in the next
step. 8: 1H-NMR: (300 MHz, DMSO-d6) d 2.35 (3H, s, CH3 toluoyl), 2.42 (3H, s, CH3
toluoyl), 2.60 (2H, m, H-2’), 4.02 and 4.08 (2H, 2 d, 2J = -11.7 Hz, 5-CH2), 4.52 (2H, s,
CH2Ph), 4.51-4.64 (3H, m, H-5’ and H-4’), 5.62 (1H, m, H-3’), 6.32 (1H, t, J = 7.1 Hz, H-1’),
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7.25-7.39 (9H, m, 4H toluoyl and 5H benzyl), 7.73 (1H, s, 6-H), 7.88 (2H, d, toluoyl), 7.94
(2H, d, J = 7.5 Hz, toluoyl); HRMS (ESI-MS) for C33H32N2O8Na [M+Na]+: found, 607.2081;
calcd, 607.2056.
1-(2-Deoxy-b -D-erythro-pentofuranosyl)-5-(benzyloxymethyl)thymine (10) and 1-(2-de-
oxy-a -D-erythro-pentofuranosyl)-5-(benzyloxymethyl)thymine (11)
A mixture of 8 and 9 (932 mg, 1.70 mmol) was dissolved in EtOH (60 mL) and NaOH 2N
(37 mL) was added. The mixture was stirred at room temperature for 15 min and evaporated.
The obtained residue was dissolved in 5 mL H2O and neutralised with HCl. The precipitate
was filtered and the filtrate was evaporated and coevaporated with EtOH. The obtained
residue was purified by column chromatography (silica, CH2Cl2-MeOH, 93:7), to give 10
(261 mg, 44%) and 11 (284 mg, 48%) as white foams. 10: 1H-NMR: (500 MHz, DMSO-d6)
d 2.08 (1H, ddd, H-2’A), 2.12 (1H, ddd, J = -13.4 Hz, H-2’B), 3.54 (1H, m, dd after addition
of D2O, J = 3.9 and -12.0 Hz, H-5’A), 3.58 (1H, m, H-5’B), 3.79 (1H, q, H-4’), 4.15 (1H, d,
J = -14.8 Hz, H-5A), 4.19 (1H, d, H-5B), 4.24 (1H, m, dt after addition of D2O, H-3’), 4.48
(2H, s, CH2Ph), 5.04 (1H, t, J = 4.9 Hz, 5’-OH), 5.26 (1H, d, J = 4.0 Hz, 3’-OH), 6.16 (1H, t,
J = 6.8 Hz, H-1’), 7.25-7.34 (5H, m, CH2Ph), 7.93 (1H, s, 6-H); 13C-NMR: (125 MHz,
DMSO-d6) d 39.83 (C-2’), 61.38 (C-5’), 64.56 (5-CH2), 70.48 (C-3’), 71.61 (CH2Ph), 84.45
(C-1’), 87.52 (C-4’), 110.76 (C-5), 127.58 (Cp arom), 127.63 (Co arom), 128.43 (Cm arom),
138.61 (Ci arom), 139.31 (C-6), 150.42 (C-2), 162 (C-4); HRMS (ESI-MS) for C17H20N2O6
[M+H]+: found, 371.1187; calcd, 371.1219.
1-(2-Deoxy-5-O-phosphoryl-b -D-erythro-pentofuranosyl)-5-(hydroxymethyl)thymine (1),
1-(2-deoxy-5-O-phosphoryl-b -D-erythro-pentofuranosyl)-5-(benzyloxymethyl)thymine (2)
and 1-(2-deoxy-b -D-erythro-pentofuranosyl)-5-(hydroxymethyl)thymine (12)
A solution of 10 (261 mg, 0.75 mmol) in trimethyl phosphate (3.5 mL) was cooled to 0° C,
POCl3 (0.22 mL, 2.4 mmol) was added dropwise and the mixture was stirred for 4 h at 0° C.
The mixture was poured into crushed ice-water (20 mL), neutralised with concentrated
NH4OH and evaporated to dryness. The residue was subjected to column chromatography
(silica, iPrOH-NH4OH-H2O, 77.5:15:2.5®60:30:5), yielding 12 (38.7 mg, 20 %) as a white
foam, as well as an oily mixture of 1 and 2. This mixture was further purified by HPLC
(C-18, CH3CN-MeOH-0.05% HCOOH in H2O, 45:45:10 3 mL/min) and the fractions
containing the nucleotides were lyophilised yielding 2 (47 mg, 14 %) and 1 (109 mg, 41 %) as
white powders. 12: 1H-NMR: (300 MHz, DMSO-d6) d 2.09 (2H, m, H-2’), 3.55 (2H, m,
H-5’), 3.78 (1H, dd, H-4’), 4.13 (2H, d, 5-CH2), 4.24 (1H, m, H-3’), 4.92 (1H, t, J = 5.09 Hz,
5-CH2OH), 4.99 (1H, t, J = 4.8 Hz, 5’-CH2OH), 5.27 (1H, d, J = 4.0 Hz, 3’-OH), 6.19 (1H, t,
J = 7.2 Hz, H-1’), 7.74 (1H, s, 6-H); MS(ESI): m/z (%) 259.1 ([M+H]+, 100); 2: 1H-NMR:
(300 MHz, D2O) d 2.35 (2H, m, H-2’), 4.03 (2H, m, H-5’), 4.19 (1H, m, H-4’), 4.43 (2H, s,
5-CH2), 4.55 (1H, dt, H-3’), 4.63 (2H, s, CH2PH), 6.28 (1H, t, J = 6.7 Hz, H-1’), 7.35-7.48
(5H, m, arom. H), 8.09 (1H, s, 6-H); 31P-NMR: (500 MHz, D2O) d 1.58; HRMS (ESI-MS) for
C17H21N2O9PNa [M+Na]+: found, 451.0860; calcd, 451.0882; 1: 1H-NMR: (300 MHz, D2O)
d 2.39 (2H, m, H-2’), 4.05 (1H, ddd, H-5’A), 4.11 (ddd, J = -11.58 Hz, H-5’B), 4.19 (1H, m,
H-4’), 4.39 (2H, s, 5-CH2), 4.59 (1H, dt, H-3’), 6.34 (1H, t, J = 6.8 Hz, H-1’), 8.04 (1H, s,
H-6); 13C-NMR: (125 MHz, D2O) d 41.73 (C-2’), 59.06 (C-5), 67.02 (C-5’, 2JC, P = 4.9 Hz),
73.60 (C-3’), 88.20 (C-1’), 88.57 (C-4’, 3JC, P = 8.8 Hz), 116.49 (C-5), 142.44 (C-6), 154.27
(C-2), 167.74 (C-4); 31P-NMR: (500 MHz, D2O) d 1.58; HRMS (ESI-MS) for
C10H15N2O9PNa [M+Na]+: found, 361.0419; calcd, 361.0413.
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1-(2-Deoxy-5-O-phosphoryl-a -D-erythro-pentofuranosyl)-5-(hydroxymethyl)thymine (3)
and 1-(2-deoxy-5-O-phosphoryl-a -D-erythro-pentofuranosyl)-5-(benzyloxymethyl)thymi-
ne (13)
A solution of 11 (248 mg, 0.71 mmol) in trimethyl phosphate (3.5 mL) was cooled to 0° C,
POCl3 (0.21 mL, 2.3 mmol) was added dropwise and the mixture was stirred for 4 h at 0° C.
The mixture was poured into crushed ice-water (20 mL), neutralised with NH4OH and
evaporated to dryness. 3 and 13 were separated by column chromatography (silica, iPrOH-
NH4OH-H2O, 77.5:15:2.5®60:30:5). Further purification was accomplished by HPLC (C-18,
CH3CN-MeOH-0.05% HCOOH in H2O, 45:45:10, 3 mL/ min). The fractions containing the
title nucleotides were lyophilised yielding 3 (106 mg, 42 %) and 13 (47 mg, 15 %) as white
powders. 3: 1H-NMR: (300 MHz, D2O) d 2.15 (1H, dt, H-2’A), 2.79 (1H, ddd, H-2’B), 3.82
(2H, t, J = 5.2 Hz, 5’-CH2), 4.37 (2H, s, 5-CH2), 4.53 (2H, m, H-3’ and H-4’), 6.22 (1H, dd,
J = 2.5 Hz and 7.3 Hz, H-1’), 7.95 (1H, s, H-6); 13C-NMR: (125 MHz, D2O) d 42.06 (C-2’),
59.40, 66.73 (5-CH2 and C-5’), 73.83 (C-3’), 90.25 (C-1’), 90.84 and 90.90 (C-4’,
JC, P = 7.5 Hz), 115.53 (C-5), 143.15 (C-6), 154.28 (C-2), 168 .03 (C-4); 31P-NMR:
(500 MHz, D2O) d 2.64; MS (ESI): m/z (%) 361.0 ([M+Na]+,100); 13: 1H-NMR: (300 MHz,
D2O) d 2.13 (1H, dt, H-2’A), 2.78 (1H, ddd, H-2’B), 3.88 (2H, dd, J = 5.8 and 4.4 Hz), 4.34
(1H, d, 5-CH2A), 4.37 (1H, d, J = -12.2 Hz, 5-CH2B), 4.52 (2H, m, H-3’ and H-4’), 4.58 (2H,
s, CH2Ph), 6.20 (1H, dd, J = 2.5 Hz and 8.0 Hz, H-1’), 7.40 (5H, m, arom H), 7.96 (1H, s,
H-6); 13C-NMR: (125 MHz, D2O) d 42.20 (C-2’), 67.25, 67.34 (5-CH2 and C-5’), 73.81
(C-3’), 74.55 and 74.57 (CH2Ph), 90.40 (C-1’), 90.76 and 90.83 (C-4’, JC,P = 7.8 Hz), 112.72
(C-5), 130.94 (Cp benzyl), 131.18 (Cm benzyl), 131.34 (Co benzyl), 140.18 (Ci benzyl), 144.65
(C-6), 167.93 (C-4); 31P-NMR: (500 MHz, D2O) d 2.29; MS(ESI): m/z (%) 451.0 ([M+Na]+,
100).
2’-Deoxy-5-(furan-2-yl)-5’-O-phosphoryluridine (4)
A solution of 15 (382 mg, 1.22 mmol) in trimethyl phosphate (5.8 mL) was cooled to 0° C.
POCl3 (0.4 mL, 4.29 mmol) was added dropwise and the mixture was stirred for 4 h at 0° C. It
was poured into crushed ice-water (40 mL), was neutralised with NH4OH and evaporated to
dryness. The resulting residue was purified by column chromatography (silica, iPrOH-
NH4OH-H2O, 77.5:15:2.5®60:30:5). The obtained white powder was further purified on
DEAE SephadexTM A-25 (triethylammoniumbicarbonate 0 ® 0.5 M) yielding the triethylam-
monium salt of 4. This was converted to its corresponding sodium salt (NaI, acetone)
(248 mg, 51 %) as a white powder. 1H-NMR: (300 MHz, D2O) d 2.43 (2H, m, H-2’), 4.09
(2H, app. t, H-5’), 4.23 (1H, m, H-4’), 4.59 (1H, dt, H-3’), 6.38 (1H, t, J = 7.1 Hz, H-1’), 6.57
(1H, dd, H-4’’), 6.89 (1H, d, H-3’’), 7.57 (1H, d, H-5’’), 8.21 (1H, s, H-6); 13C-NMR:
(125 MHz, D2O) d 41.45 (C-2’), 67.41 (C-5’), 73.76 (C-3’), 88.49 (C-4’ and C-1’), 111.52
and 114.16 (C-5’, C-3’’ and C-4’’), 138.69 (C-6), 145.22 (C-5’’), 151.15 (C-2’’); 31P-NMR:
(500 MHz, D2O) d 1.10; HRMS (ESI-MS) for C13H14N2O9P [M-H]-: found, 373.0448; calcd,
373.0436.
2’-deoxy-5-(thien-2-yl)-5’-O-phosphoryluridine (5)
A solution of 16 (320 mg, 1.03 mmol) in trimethyl phosphate (4.6 mL) was cooled to 0° C,
POCl3 (0.31 mL, 3.3 mmol) was added dropwise and the mixture was stirred for 4 h at 0° C.
The mixture was poured into crushed ice-water (20 mL), neutralised with 28 % ammonia and
was evaporated to dryness. The resulting residue was purified by column chromatography
(silica, iPrOH-NH4OH-H2O, 77.5:15:2.5®60:30:5). The obtained white powder was further
purified on DEAE Sephadex A-25 (triethylammonium bicarbonate 0 ® 0.5 M) yielding the
triethylammonium salt of 5. This was converted to its corresponding sodium salt (NaI,
79
acetone) (240 mg, 57 %) as a white powder. 1H-NMR: (300 MHz, D2O) d 2.45 (2H, m, H-2’),
4.03 (2H, m, H-5’), 4.22 (1H, m, H-4’), 4.59 (1H, dt, H-3’), 6.36 (1H, t, J = 7.3 Hz, H-1’),
7.17 (1H, dd, H-4’’), 7.49 (2H, m, H-3’’ and H-5’’), 8.14 (1H, s, H-6) ppm; 13C-NMR: (125
MHz, D2O) d 41.29 (C-2’), 66.83 (C-5’, 2JC, P = 4.9 Hz), 73.93 (C-3’), 88.54 (C-1’), 88.81
(C-4’, 3JC, P = 8.3 Hz), 112.85 (C-5), 128.14 (C-5’’), 129.34 (C-4’’), 129.99 (C-3’’), 135.26
(C-2’’), 139.77 (C-6), 153.50 (C-2); 31P-NMR: (500 MHz, D2O) d 3.11 ppm; HRMS (ESI-
MS) for C13H14N2O8SP [M+H]: found, 389.0181; calcd, 389.0208.
Enzymatic assay
The TMPK activity was measured by HPLC separation of nucleotide substrates and products,
as described below. The major reason for using this test instead of the more rapid coupled
spectrophotometric assay30 is that some inhibitors absorb light at 340 nm (4 and 5), thereby
rendering difficult the evaluation of NADH concentration in the coupled reaction. Also,
coupled enzymatic tests might be error-prone in the determination of the true value of Ki and
Km of inhibitors and substrate respectively, through the recycling of some substrate or product
during the reaction coupling.31 The reaction is carried out in a 1 ml final volume of a solution
50 mM Tris-HCl, pH 7.5, 20 mM magnesium acetate, 100 mM KCl, 1 mM EDTA, 0.5 mM
DTT, using different initial concentrations of ATP and dTMP, in the presence or absence of
various inhibitors. To follow the enzymatic kinetics an aliquot of 100 ml is taken at different
times after enzyme addition and the reaction is quenched by adding 900 ml of 100 mM sodium
phosphate pH 7. The concentration of each nucleotide at different times during the reaction is
measured at 260 nm by HPLC (isocratic mode) using a SephasilTM C18, 5 mm SC 2.1/10
(Amersham Biosciences) column. The buffer used for elution is 50 mM sodium phosphate,
pH 6.5, 2.5% (V/V) ethanol, 40 mM of tetrabutyl ammonium bromide with a flow rate of
250 ml per minute. All the reaction velocities are calculated by monitoring the production of
dTDP expressed in terms of optical absorbance per minute at 260 nm. It was checked that all
four sources of information (appearance of dTDP or ADP, disappearance of ATP or dTMP)
can be used and lead to the same results (see also Ref. 11).
Crystallisation and diffraction data collection
Co-crystals of M. tuberculosis TMPK in complex with compound 1 (see Figure 1) were
obtained as described for crystals with the dTMP substrate.14 Briefly, a 6 ml drop of 1:1
mixture of the protein solution 3.5 mg/ml incubated overnight with 5 mM of analog 1 and the
reservoir solution was equilibrated with 34 % (w/v) ammonium sulphate solution, 100 mM
HEPES pH 6.0, containing 2 % (w/v) PEG2000, 20 mM magnesium acetate, and 0.5 mM
b-mercaptoethanol. Crystals grew in 1-3 weeks to bipyramids of 400x200x200 mm3. X-ray
data were collected from cryo-cooled crystals using 25 % (w/v) glycerol as cryoprotectant.
Soaking experiments were performed by first transferring dTMP-TMPK co-crystals to a stabi-
lising solution containing 70 % ammonium sulfate and 1 mM dTMP, and then to a fresh
solution containing 70 % ammonium sulfate and 10 mM inhibitor (but no dTMP). This last
solution was replaced three times, each soaking time being 24 hours.
Diffraction data were processed using DENZO/SCALEPACK32 package. The CCP4
package 33 was used to calculate structure factors from the observed intensities (TRUNCATE).
Reflections in the resolution ranges 2.28-2.22 and 2.70-2.64 Å had to be suppressed due to the
presence of ice rings during data collection for the 1-TMPK complex.
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Model building and refinement
Refinement was performed up to 2.0 Å resolution with CNS.34 Standards protocols, including
maximum likelihood target, bulk solvent correction and isotropic B-factors were used.34,35
The model was inspected manually with SIGMAA-weighted 2F0 - Fc and F0 - Fc maps,36 and
progress in the model refinement was evaluated by the decrease in the free R-factor. Manual
rebuilding in the electron density maps was done with O.37 Stereochemistry of the final model
was assessed using PROCHECK.38 Coordinates of the 1-TMPKmt binary complex have been
deposited in the Research Collaboratroy for Structural Bio-informatics (RSCB) Protein
Databank (access code: 1MRS). Similar structural details apply to the Ap5T-TMPK complex,
where all the dictionaries necessary for O and CNS come from the database of G. Kleywegt2.
The coordinates have been deposited in the RSCB Protein Databank (access code: 1MRN).
Results
Enzymatic test: calibration with the natural substrates
In all experiments, the enzyme concentration was set to a value at least 200 times lower than
the substrates concentrations, i.e. typically 5*10-8 M. The reaction catalytised by TMPK was
found to follow the Michaelis model. 39 The initial velocity of the reaction at different fixed
(saturating) concentrations of ATP and different concentrations of dTMP allows for the
determination of the apparent Km for dTMP and for ATP. With this protocol we find an
apparent Km = 40 mM dTMP. For ATP, we measured Km = 100 mM. Both values compare
well with the ones obtained with the coupled assay.13 The Km of 40 mM for dTMP has been
measured at the fixed concentration of ATP of 0.5 mM and shows some dependence upon
ATP concentration. The Km value of dTMP extrapolated at zero ATP concentration is
4-5 mM, in agreement with results reported earlier.13
The role of ATP as the phosphoryl donor has been explored in Ref. 13, where other NTP were
tried and found to be less efficient than ATP. Similar results were obtained using the direct
assay method described here (data not shown).
Inhibition of TMPK activity with synthetic compounds
Measuring the initial velocity of the reaction at a fixed saturating concentration of ATP and
different concentrations of dTMP, both in the absence and in presence of inhibitors, allows to
test the nature of the inhibition.39,40 In our case, the reciprocal plot confirms that all inhibitors
are competitive with dTMP because the least-squares fitted best lines in absence and presence
of the inhibitor cross exactly on the y-axis. In the classical competitive inhibition model (with
the Lineweaver-Burk representation), we can use the equation39:
 K m 
' = K m ( 1 + 
[ I ] 
K i 
) 
where K’m and Km are the apparent Michaelis constants determined in the presence and the
absence of inhibitor, respectively. Knowing the concentration of inhibitor [I], it is possible to
calculate Ki, which is shown in Table 1.
For AZTMP, the dependence of the Ki value upon ATP concentration was found to be
significant, in accordance with Ref. 13. However, for all the inhibitors reported here, we
report only the apparent Ki value at the fixed concentration of ATP of 1.0 mM. AZTMP will
serve as a reference compound here since our aim is to do better than this compound.
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Exploring the 5-position of the thymine ring.
Systematic substitution of the methyl group in the 5-position of the base into halogen atoms
was explored in ref 8.8 Bromine, which has the same size as CH3, was found previously to be
very similar to dTMP in terms of both Ki and Vmax.13 The difference in the kinetic parameters
of these compounds reflects essentially a size effect, with the halogen atoms serving as cavity
filling atoms. In this work, other compounds substituted at the 5-position of the base moiety
of dTMP have been synthesised and will be described here.
Nucleotide analog 1 was designed in an effort to induce an additional contact between the
5-CH2OH group and the side chain of Arg74. The value of the Ki constant indicates a
moderately active inhibitor, as compared to AZTMP (Table 1).
Analog number or
name
5-position of the
pyrimidine ring 1’ (sugar) 5’ (sugar) 3’ (sugar)
 Ki 
app
(mM)
1a
2a
3a
4a
5a
BVDUb
Thymidine
dUMP (8)
5-F-dUMP (8)
5-Br-dUMP (8)
5-I-dUMP (8)
6a
AZTMP
Ap5T
CH2OH
CH2-O-CH2-phenyl
CH2OH
Furan-2-yl
Thien-2-yl
CH=CHBr
CH3
H
F
Br
I
CH3
CH3
CH3
b 
b
a
b
b
b
b
b
b
b
Hexose
b
b
Phosphate
Phosphate
Phosphate
Phosphate
Phosphate
OH
OH
Phosphate
Phosphate
Phosphate
Phosphate
Phosphate
Phosphate
p5A
c
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
N3
OH
110
280
450
140
270
900
280
substrate
substrate
substrate
substrate
150
50
30
Table 1: Apparent Inhibition Constant (Ki
 app) of different synthesised inhibitors.
a See Figure 1 for the structures of compounds 1-6.
b BVDU: ( E)-5-(2-bromovinyl)-2'-deoxyuridine
c p5A: adenosine 5'-pentaphosphate
Other dTMP analogues were synthesised in which the volume of the substituent at this
position was further increased while maintaining one polar atom, namely a thiophene and a
furane derivative. The resulting compounds (4 and 5) were less active than the 5-CH2OH
dUMP, indicating that the volume of this cavity cannot be stretched too much. Another
compound (2) aiming towards a stacking interaction with Phe36 residue resulted in a less
active compound (Table 1).
The unnatural a-isomer of 1 was also synthesised (3, see Figure 1) and assayed but proved
less active than 1 (see Table 1).
Another possibility would be to increase the length of the linker from the C5 position up to a
polar atom to replace directly the W12 water molecule, which is located at 3.95 Å from the
C5 atom of dTMP, behind the pyrolidine ring of Pro37. Pro37 has a cis-peptide bond
conformation that is maintained through an hydrogen-bond between its carbonyl atom and a
water molecule W26, which is also in contact with one of the oxygens of the phosphate group
of dTMP. Therefore, the exact position of Pro37 is expected to be important for catalysis.
This cis-peptide bond is also present in the three other known structures of dTMP
kinases.16,17,18,19,20 The deoxyribose analog of dU with a substituent of exactly the size to reach
out for the water molecule W12 (-CH=CH-Br) has been tried and compared to dT. This
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compound, BVDU, has already proved efficient for inhibition of HSV-type 1 thymidine
kinase.12 It was predicted that the electronegative bromine atom would play the role of W12.
However, this compound proved relatively inefficient for M. tuberculosis TMPK (Table 1).
Inhibition by Ap5T
The bisubstrate analogue Ap5T has been found to be more efficient than AZTMP with an
inhibition constant Ki = 30mM, making it one of the most powerful inhibitors of M.
tuberculosis TMPK known to date. This compares well with similar inhibitors designed
against other NMP kinases.18,41 The inhibition mechanism inferred from the reciprocal plot
analysis is compatible with the one described for adenylate kinase, where it is a competitive
inhibitor for the forward reaction and a mixed noncompetitive inhibitor for the backward
reaction. 42 To understand the chemical nature of the interaction of this inhibitor with its target
and to further increase the efficiency of this compound, the structure determination of its
complex with its TMPK was undertaken (see below).
Inhibition by the 1-5 anhydrohexitol analogue of dTMP
Modification of the sugar moiety of dTMP into an 1,5-anhydrohexitol was performed (6).
This analogue is actually a member of a novel series of inhibitors already tried for HSV-type
1 TK.24 The 5’-O-monophosphate was tested against M. tuberculosis TMPK but proved to be
a moderately potent competitive inhibitor, again using AZTMP as a reference (see Table 1).
Structure determination of bound drugs in the dTMP binding site of TMPK
In order to better understand the molecular origin of the differences in the Ki inhibition
constants of all these compounds, we tried either to co-crystallise them with TMPK or to
exchange them with dTMP by soaking TMPK-dTMP crystals with an excess of inhibitor.
Figure 2: Electron density difference map around the analog 1 (drawn with Bobscript43). The F0-Fc
SIGMAA-weighted map is contoured at 3.0s (red), while the 2F0-Fc is contoured at 1.0s (blue).
No exchange of dTMP by any of the analogues studied here was observed even after
extensive soaking experiments on TMPK-dTMP crystals, in contrast with the control
experiment with I-dUMP, which worked well as already reported in ref 15.15 However, one
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should bear in mind that I-dUMP is a substrate whereas none of the compounds tried here are
substrates.
No co-crystals were obtained either except with compound 1, whose structure was determined
at 2.0 Å resolution (see Tables 2 and 3 for data collection and refinement statistics,
respectively). The Fourier difference map clearly shows density for the OH group of CH2OH
(Figure 2). The hydroxyl group makes an extra hydrogen bond with W12, which is also held
in place by the side chain of Asp73 and the essential Arg74. After inspection of the residual
SIGMAA-weighted F0 – Fc map, we found density at the 2.5 s level for a possible alternative
conformation of the hydroxyl group that reaches out for the side chain of the strictly
conserved Ser99 (for which no definite role has been proposed yet).
TMPK-1 cocrystals TMPK-Ap5 T cocrystals
X-ray source
Wavelength in (Å)
Detector
Space group
a = b, c (Å)
Resolution (Å)
Total of unique refl.
Multiplicity
Completeness (%)
Rmerge
b
I/s(I)
ESRFa, ID14-3
0.940
MARCCD
P6522
76.34, 134.42
25.0-2.00 (2.07-2.00)
14739 (1575)
6.0 (5.9)
89.5 (98.6)
0.082 (0.271)
27.8 (18.8)
Rotating anode (lab.)
1.5418
MAR-IP
P6522
75.48, 133.35
30.0-2.45 (2.54-2.45)
8407 (768)
3.3 (3.0)
95.1 (90.1)
0.066 (0.366)
10.2 (9.2)
Table 2: Data-collection statistics of the TMPK-1 and TMPK-Ap5T complexes.
a ESRF: European Synchrotron Radiation Facility
b Rmerge = ShSiôIhi - <Ih>ô/ShSiIhi, where Ihi is the ith observation of the reflection h, while <Ih> is the
mean intensity of reflection h
Figure 3: Network of interactions of the analog 1 in the active site of TMPK (drawn with Chemdraw).
No attempt has been made to refine this alternative conformation since the limited resolution
of our data makes it difficult to estimate their relative occupancies. Ser99 is part of a
hydrogen bond network involving both Glu6 (strictly conserved) and Tyr179 and helps to
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position Arg95 correctly (Figure 3), which is strictly conserved among all known TMPKs,
except for the one from African swine fever virus, where it is a histidine.15 Arg95 is the only
residue of the whole protein whose main chain dihedral angles lie outside the “allowed”
regions in a Ramachandran plot (Table 3), an observation that holds true in the other
structures of TMPKs known, so it must have an important functional role. The guanidinium
group of Arg95 is located 3.2 Å away from the carboxylate group of Asp9. Although the
conformation of the side chain Arg95 is well conserved in the different TMPK structures, it
has been shown that it can exist in another conformation in the complex with the products
dTDP and ADP, pointing towards the carbonyl of residue 36, just before the cis-peptide bond
of Pro37.17
1-TMPK Ap5T-TMPK
Resolution range (Å)
Cutoff I/s (I)
Number of reflections used for refinement
Number of reflections used for R free calculation
Number of non hydrogen atoms
Protein
Inhibitor
SO4
-- (two molecules)
Mg++
Water
Refinement statistics
Rfactor
a (%)
Rfree
b (%)
Root mean square deviations from ideality
Bond lengths (Å)
Bond angles (°)
Dihedral angles (°)
Average temperature factors
Main chain
Side chain atoms
Inhibitor
SO4 
- molecule 1 (molecule 2)
Mg++
Water
Scaling parameters (k in e/Å3, overall B-factor in Å2)
Ramanchandran plot
Residues in most favoured regions (%)
Residues in additional allowed regions (%)
Residue in disallowed regions (%)
Overall G-factorc
25.0-2.00
1.0
12400
641
1543
22
10
1
77
22.8
26.5
0.0068
1.19
20.67
35.35
38.2
31.2
30.1 (34.4)
46.96
43.7
0.333 (50.5)
96.1
3.4
0.5 (Arg95)
0.36
30.0-2.45
0.1
7769
379
1543
53
10
1
58
23.6
28.4
0.0079
1.21
20.1
38.2
39.2
40.4
30.1 (36.2)
34.5
42.6
0.359 (42.56)
91.1
8.4
0.5 (Arg95)
0.31
Table 3: Refinement statistics of the TMPK-1 and the TMPK-Ap5T complexes.
a Rfactor =S ||Fo| - |Fc|| / |Fo|
b Rfree is calculated with 5% of randomly selected reflections
c G-factor is an overall measure of the structure quality calculated with PROCHECK.38
Structure determination of bound Ap5T
The crystal structure of the complex of M. tuberculosis TMPK with Ap5T has been
determined at 2.45 Å resolution (see Tables 2 and 3 for data collection and refinement
statistics, respectively). The structure reveals an unexpected binding mode for the adenine
moiety of this compound. While the thymidine moiety of the bisubstrate analogue indeed
occupies the binding pocket of the dTMP substrate, the rest of the molecule departs from its
expected position after the 5’-O-phosphate of the dTMP moiety (Figure 4). This is inferred
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from the superimposed crystal structures of both the E. coli and H. sapiens enzymes
complexed with the same bisubstrate analog.18,19 The phosphate backbone of the bound Ap5T
is making an angle of almost 90° with the superposed same molecule from E. coli at the alpha
phosphate. The surprise comes from the fact that the ADP moiety of the Ap5T molecule
snugly fits into a cavity on the surface of TMPK that appears to be specific to the M.
tuberculosis enzyme (Figure 5). This cavity involves packing interactions against helix a2
(residues 42-53) on one side and the region 152-162 on the other side. His53 is nicely stacked
on the adenine ring.
Figure 4: Electron density difference map around the Ap5T compound (drawn with Bobscript
43). The
Fo-Fc SIGMAA-weighted map with phases calculated with a model deprived of the inhibitor is
contoured at 2.5s (blue). Both the refined model and the expected binding mode of the same molecule
in the E. coli TMPK complex structure are shown, for comparison (ball and stick representation).
Discussion
One of the most striking findings of this study is that none of the 5-substituted dUMP
analogues investigated here behaves as a substrate for M. tuberculosis TMPK, contrary to
what had been observed for halogen-substituted compounds at the same position.13,15 Our
current interpretation is that any modification that significantly perturbs the volume of the
substituent at this position will change the orientation of the sugar moiety of the dTMP
molecule as well as that of the alpha phosphate. Indeed, recent results obtained on a series of
compounds modified at the 3’ and 2’ positions of the sugar21 indicated an extreme sensitivity
of the reaction to the exact positioning of at least the 3’-OH group of the sugar moiety, which
is in a C2’-endo conformation in the active site. This is also illustrated in the present study
with compound 6, which behaves as an inhibitor probably because of its inability to place
correctly both the 5’-O-phosphate and the 3’-OH groups in a favorable arrangement for
catalysis.
Similarly, AZTMP is an inhibitor of the M. tuberculosis enzyme contrary to what is observed
in TMPKs of other species,13 where it is either a weak substrate (in H. sapiens) or a good
substrate (E. coli). This may be related to a unique feature of this enzyme revealed by its
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three-dimensional structure, namely the presence of a Mg++ ion in the vicinity of Asp9 and the
3’-OH position. Inhibition by AZTMP in the M. tuberculosis TMPK is probably due to a
steric and/or electrostatic effect of the azido group, which would prevent the binding of the
Mg++ ion.
A B
Figure 5: Comparison of the observed binding mode of Ap5T both in the crystal state (A) and in the
binding mode (B) expected from the structure of the same compound with the E. coli enzyme.19 Surface
representation was drawn using Grasp.44 The thymidine moiety of the molecule is hidden in its binding
pocket.
No Mg++ ion has been observed in this position in any of the three other structures of TMPK
reported so far (E. coli, yeast and human enzymes) in various complexes.16,17,18,19,20 This is
especially intriguing since most of the side chain ligands for the divalent cation observed in
the M. tuberculosis are conserved in the three other known TMPK structures. A possible
explanation for this phenomenon may be the peculiar coordination of the 5’-O-phosphate of
dTMP, which involves not only the Mg++ ion but also Tyr39, a specific feature of the M.
tuberculosis sequence. Normally, at this Tyr39 position, an arginine or a lysine residue is
expected, as seen in the human, yeast and E. coli enzyme structures and in the multialignment,
to neutralise the dTMP phosphate negative charge. Since Tyr39 cannot play this role, it is
tempting to postulate that it is fulfilled by the Mg++ cation in both M. tuberculosis and M.
leprae enzymes, but then the positive charge is located on the opposite side of the phosphate,
compared to the other known TMPKs, i.e. close to the essential Asp9. Mg++ may also
contribute to deprotonate both the Asp9 residue and the phosphate of dTMP. We note that one
of the water molecule ligands of the octahedral environment of the Mg++ ion is likely to be
replaced by one of the non-bridging oxygens of the g-phosphate of ATP, as seen in the
structure of the complex with Ap5T, thereby contributing to the exact positioning of all the
reactants and stabilising the transition state. This is inferred from the superimposed structures
of the complex of Ap5T with the enzymes from E. coli19 and/or H. sapiens17 with the M.
tuberculosis TMPK-dTMP structure.15
In the human enzyme, a magnesium ion is found on the ATP molecule. Since M. tuberculosis
TMPK has been crystallised only in the presence of dTMP, one can only speculate about the
presence of a second magnesium ion in the active site when ATP is bound. This (ATP-bound)
second magnesium ion, weakening the bond between the beta and gamma phosphates and
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therefore assisting in the departure of the leaving group, is a general feature of various kinases
and is therefore expected also in the M. tuberculosis enzyme.45 Two magnesium ions in the
active site of kinases would not be surprising, as this has been observed in several instances
already. However, looking again at the multialignement of all known TMPK sequences,15 one
notices that Thr14 of the Walker A motif, which is essential in the coordination of this second
magnesium ion, is not conserved in both M. leprae and M. tuberculosis sequences. Instead, it
is replaced by an arginine residue whose guanidinium group can easily be brought, through a
simple chi-1 rotation, at the expected binding site of the ATP-bound Mg++ ion.
The next surprising point is that most crystal soaking experiments did not work, indicating
that the dTMP molecule could not be exchanged, at least in the conformation of the enzyme
that has been captured in the crystal. In very much the same way, most co-crystallisations did
not work (except for 1), indicating the inability of the analogues tried here to induce the
conformational change leading to the form of the enzyme that crystallises, namely the closed
form. Our current interpretation is that the crystal structure has trapped an intermediate
already well engaged along the reaction coordinate pathway: most of the inhibitors described
here exert their binding abilities on a more open form of the enzyme but are unable to induce
the transition from this open form to the closed form. In that sense, the transition to the closed
form deserves the name of an induced fit mechanism.46,47 M. tuberculosis TMPK is unique
among the other known crystal structures of TMPKs in that the closed form is already formed
upon dTMP binding, with the ATP binding site clearly preformed, whereas virtually all other
NMP kinases need the binding of the two substrates to be in the fully closed form.16,17,18,19,20
Two extrinsic factors contribute to this phenomenon: one is the Mg++ ion and the other is the
sulphate ion, which drives the closing and the disorder-order transition of the LID region and
which comes from the precipitating agent used to obtain crystals. The Mg++ role has been
mentioned above while discussing the inhibition by AZTMP. The role of the sulphate is worth
discussing in light of the Ap5T complex structure.
Even though the ATP binding site is preformed in our crystal form, the “ADP” part of Ap5T
was found to bind to an unexpected site. This probably results from the inability of Ap5T to
displace the strongly bound sulphate ion that is located at the ATP beta phosphate binding
site. Since this sulphate ion comes from the mother liquor of crystallisation, the alternative
binding mode of the ADP moiety of Ap5T might be seen as an artefact of crystallisation.
However, since it binds already well into a cavity on the surface of the molecule for which it
has not been especially designed, it is easy to imagine how one might improve its binding
energy. For instance, it might be possible to take advantage of the close proximity of Glu55 to
C2 of the adenine ring and of Glu50 and Asp46 to two different water molecules bound to the
2’ and 3’ position of ADP. It should then be possible to design new drugs against TMPK by
synthesising branched molecules at the alpha phosphate of Ap5T, with an extra chemical
group reaching out to this cavity that is present only in the M. tuberculosis enzyme and
designed specifically to bind there.
An important finding of the present study is the structural characterisation of the binding of
TMPK to compound 1. The structure partly verifies our expectation, by showing an
anticipated hydrogen-bond between 1 and a known water molecule (W12 in PDB structure
1G3U), and partly brings a surprise, by displaying an alternative binding mode, with the
hydroxyl group pointing towards the network of interactions between Glu6, Arg95, Tyr179
and Ser99. Both binding modes contribute to the rigidification of the dTMP binding pocket
and explain why this compound is an inhibitor rather than a substrate, compared to 5-I-
dUMP,13,15 of comparable volume.
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We now discuss in more detail the role of Ser99, a strictly conserved residue whose function
has remained unclear up to now. First we observe that the network of interactions in which
Ser99 is involved contains Glu6, the only other non-glycine strictly conserved residue among
all known TMPK sequences,15 as well as Arg95, which is almost universally conserved
(except for one exception out of 32 sequences, where it is an histidine). It is tempting
therefore to assume a central role in catalysis for this cluster of interacting residues.
Figure 6: Proton wire involving Glu6, Ser99, Arg95 and Asp9. Glu6 and Ser99 are the only non-
glycine residues strictly conserved among all known TMPK sequences, Arg95 has only one exception
(where it is replaced by an histidine) and Asp9 is always either an aspartate or a glutamate residue.15
A) Asp9 gets its proton from Arg95. B) Arg95 gets its proton back from Ser99. C) Ser99 draws a
proton from water through Glu6, while Asp9 gives its proton to the newly transferred phosphoryl
group.
89
In fact, we can describe this structural catalytic core as a “proton wire” in the active site of
TMPKs, i.e. a continuous chain of several side chains in line and sharing a proton, including
W13, Glu6, Ser99, Arg95 and Asp9 (Figure 6). W13 is in contact with the solvant, so this
“proton wire” couples Asp9 to a reservoir of water molecules (and protons). Asp9, which is
always either an aspartate or a glutamate in all known TMPK sequences, is within hydrogen
bond distance of two non-bridging oxygens of phosphates, one from the a-phosphate of
dTMP (acceptor) and the other from the g-phosphate of ATP (donor). The distances between
the residues in this “proton wire” are within 2.55-2.85 Å, with the exception of one definitely
weak link between Arg95 and Asp9 (3.19 Å). We suggest that this distance becomes shorter
upon ATP binding, making it possible to consider the Ser99-Arg95-Asp9 set as yet another
variation of the well known catalytic triad of serine proteases (Ser-His-Asp/Glu). Asp9 could
get a proton from Arg95 (Figure 6a), which immeditaely gets reprotonated from Ser99 and
Glu6 (Figure 6b and 6c). The role of Asp9 would then be to provide the proton for the
transferred phosphoryl group, playing the role of a general acid (Figure 6c). We believe that
the proton from the hydroxyl group of the 5’-phosphate of dTMP has already been removed
by the Mg++ ion. In that sense, we are one step further along the reaction pathway, compared
to all other transition-state analog complex structures of other TMPKs. To sustain this
hypothesis, we note that catalytic triads show considerable variation of sequence in the three
different positions of the classical catalytic triad.48 There is even one case where the histidine
residue is replaced by a lysine, so arginine is not unconceivable between a serine and an
aspartate.48 Second, it has recently been observed that a previously hitherto unidentified
catalytic triad is present in different families of cellulases, where the Asp/Glu residue plays
the role of a proton donor.49 Third, the recent work of Hutter and Helms50 urges one to find a
proton donor since their QMM calculations point to a concerted phosphoryl transfer
mechanism involving the synchronous shift of a proton from the nucleotide monophosphate to
the transferred PO3 in the related enzyme UMP/CMP kinase. According to these authors50,
most of the activation energy of the phosphoryl transfer is spent on moving the proton
towards its destination on the g-phosphate group, so it is perhaps not surprising to find that
TMPKs have evolved such a sophisticated network of four interacting highly conserved
residues to accomplish this process.
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Abstract
Thymidine monophosphate kinase of Mycobacterium tuberculosis (TMPKmt) represents an
attractive target for blocking the bacterial DNA synthesis. In an attempt to find high-affinity
inhibitors of TMPKmt, a cavity in the enzyme at the 3’-position was explored via the
introduction of various substituents at the 3’-position of the thymidine monophosphate
(dTMP) scaffold. Various 3’-C-branched chain substituted nucleotides in the 2’-deoxyribo
(3-6) and ribo series (7-8) were synthesised from one key intermediate (23). 2’-Deoxy
analogues proved to be potent inhibitors of TMPKmt: 3’-CH2NH2 (4), 3’-CH2N3 (3) and
3’-CH2F (5) nucleotides exhibit the highest affinities within this series with Ki values of 10.5,
12 and 15 mM, respectively. These results show that TMPKmt tolerates the introduction of
sterically demanding substituents at the 3’-position. Ribo analogues experience a significant
affinity decrease, which is probably due to steric hindrance of Tyr103 in close vicinity of the
2’-position. Although the 5’-O-phosphorylated compounds have somewhat higher affinities
for the enzyme, the parent nucleosides generally exhibit affinities for TMPKmt in the same
order of magnitude and display a superior selectivity profile versus human TMPK (TMPKh).
This series of inhibitors holds promise for the development of a new class of anti-tuberculosis
agents.
Introduction
Mycobacterium tuberculosis is responsible for at least 2 million deaths per year worldwide
and 30 million people are at risk of dying from tuberculosis (TB) in the next 10 years.1 Due to
demographic factors, socio-economic trends, neglected tuberculosis control in many countries
and HIV-infection, this epidemic has been able to adopt such proportions. Efforts to stop this
frightening trend are hampered by the lack of financial resources in developing countries, the
appearance of multi-drug resistant strains of M. tuberculosis and bad therapy compliance. As
a current strategy in the battle against TB, Directly Observed Treatment Short-course (DOTS)
is preferred. In DOTS, TB patients are subjected to standardised treatment regimens
(generally consisting of combinations of the most powerful anti-TB drugs), which last
6-8 months under direct observation of drug intake. As a consequence, the duration of illness,
the risk of death and the appearance of resistant strains are reduced. For those that are or will
be infected with the multi-drug-resistant bacteria or that develop resistance after a previous
drug treatment (50-80% of previously treated cases), however, more effective drugs acting on
novel targets are eagerly awaited.2
Thymidine monophosphate kinase (TMPK) catalyzes the conversion of dTMP to dTDP. This
enzyme is ubiquitous in all living organisms. It lies at the junction of the de novo and salvage
pathways for thymidine triphosphate (dTTP) synthesis. These enzymes are well characterised,
both at biochemical3 and structural4 levels. Li de la Sierra et al. recently determined the
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structure of M. tuberculosis TMPK (TMPKmt) using X-ray diffraction. 5 Because of its crucial
role in thymidine metabolism and in view of its low (22%) sequence identity with the human
isozyme, it represents an attractive target for blocking mycobacterial DNA synthesis. The
main interactions between dTMP and the enzyme are depicted in Figure 1. The most
important catalytic regions are:
§ the P-loop (amino acid residues 6-17), which binds and positions the a- and b-phosphoryl
groups of the phosphate donor (ATP); it is unique among all known TMPK sequences in
that it does not have an arginine at the position where it is found in the yeast and human
enzymes; instead, it possesses a distant arginine residue four amino acids further;
§ the DRY/H-motif (residues 94-96), which acts as a clip that favorably orients the
phosphate donor and acceptor;
§ the LID-region (residues 144-154) that leans over the phosphoryl donor, when dTMP
binds the enzyme; it is very similar to E. coli TMPK having three arginines.
Figure 1: Schematic representation of the most important amino acid residues of TMPKmt interacting
with dTMP (in black). The main bonding forces between dTMP and the enzyme are: (i) a stacking
interaction between the pyrimidine ring and Phe70, (ii) a hydrogen bond between O4 of thymine and
the Arg74 side-chain, which results in a preference for thymine over cytosine, (iii) a hydrogen bond
between Asn100 and N3 of the thymine ring, (iv) a hydrogen bond between the 3’-hydroxyl of dTMP
and the terminal carboxyl of Asp9, that in its turn interacts with the magnesium ion that is responsible
for positioning the phosphate oxygen of dTMP, and (v) hydrogen bonds and an ionic interaction
between the 5’-O-phosphoryl and Tyr39, Arg95 and Mg2+, respectively. The presence of Tyr103 close
to the 2’-position is believed to render the enzyme catalytically selective for 2’-deoxy nucleotides
versus ribo nucleotides.
Moreover, 3’-azido-3’-deoxythymidine monophosphate (AZTMP) was identified as a
competitive inhibitor of TMPKmt with a Ki of 10 mM.5 TMPKmt represents the first reported
TMPK that does not phosphorylate AZTMP, a feature that could be exploited in the search for
other selective inhibitors of TMPKmt. Lavie et al.4a postulated that, in yeast TMPK, the azido
group interacts via its terminal nitrogen with the side-chain carboxyl of Asp9, resulting in a
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P-loop displacement. Thus, Arg15 binds ATP less efficiently, slowing down catalysis. A
similar mechanism may account for the lack of phosphorylation of AZTMP by TMPKmt.
Li de la Sierra et al. suggested that the azido group displaces the magnesium ion in the active
site of TMPKmt (responsible for positioning one oxygen of the phosphate and Asp9), thereby
abolishing catalysis.5 Despite the uncertainty of the mechanism, it should be interesting to
explore changes at position 3’ of the dTMP-scaffold for finding more potent inhibitors of
TMPKmt. The X-ray structure of TMPK complexed with dTMP reveals that relatively bulky
substituents at the 3’-position could be accommodated.5 Therefore, we decided to synthesise a
series of 3’-C-branched-chain nucleotides, namely the 3’-C-azidomethyl, 3’-C-aminomethyl,
3’-C-fluoromethyl, and 3’-C-hydroxymethyl derivatives of dTMP (3-6). To delineate the most
appropriate length of the spacer between the 3’-carbon and the introduced functionality, also
3’-deoxy-3’-hydroxyethylthymidine (15) was investigated for its affinity for TMPKmt.
O
--O3PO
N NH
O
O
N3 NH2
O
--O3PO
N NH
O
O
OH
O
--O3PO
N NH
O
O
NH2
AZTMP 1 2
O
--O3PO
N NH
O
O
R1R2
O
OH
N NH
O
O
R1R2
9 R1= H, R2= N3
10 R1= H, R2= NH2
11 R1= H, R2= F
12 R1= H, R2= OH
13 R1= OH, R2= N3
14 R1= OH, R2= NH2
15 R1= H, R2= CH2OH 
3 R1= H, R2= N3
4 R1= H, R2= NH2
5 R1= H, R2= F
6 R1= H, R2= OH
7 R1= OH, R2= N3
8 R1= OH, R2= NH2
We have already reported that a ribo analogue exhibits a higher affinity for TMPKmt than its
corresponding 2’-deoxy analogue, i.e. the ribo analogue of 3’-amino-3’-deoxy-5’-O-phospho-
rylthymidine (2) with a Ki of 27 mM versus 235 mM for 1.6 In order to gain detailed insight in
the postulated steric hindrance caused by Tyr103 at the 2’-position, the ribo analogues of the
azido and amino compounds were also synthesised (7-8). The non-phosphorylated analogues
9-14 of the above-mentioned compounds were included in this report as well.
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Results and Discussion
Chemistry
Although an efficient synthetic route for the synthesis of 3'-C-branched-chain 2’,3'-deoxy
substituted thymidine has been established,7 we developed a route that gives access to both
2’-deoxy and ribo analogues and allows easier conversion to the corresponding monophos-
phates. The synthesis of the parent 3’-C-branched-chain substituted nucleosides 9-14 was
described by Lin et al.8 In this procedure, all 3’-C-modifications are introduced on the sugar
moiety before coupling with thymine. In our approach, the 3’-C-modifications are effected
following sugar-base coupling, which allows synthesising all derivatives from a unique key
intermediate. This approach requires a judicious choice of 5’- and 6’-O-protective groups,
which must be stable under various reaction conditions and be chemoselectively removed to
permit conversion of the key compound to the 3’-hydroxymethylnucleotide, on one hand and
to the 3’-azidomethyl-, 3’-aminomethyl- and 3’-fluoromethyl-derivatives, on the other hand.
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Scheme 1: Reagents: (a) BnCl, NaH, DMF.
First, we chose to combine 5-O-(tert-butyldimethyl)silyl and a 6-O-benzyl protecting groups
(Scheme 1). However, introduction of the 6-O-protective group in 16 (prepared in 3 steps
from 1,2-O-isopropylidene-a-D-xylofuranose8) using BnCl and NaH in DMF9 was
cumbersome. The 5-O-(tert-buthyldimethyl)silyl group was cleaved thereby furnishing a
mixture of 3-deoxy-3-(benzyloxymethyl)-1,2-O-isopropylidene-a-D-ribofuranose (17) (17%)
and 5-O-benzyl-3-deoxy-3-(hydroxymethyl)-1,2-O-isopropylidene-a-D-ribofuranose (68%)
(18) resulting from silyl ether cleavage under basic conditions.10 Therefore, we decided to
take the 5-O-p-anisyl protecting group instead of the 5-O-(tert-butyldimethyl)silyl, as
cleavage during introduction of the benzyl would be obviated under the given reaction
conditions (Scheme 2). Unfortunately, attempts to selectively protect the primary hydroxyl of
1,2-O-isopropylidene-a-D-xylofuranose (19) with p-methoxyphenol under Mitsunobu
conditions11 did not afford the desired 5’-O-protected derivative. Instead, 3,5-anhydro-1,2-O-
isopropylidene-a-D-xylofuranose12 (20) was formed via intramolecular dehydration.
To circumvent this problem, we protected the 5-hydroxyl as a benzyl ether and the 6-hydroxyl
with a p-anisyl group (Scheme 3). 5-O-Benzyl-3-deoxy-3-(hydroxymethyl)-1,2-O-isopropyli-
dene-a-D-ribofuranose (18) was prepared using the method of Tino et al.12 The 3-hydroxy-
methyl group was protected as a p-anisyl ether under Mitsunobu conditions,11 affording the
fully protected sugar 21. Acidic cleavage of the 1,2-O-isopropylidene group, followed by
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acetylation, provided 22. Vorbrüggen-type coupling13 of this acetylated sugar with silylated
thymine, followed by alkaline removal of the 2’-O-acetyl protecting group yielded 23 (78% in
two steps), a convenient key intermediate for further derivatisation. Removal of the 2’-hydro-
xyl function was performed by reduction of its phenoxythiocarbonate ester with AIBN and
nBu3SnH affording 24 (40% yield from 18). Selective deprotection of the 5’-O-benzyl group
of 24 by catalytic hydrogenolysis, followed by 5’-O-phosphorylation and removal of the
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Scheme 2: Reagents: (a) p-methoxyphenol, DEAD, Ph3P, THF.
p-anisyl group, gave the desired 2’,3’-dideoxy-3’-C-hydroxymethylthymidine-5’-O-mono-
phosphate (6) (Scheme 4). To obtain the corresponding free nucleoside 12, 25 was treated
with ceric ammonium nitrate. Besides the removal of the 6’-O-anisyl group, oxidation of the
5-methyl group occurred during work-up of the aqueous layer (possibly by residual ceric
ammonium nitrate) thereby leading to the undesired 5-hydroxymethylthymine analogue 27.
The 5-hydroxymethyl was identified by COSY (an extra hydroxymethyl was present that did
not show COSY contacts with any other proton) and gHMBC experiments (3J contact
between 5-CH2OH and H-6 and between 5-CH2OH and C-4 and C-6; 2J contact between
5-CH2OH and C-5). Consequently, we interchanged the deprotection steps c and a described
in Scheme 4 and obtained 12 via 28 (68% yield from 24).
Compound 28 also served as precursor for the synthesis of the 3’-CH2N3, 3’-CH2NH2 and
3’-CH2F derivatives. Fluorination of 28 with (diethylamino)sulfur trifluoride (DAST),
followed by reductive debenzylation, afforded the desired 2’,3’-dideoxy-3’-fluoromethyl-
nucleoside 11. Phosphorylation of the 5’-hydroxyl group led to the corresponding nucleoti-
de 5 (Scheme 4).
Mesylation of 28 followed by treatment with NaN3 afforded azide 30 in 79% yield (2 steps)
(Scheme 5). Debenzylation (BCl3 in CH2Cl2), followed by 5’-phosphorylation, furnished
3’-C-azidomethyl nucleotide 3. Reduction of the azido group in 3 with Ph3P and NH4OH in
pyridine led to the 3’-CH2NH2 derivative 4. Likewise 9 was converted to 10.
The synthesis of the 3’-C-aminomethyl and 3’-C-azidomethyl ribo analogues from 23 was
performed in a similar way as for the 2’-deoxy analogues. After selective removal of the
p-anisyl group of 23, the 6’-azido moiety was introduced via mesylation and treatment with
NaN3 to yield nucleoside 13 after deprotection. Phosphorylation of 13 led to analogue 7 and
subsequent reduction of the 6’-azido group afforded analogue 8. Similarly, reduction of the
azido group of 13 afforded 14.
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Compound 15 was obtained according to reported procedures with slight modifications
(Scheme 6). An allyl group was introduced at the 3'-position of 5'-silylated thymidine by a
free-radical coupling described by C.K. Chu14 to give nucleoside 33. Aldehyde 34 was
obtained from 33 by a two-step one-pot procedure involving cis-hydroxylation with osmium
tetraoxide in the presence of 4-methylmorpholine N-oxide and sodium periodate cleavage of
the diol. 15 Reduction of 34 with sodium borohydride in aqueous ethanol, followed by
5'-desilylation of the alcohol 35, afforded the free nucleoside 15 in 24% yield from 33.16
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Binding Assay
All compounds were tested as described in the experimental section17 and are presented in
Table 1. Clearly, 2’-deoxy nucleotides 3-6 are potent inhibitors of the enzyme. The
3’-CH2NH2 nucleotide 4 , its 3’-CH2N3 precursor 3 and the 3’-CH2F nucleotide 5 exhibit the
highest affinities within this series with Ki values of 10.5 mM, 12 mM and 15 mM,
respectively. A modeling experiment (in GOLD) showed that 4 adopts a 2’-exo-3’-endo
conformation (dTMP, in contrast, is in the 2’-endo-3’-exo conformation). Consequently, the
amino group occupies the same space as the 3’-hydroxylgroup of dTMP, hence it is in an
appropriate position to interact with Asp9 (Figure 2).
O
R3
N NH
O
O
R1R2
Compound
code R1 R2 R3
Ki (mM)
TMPKmt
Ki (mM)
TMPKh
SI(Ki TMPKh/
Ki TMPKmt)
dTMP H OH OPO3
2- 4.5a 5.0a 1.1a
Thymidine33 H OH OH 27 n.d. n.d.
AZTMP34 H N3 OPO3
2- 10 n.d. n.d.
AZT33 H N3 OH 28 n.d. n.d.
16 H NH2 OPO3
2- 235 n.d. n.d.
26 OH NH2 OPO3
2- 27 n.d. n.d.
3 H CH2N3 OPO3
2- 12 32 2.7
4 H CH2NH2 OPO3
2- 10.5 4.7 0.4
5 H CH2F OPO3
2- 15 40 2.7
6 H CH2OH OPO3
2- 29 43.5a 1.5
7 OH CH2N3 OPO3
2- 116 n.i.b >9
8 OH CH2NH2 OPO3
2- 315 280 0.9
9 H CH2N3 OH 40 1040 26
10 H CH2NH2 OH 57 220 3.9
11 H CH2F OH 45 970 21.6
12 H CH2OH OH 41 420 103
13 OH CH2N3 OH 770 n.i.
c >5
14 OH CH2NH2 OH 393 110 0.3
15 H (CH2)2OH OH 156 n.d. n.d.
Table 1: Kinetic parameters of TMPKmt with the 3’-deoxy-3’-C-branched-chain-substituted
nucleosides and nucleotides. Abbreviation n.d.: not determined
a Km-value
b No inhibition (n. i.) at 1000 mM
c No inhibition (n. i.) at 4000 mM
These results indicate that the enzyme can accommodate sterically more demanding
substituents at the 3’-position. Since 5 binds the enzyme as efficiently as 3 and 4, ionic
interaction with Asp9 seems not a prerequisite for effective affinity. Interestingly, deletion of
the phosphate moiety typically results in a modest (at most 6-fold) affinity loss, while this
effect is negligible in the case of the 3’-CH2OH substituent. The largest discrepancy between
the Ki values of the free and phosphorylated forms is found for the 3’-CH2NH2 couple. The
positively charged ammonium ion may well interact with the negatively charged phosphate
moiety, thereby forcing the nucleotide in a favorable conformation for interaction with
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TMPKmt. In the absence of the phosphoryl group, this conformation is no longer preferred
and the conformational mobility of the 3’-CH2NH2 may account for the loss of affinity.
Because nucleotide 2 has a much higher affinity than the corresponding 2’-deoxyribo
analogue 1, compound 8 was expected to be active. However, introduction of a methylene
spacer between the NH2-group and C-3’ of 2, leads to 8 with a 30-fold lower affinity than the
deoxyribo analogue 4. The affinities of the other ribo analogues were weak, the smallest
decrease (6-fold) in affinity upon introduction of the 2’-hydroxyl being found for 14.
Apparently, the presence of Tyr103 close to the 2’-position impedes favorable binding
characteristics of these ribo analogues. Thus, compound 2 is the only ribo analogue with a
higher affinity than its deoxy counterpart.
Figure 2: Predicted binding mode of 4 with TMPKmt. The sugar ring is in the 2’-exo -3’-endo
conformation and the 6'-amine lies at 2.64 Å of the carboxylic oxygen of Asp9.
In order to probe the influence of the arm length at position 3’, 15 was synthesised. Its Ki
value was 5.8 and 3.8 times higher than that of dT (n = 0) and 12 (n = 1), respectively.
The selectivity of all target compounds for TMPKmt versus TMPKh was evaluated . All are
inhibitors of TMPKh except the 3'-hydroxymethylnucleotide 6, which behaves as a weak
substrate. Most nucleotides (3, 5, 6 and 8) show affinities for the human enzyme that lie in the
same order of magnitude as those for the Mycobacterium tuberculosis enzyme. The non-
phosphorylated 3'-C-branched-chain nucleosides 9, 11 and 12, on the other hand exhibit very
low affinities for the human enzyme, which results in selectivity indices between 10 and 26.
Somehow a 3'-CH2N3 functionality combined with a 2'-hydroxyl seems to introduce a
TMPKmt versus TMPKh selectivity in these 3'-C-branched-chain analogues, whereas an
opposite tendency is observed upon reduction of the 3'-CH2N3 group. To conclude,
nucleosides 9, 11 and 12 emerge as the inhibitors that combine a low Ki-value with a
favourable SI ratio and are therefore put forward as promising leads for further research.
Conclusions
In the search for more potent drugs to treat tuberculosis, the discovery of new leads with a
novel mechanism of action is of utmost importance. From this point of view, TMPKmt
represents an attractive potential target for the rational design of inhibitors, mainly because of
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its crucial positioning in the metabolic activation of thymidine and because of the different
structures between the enzymes of the bacterium and the host. This work describes the
synthesis of a number of 3’-C-branched chain-substituted substrate analogues of dTMP in the
ribo and 2’-deoxyribo series.
Several 3'-deoxy 3'-C-branched chain-substituted dTMP analogues (3-5) emerged as
promising leads for the design of novel anti-tuberculosis agents. These molecules have a high
diversity at the 3’-substitution site: the fluorine atom in 5 is sterically much smaller than an
azido group in 3, while the amino group of 4 is positively charged. The Ki values of these
compounds are very similar. This suggests that they bind in a different way, involving (most
probably) Asp9 and Tyr103 and the Mg2+ ion present near the 5’-O-phosphate group. As these
nucleosides have a 3’-C substituent, they lack the gauche effect that might stabilise 2’-deoxy-
nucleosides in the South type conformation. In a cooperative manner, a voluminous 3’-substi-
tuent should preferably occupy a pseudoequatorial position, which is achieved in the North
type conformation. On the other hand, the steric interactions between the 3'-H and the
thymine base should theoretically drive their pseudorotational equilibria to the South type
sugar conformation. This conformational mobility, together with the flexibility of the amino
acid side chain in the active site, renders prediction of binding affinities of nucleoside
analogues difficult.
Importantly, it should be noted that introduction of a hydroxyl group at the 2’-position leads
to an increase in affinity for the 3’-amino analogues 1 and 2, which is a remarkable feature for
an enzyme that metabolises only 2’-deoxynucleotides. However, protonation of the 3’-amino
group may affect the conformation of the nucleotide, as well as its interaction with the
enzyme. The most important observation refers to the small differences in binding affinities of
the 5’-O-phosphorylated and non-phosphorylated analogues, as adequately shown in the very
similar activities of 6 and 12. This result facilitates further elaboration, as it is generally
accepted that 5’-O-phosphorylated nucleosides are hardly taken up by cells. Originally, our
objective was to synthesise modified nucleoside 5’-O-phosphates that are not prone to further
phosphorylation in order to avoid cell toxicity. However, we confirmed that non-
phosphorylated analogues are as active as their phosphorylated analogues. In addition affinity
tests on TMPKh indicated that nucleosides have a significantly better selectivity profile vis à
vis TMPKh. Therefore, we will pursue in this area. Further research will be directed to
(i) exploration of other 3’-substituents of 2’,3’-dideoxythymidine with increased affinities and
(ii) investigation of the most appropriate 5’-substituent devoid of phosphorylation capacity
and, thus, associated to a low risk of toxicity.
Experimental Section
Spectrophotometric binding assay.
The in vitro tests were done on recombinant enzymes overexpressed in E. coli: TMPKmt34
and TMPKh (will be described elsewhere by Pochet et al.). TMPKmt and TMPKh activity
was determined using the coupled spectrophotometric assay described by Blondin et al.17 at
334 nm in an Eppendorf ECOM 6122 photometer. The reaction medium (0.5 ml final volume)
contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM
phosphoenol pyruvate and 2 units each of lactate dehydrogenase, pyruvate kinase and
nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept constant at
0.5 mM and 0.05 mM respectively, whereas the concentrations of analogues varied between
0.01 and 2 mM.
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Modeling
The X-ray structure published by de la Sierra et al.5 (pdb entry 1G3U) was used in all docking
experiments. Water molecules and sulphate counter ions were removed. The Mg2+ was
considered as being part of the enzyme. Explicit hydrogen atoms were added to the enzyme
and inhibitor structures using Reduce.18 PDB files were then converted to mol2 files using
Babel.19 The position of atom C1' in the dTMP ligand in the pdb file 1G3U was used as the
center of a 20 Å docking sphere. Default settings were used in Gold for all dockings.20,21 The
structures in the top 25 of the docking scores were retained for visual inspection and analysis.
Figures 1 and 2 were generated using Molscript.22
Synthesis
General
NMR spectra were obtained with a Varian Mercury 300 or a Unity 500 spectrometer.
Chemical shifts are given in ppm (d) relative to residual solvent peak in the case of DMSO-d6
(2.5 ppm). All signals assigned to amino and hydroxyl groups were exchangeable with D2O.
Mass spectra and exact mass measurements were performed on a quadrupole/orthogonal-
acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer (qTof 2, Micromass,
Manchester, UK) equipped with a standard electrospray ionisation (ESI) interface. Samples
were infused in a 2-propanol:water (1:1) mixture at 3 µL/min. The final nucleoside 5’-O-mo-
nophosphates were ultimately purified using a Gilson HPLC system with a Gilson 322 pump,
a UV/VIS-156 detector on a C18 column (10 µM; Altech; Altima; 250 ´ 22 mm). The final
nucleosides were purified by HPLC on a Perkin Elmer system with a diode-array ultraviolet
absorption detector. A Kromasil reverse phase column (C18, 250 x 4.6 mm) was used with a
linear gradient of acetonitrile (A) in 10 mM triethylammonium acetate buffer at pH 7.5 (B)
over 20 min at a flow rate of 5.5 ml/min. The purity of all target compounds was assessed by
HPLC using either a reverse phase column (Kromasil C18) with a linear gradient of A in B at
a flow rate of 1 ml/min over 20 min (method A) or an anion-exchange column (Mono Q
HR5/5) with a linear gradient of 1 M triethylammonium bicarbonate buffer at pH 7.8 in water
(method B).
Precoated Merck silica gel F254 plates were used for TLC and spots were examined under UV
light at 254 nm and revealed by sulfuric acid-anisaldehyde spray or phosphomolybdic acid
(0.5% in EtOH) solution. Column chromatography was performed on Uetikon silica
(0.2-0.06 mm).
Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone;
pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane,
dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF
was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure.
3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy-1,2-O-(isopropylidene)-a -D-ribofuranose
(21)
To a solution of 1812 (612 mg, 2.08 mmol), Ph3P (708 mg, 2.7 mmol) and p-methoxyphenol
(775 mg, 6.24 mmol) in THF (6 mL) was added dropwise diethyl azodicarboxylate (0.42 mL,
2.7 mmol). The reaction mixture was heated to 80 °C and stirred for 1.5 h. The mixture was
diluted with ether (150 mL) and the organic layer was washed with water (150 mL), dried
over MgSO4 and evaporated. The resulting residue was purified by column chromatography
(pentane-EtOAc, 9:1) yielding 21 (724 mg, 87%) as a foam. 1H NMR (300 MHz, CDCl3):
d 1.28 and 1.43 (6 H, 2s, CMe2), 2.38 (1H, m, H-3), 3.63 (1H, dd, H-5A), 3.78 (3H, s, OCH3),
3.83 (1H, dd, J5A, 5B = -10.8 Hz, H-5B), 3.97 and 4.25 (2H, 2dd, 6-H) , 4.15 (1H, m, H-4),
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4.54 and 4.66 (2H, 2d, CH2Ph), 4.79 (1H, app t, H-2,) 5.89 (1H, d, J = 3.7 Hz, H-1), 6.80
(4H, m, 4-MeOPh), 7.34 (5H, m, CH2Ph); HRMS (ESI-MS) for C23H28O6Na [M + Na]+:
found, 423.1813; calcd, 423.1783.
1,2-Di-O-Acetyl-3-[(p-anisyloxy)methyl]-5-O-benzyl-3-deoxy-a -D-ribofuranose (22)
A solution of 21 (7.812 g, 19.51 mmol) in 75% HOAc (200 mL) was stirred at 80 °C for 8 h.
The reaction mixture was evaporated to give crude 5-O-benzyl-3-deoxy-3-[(p-anisyloxy)me-
thyl]-a-D-ribofuranose as a syrup. The obtained residue was dissolved in pyridine (150 mL)
and acetic anhydride (23 mL, 246 mmol) was added. The solution was stirred at room
temperature for 3 h. The solvent was removed under vacuum and the resulting residue was
purified by column chromatography (pentane-EtOAc, 8:2) to yield 22 (8.039 g, 93%) as a
foam. 1H NMR (300 MHz, CDCl3): d 1.96 and 2.05 (6H, 2s, 2 COCH3), 2.96 (1H, m, H-3),
3.57-3.73 and 4.00-4.14 (4H, 2m, H-5 and H-6), 3.78 (3H, s, OCH3), 4.33 (1H, m, H-4), 4.59
(2H, app d, CH2Ph), 5.40 (1H, m, H-2), 6.12 and 6.46 (1H, s and d, H-1a and H-1b  ), 6.81
(4H, m, 4-MeOPh), 7.34 (5H, m, CH2Ph); HRMS (ESI-MS) for C24H28O8Na [M + Na]+:
found, 467.1707; calcd, 467.1682.
1-{3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy-b -D-ribofuranosyl}thymine (23)
Thymine (225 mg, 1.78 mmol) was suspended in hexamethyldisilazane (20 mL, 95 mmol)
containing trimethylsilylchloride (0.16 mL, 1.26 mmol) and pyridine (1.6 mL). The mixture
was heated at reflux overnight. The reaction mixture was evaporated and coevaporated with
toluene. The resulting residue and 22 (720 mg, 1.62 mmol) were dissolved in dry 1,2-di-
chloroethane (12 ml) and trimethylsilyl triflate (0.34 ml, 1.88 mmol) was added dropwise.
The clear solution was stirred 5 h at room temperature. The reaction mixture was diluted with
CH2Cl2 (200 mL) and washed with saturated aqueous NaHCO3. The organic layer was dried
over MgSO4 and evaporated. The resulting crude 1-[2-O-acetyl-3-[(p-anisyloxy)methyl]-5-O-
benzyl-3-deoxy-b-D-ribofuranosyl]thymine was treated with a 7N methanolic ammonia
solution (19 mL) at room temperature for 15 h. Evaporation yielded a residue which was
purified by column chromatography (CH2Cl2-MeOH, 98:2) to afford 23 (592 mg, 78%) as a
white foam. 1H NMR (300 MHz, DMSO-d6): d 1.39 (3 H, s, 5-CH3), 2.68 (1H, m, H-3’), 3.69
(3H, s, OCH3), 3.73 (1H, app dd, H-2’), 3.95 (2H, m, H-5’), 4.17-4.31 (3H, m, H-4’ and
H-6’), 4.59 (2H, 2 app d, CH2Ph), 5.72 (1H, app s, H-1’), 5.88 (1H, d, 2’-OH), 6.85 (4H, s,
4-MeOPh), 7.33 (5H, m, CH2Ph), 7.74 (1H, d, J6, 5-CH3 = 1.0, H-6); HRMS (ESI-MS) for
C25H28N2O7Na [M + Na]+: found, 491.1820; calcd, 491.1794.
1-{3-[(p-Anisyloxy)methyl]-5-O-benzyl-2,3-dideoxy-b -D-erythro-pentofuranosyl}thymine
(24)
To an ice-cold solution of 23 (6.55 g, 14.0 mmol) and DMAP (3.42 g, 28.0 mmol) in CH3CN
(290 mL) was gradually added phenyl chlorothionocarbonate (2.6 mL, 18.8 mmol). The
mixture was stirred at 0 °C for 1.5 h. The solvent was removed in vacuo, and the residue was
dissolved in EtOAc (500 mL). The solution was washed with water (2 x 500 mL), dried over
anhydrous MgSO4, filtered, and evaporated in vacuo to give 1-[3-[(p-anisyloxy)methyl]-5-O-
benzyl-3-deoxy-2-O-(phenoxythiocarbonyl)-b-D-ribofuranosyl]thymine as a syrup. The syrup
was dissolved in toluene (290 mL) to which 2,2’-azobis(2-methyl-propionitrile) (AIBN, 5.89
g, 35.87 mmol) and tri-n-butyltinhydride (8.00 g, 27.5 mmol) were added at 50-60 °C under
N2. The reaction mixture was stirred at 95-100 °C for 1 h. The solvent was removed in vacuo
and the residue was purified by column chromatography (pentane-EtOAc, 2:1) to yield 24
(3.98 g, 63%) as a foam. 1H NMR (300 MHz, DMSO-d6): d 1.52 (3 H, s, 5-CH3), 2.24-2.29
(2H, m, H-2’), 2.80 (1H, m, H-3’), 3.69 (3 H, s, OCH3), 3.71 (1H, m, H-5’A), 3.87 (1H, dd,
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J5’A, 5’B = -10.9 Hz, H-5’B), 3.94-4.06 (3H, m, H-4’ and H-6’), 4.53 and 4.57 (2H, 2d,
CH2Ph), 6.1 (1H, dd, J = 7.0 Hz, H-1’), 6.87 (4H, s, 4-MeOPh), 7.28-7.36 (5H, m, CH2Ph),
7.67 (1H, br s, H-6); MS (ESI) m/z (%) 475.2 ([M + Na]+, 100), 453.2 ([M + H]+, 47).
1-{3-[(p-Anisyloxy)methyl]-2,3-dideoxy-b -D-erythro-pentofuranosyl}thymine (25)
A solution of 24 (730 mg, 1.61 mmol) in MeOH (40 ml) was hydrogenated at atmospheric
pressure for 5h in the presence of 10% Pd/C (390 mg). The catalyst was removed by filtration
through celite and the filtrate was concentrated in vacuo. The residue was purified by column
chromatography (CH2Cl2-MeOH, 98:2) to give 496 mg (85%) of the debenzylated
intermediate 25 as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.78 (3 H, s, 5-CH3),
2.13-2.28 (2H, m, H-2’), 2.70 (1H, m, H-3’), 3.64 (1H, m, H-5’A), 3.69 (3H, s, OCH3) 3.78
(1H, m, H-5’B), 3.88 (1H, m, H-4’), 3.96 (2H, d, H-6’), 5.13 (1H, t, J = 5.3 Hz, 5’-OH), 6.09
(1H, dd, H-1’), 6.87 (4H, m, 4-MeOPh), 7.88 (1H, d, J = 1.2 Hz, H-6); HRMS (ESI-MS) for
C18H22N2O6Na [M + Na]+: found, 385.1413; calcd, 385.1375.
1-(2,3-Dideoxy-3-hydroxymethyl-b -D-erythro-pentofuranosyl)-5-hydroxymethylthymine
(27)
To a solution of 25 (124 mg, 0.34 mmol) in CH3CN-H2O (4:1) (5.5 mL) was added ceric
ammonium nitrate (940 mg, 1.70 mmol). After 5 min the mixture was diluted with water
(20 mL), washed with CHCl3 (20 mL) and the aqueous layer was evaporated. The residue was
purified by column chromatography (CH2Cl2-MeOH, 95:5®90:10) to give 27 (36 mg, 39%)
as a foam. 1H NMR (500 MHz, DMSO-d6): d 2.17 (ddd, J1’, 2’ = 4.6 Hz, H-2’), 2.00 (1H, dt,
J2’, 2’’ = 13.7 Hz, J1’, 2’’ = 7.2 Hz, H-2’’), 2.31 (1H, m, H-3’), 3.44 (2H, m, H-6’), 3.67 and 3.55
(2H, 2m, H-5’), 3.78 (1H, dt, H-4’), 4.13 (2H, s, 5-CH2), 4.76 (1H, t, 6’-OH), 4.86 (1H, t,
5-CH2OH), 4.94 (1H, t, 5’-CH2OH), 6.01 (1H, dd, J1’, 2’ = 4.4 and J1’, 2’’ = 6.9 Hz, H-1’), 7.81
(1H, s, H-6), 11.24 (1H, s, H-3); 13C NMR (125 MHz, DMSO-d6): d 35.04 (C-2’), 40.82
(C-3’), 56.07 (5-CH2), 61.59 (C-6’), 62.62 (C-5’), 83.47 (C-4’), 84.26 (C-1’), 113.7 (C-5),
137.01 (C-6), 150.33 (C-2), 162.98 (C-4); MS (ESI) m/z (%) 295.1 ([M + Na]+, 70).
General procedure for the selective phosphorylation of the 5’-hydroxylgroup
To a cooled (0 °C) solution of the nucleoside (0.42 mmol) in trimethyl phosphate
(10 mL/mmol), POCl3 (6.5 eq) was added dropwise and the mixture was stirred for 5 h at 0° C
and for 30 min at room temperature, after which it was poured into crushed ice-water
(10 mL), neutralised with concentrated NH4OH and evaporated to dryness. The resulting
residue was purified by column chromatography (iPrOH-NH4OH-H2O,
77.5:15:2.5®60:30:5). Further purification of the white powder by HPLC (C-18,
CH3CN-MeOH-0.05% HCOOH in H2O 45:45:10, 3 mL/min) and lyophilisation of the
appropriate fractions, provided the nucleotide as a white powder.
1-{3-[(p-Anisyloxy)methyl]-2,3-dideoxy-5-O-phosphoryl-b -D-erythro-pentofurano-
syl}thymine (26)
25 was phosphorylated as described in the general procedure and nucleotide 26 isolated in
52% yield. 1H NMR (300 MHz, D2O): d 1.94 (3 H, s, 5-CH3), 2.28-2.44 (2H, m, H-2’), 2.86
(1H, m, H-3’), 3.81 (3H, s, OCH3), 4.05-4.26 (5H, m, H-6’, H-4’ and H-5’), 6.22 (1H, dd,
J = 5.2 and 6.6 Hz, H-1’), 6.98 (4H, m, 4-MeOPh), 7.80 (1H, d, J = 0.9 Hz, H-6); 13C NMR
(125 MHz, D2O): d 14.26 (5-CH3), 37.21 (C-2’), 40.77 (C-3’), 58.51 (OCH3), 68.36 (C-5’,
2JC, P  = 19.6 Hz), 72.19 (C-6’), 84.83 (C-4’, 3JC, P = 8.8 Hz), 88.15 (C-1’), 113.86, 117.71 and
118.76 (C-5 and arom H), 140.13 (C-6), 154.18, 155.28, 156.10 (C-2 and arom H), 169 (C-4);
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 31P NMR (500 MHz, D2O): d 1.03; HRMS (ESI-MS) for C18H24N2O9P [M + H]+: found,
443.1231; calcd, 443.1219.
1-[2,3-Dideoxy-3-(hydroxymethyl)-5-O-phosphoryl-b -D-erythro-pentofuranosyl]thymine
(6)
To a solution of 26 (106 mg, 0.23 mmol) in H2O (2 mL) was added ceric ammonium nitrate
(162 mg, 0.29 mmol). After 15 min iPrOH-NH4OH-H2O (60:30:5) (20 mL) was added, the
resulting suspension was filtered and the precipitate washed with water. The combined
filtrates were evaporated under reduced pressure and the residue was purified by column
chromatography (iPrOH-NH4OH-H2O, 77.5:15:2.5®60:30:5). The resulting white powder
was further purified by HPLC (C-18, CH3CN-MeOH-0.05% HCOOH in H2O, 45:45:10,
3 mL/min) and the appropriate fractions were lyophilised yielding 6 (62 mg, 76%) as a white
powder. 1H NMR (300 MHz, D2O): d 1.93 (3 H, d, 5-CH3), 2.30 (2H, m, H-2’), 2.62 (1H, m,
H-3’), 3.70 (2H, d, J6’, 3’ = 6.1 Hz, H-6’), 4.01 (1H, m, H-4’), 4.14 (2H, m, H-5’), 6.16 (1H,
dd, J = 5.0 and 6.7 Hz, H-1’), 7.83 (1H, d, J = 1.2 Hz, H-6); 13C NMR (125 MHz, D2O):
d 14.28 (5-CH3), 37.10 (C-2’), 43.04 (C-3’), 64.75 (C-6’), 67.88 (C-5’), 85.21 (C-4’), 88.01
(C-1’), 140.42 (C-6); 31P NMR (500 MHz, D2O): d 1.03; HRMS (ESI-MS) for C11H18N2O8P
[M + H]+: found, 337.0817; calcd, 337.0800.
1-[5-O-Benzyl-2,3-dideoxy-3-(hydroxymethyl)-b -D-erythro-pentofuranosyl]thymine (28)
To a solution of 24 (3.3 g, 7.29 mmol) in CH3CN-H2O (4:1) (120 mL) was added ceric
ammonium nitrate (19.89 g, 36.68 mmol). After 5 min the mixture was diluted with CHCl3
(300 mL), washed with brine (200 mL) and a saturated solution of Na2S2O5 (200 mL), dried
over MgSO4, filtered and evaporated. The residue was purified by column chromatography
(CH2Cl2-MeOH, 97:3) to give the expected product 28 (1.810 g, 72%) as a foam. 1H NMR
(300 MHz, DMSO-d6): d 1.52 (3 H, d, 5-CH3), 2.01-2.19 (2H, m, H-2’), 2.44 (1H, m, H-3’),
3.46 (2H, app t, H-6’), 3.64 (1H, dd, H-5’A), 3.79 (1H, dd, J5’A, 5’B = -10.8 Hz, H-5’B), 3.95
(1H, m, H-4’), 4.56 (2H, app s, CH2Ph), 4.82 (1H, t, 6’-CH2OH), 6.01 (1H, dd, J = 7.0 and
4.5 Hz, H-1’), 7.36 (5H, m, CH2Ph), 7.64 (1H, d, J = 1.1 Hz, H-6); HRMS (ESI-MS) for
C18H22N2O5Na [M + Na]+: found, 369.1455; calcd, 369.1426.
1-[2,3-Dideoxy-3-(hydroxymethyl)-b -D-erythro-pentofuranosyl]thymine (12)
Hydrogenation of 28 (62.0 mg, 0.179 mmol) was accomplished at atmospheric pressure of H2
at room temperature for 45 min using 10% Pd/C (50 mg) in MeOH (5 mL). Column
chromatography (CH2Cl2-MeOH, 95:5) yielded 12 (43.4 mg, 95%) as a white foam. 1H NMR
(300 MHz, DMSO-d6): d 1.78 (3 H, d, J = 1.0 Hz, 5-CH3), 1.97-2.04 (2H, m, H-2’), 2.36
(1H, m, H-3’), 3.44 (2H, app d, J6’, 3’ = 5.7 Hz, 6’-H), 3.56 (1H, dd, H-5’A) 3.69 (1H, dd,
J5’A, 5’B = -11.9 Hz, H-5’B), 3.78 (1H, m, H-4’), 4.76 and 5.03 (2H, 2t, 5’-OH and 3’-OH),
5.98 (1H, dd, J = 4.6 and 6.9 Hz, H-1’), 7.84 (1H, br s, H-6); HRMS (ESI-MS) for
C11H16N2O5Na [M + Na]+: found, 279.0953; calcd, 279.0957. Anal. (C11H16N2O5) C, H, N.
1-[5-O-Benzyl-2,3-dideoxy-3-(fluoromethyl)-b -D-erythro-pentofuranosyl]thymine (29)
DAST (0.280 mL, 2.12 mmol) was dissolved in CH2Cl2 (5 mL) and pyridine (0.36 mL) at
0 °C under nitrogen. Nucleoside 28 (619 mg, 1.79 mmol) was added in several portions and
the solution was allowed to warm to room temperature. After 7 h, the solvent was removed
under vacuum to give a syrup which was purified by column chromatography
(CH2Cl2-MeOH, 99:1) to yield 29 (185 mg, 30%) as a white foam. 1H NMR (300 MHz,
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DMSO-d6): d 1.54 (3 H, s, 5-CH3), 2.10-2.23 (2H, m, H-2’), 2.69-2.80 (1H, m, H-3’), 3.65
(1H, dd, H-5’A), 3.80 (1H, dd, J5’A, 5’B = -10.9 Hz, H-5’B), 4.02 (1H, m, H-4’), 4.45-4.61
(4H, m, H-6’ and CH2Ph), 6.05 (1H, dd, J = 4.7 and 7.0 Hz, H-1’), 7.35 (5H, m, CH2Ph), 7.62
(1H, d, J = 1.1 Hz, H-6); HRMS (ESI-MS) for C18H22FN2O4 [M + H]+: found, 349.1586;
calcd. 349.1563.
1-[2,3-Dideoxy-3-(fluoromethyl)-b -D-erythro-pentofuranosyl]thymine (11)
A solution of compound 29 (185 mg, 0.531 mmol) in MeOH (8 mL) was hydrogenated at
atmospheric pressure in the presence of Pd/C 10% (107 mg) for 5 h. The catalyst was
removed by filtration over a celite path, the solvent evaporated in vacuo and the residue
purified by column chromatography (CH2Cl2-MeOH, 95:5) yielding 11 (134 mg, 98%) as a
white foam. 1H NMR (300 MHz, DMSO-d6): d 1.78 (3 H, s, 5-CH3), 2.06-2.21 (2H, m,
H-2’), 2.60-2.71 (1H, m, H-3’), 3.56 (1H, dd, H-5’A), 3.71 (1H, dd, J5’A, 5’B = -12.0 Hz,
H-5’B), 3.84 (1H, m, H-4’), 4.44-4.57 (2H, dd, J6’, F = 47.3 Hz, H-6’), 5.14 (1H, br s, 5’-OH),
6.02 (1H, dd, J = 4.9 and 6.7, H-1’), 7.82 (1H, s, H-6); 13C NMR (75 MHz, DMSO-d6):
d 62.19 (C-5’), 83.04 (C-4’, J4’, F = 4.5 Hz), 84.50 (C-1’), 85.64 (C-6’, J6’, F = 179 Hz), 109.64
(C-5), 136.96 (C-6), 151.06 (C-2), 164.50 (C-4), under DMSO-signal (C-3’), 34.50 (C-2’,
J2’, F = 5.3 Hz), 12.95 (5-CH3); 19F NMR (300MHz, DMSO-d6): d -222.73; HRMS (ESI-MS)
for C11H16FN2O4 [M + H]+: found, 259.1119; calcd, 259.1093. Anal. (C11H15FN2O4) C, H, N.
1-[2,3-Dideoxy-3-(fluoromethyl)-5-O-phosphoryl-b -D-erythro-pentofuranosyl]thymine
(5)
Phosphorylation of 11 was performed as described in the general procedure and the title
compound isolated in 49% yield. 1H NMR (300 MHz, D2O): d 1.94 (3 H, s, 5-CH3),
2.29-2.44 (2H, m, H-2’), 2.77-2.89 (1H, m, H-3’), 4.00-4.22 (2H, m, H-5’), 4.25 (1H, m,
H-4’), 4.53-4.70 (2H, m, H-6’), 6.16 (1H, dd, J = 5.0 and 7.0 Hz, H-1’), 7.84 (1H, d,
J = 1.2 Hz, H-6); 13C NMR (75 MHz, D2O): d 11.69 (5-CH3), 33.45 (C-2’, J2’, F = 6.0 Hz),
65.30 (C-5’), 38.66 (C-3’, J3’, F = 19.6 Hz), 81.50 (C-4’, J4’, F = 6.7 Hz), 84.10 (C-6’,
J6’, F = 165.2 Hz), 85.43 (C-1’), 111.40 (C-5), 137.69 (C-6), 151.80 (C-2), 166.80 (C-4);
19F NMR (300 MHz, D2O): d -224.50; 31P NMR (500 MHz, D2O): d 1.12; HRMS (ESI-MS)
for C11H17FN2O7P [M + H]+: found, 339.0806; calcd, 339.0757.
1-[3-(Azidomethyl)-5-O-benzyl-2,3-dideoxy-b -D-erythro-pentofuranosyl]thymine (30)
Methanesulfonyl chloride (0.180 mL, 2.33 mmol) was added to a solution of compound 28
(306 mg, 0.883 mmol) in pyridine (3 mL) at 0 °C. The reaction mixture was stirred at 0° C
during 1 h. Then it was diluted with CH2Cl2 (50 mL), washed with saturated aqueous
NaHCO3 (50 mL) and dried over anhydrous MgSO4. The solvent was removed under
diminished pressure to give the crude mesylate. The obtained residue was dissolved in DMF
(16 mL) and treated with NaN3 (574 mg 8.83 mmol) at 95 °C for 1.5 h to complete the
reaction. The reaction mixture was evaporated to dryness in vacuo and the residue was
dissolved in CH2Cl2 (50 mL). The organic layer was washed with water (50 mL), dried over
anhydrous MgSO4 and evaporated to give a sirup which was purified by column
chromatography (CH2Cl2-MeOH, 99:1) yielding 30 (260 mg, 79%) as a white foam. 1H NMR
(300 MHz, DMSO-d6): d 1.52 (3 H, d, 5-CH3), 2.50 (2H, m, H-2’), 2.60 (1H, m, H-3’),
3.46-3.59 (2H, 2dd, H-6’), 3.66 (1H, dd, H-5’A), 3.83 (1H, dd, J5’A, 5’B = -10.4 Hz, H-5’B),
3.93 (1H, m, H-4’), 4.57 (2H, app s, CH2Ph), 6.04 (1H, app t, J = 5.9 Hz, H-1’), 7.31 (5H, m,
CH2Ph), 7.62 (1H, br s, H-6); HRMS (ESI-MS) for C18H21N5O4Na [M + Na]+: found,
394.1489; calcd, 394.1491.
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1-[3-(Azidomethyl)-2,3-dideoxy-b -D-erythro-pentofuranosyl]thymine (9)
To a solution of 30 (1.49 g, 4.01 mmol) in CH2Cl2 (160 mL) at -78 °C was slowly added a 1M
solution of BCl3 in CH2Cl2 (16.1 mL, 16.1 mmol). After 15 min MeOH (5 mL) was added and
the reaction mixture was evaporated to dryness under reduced pressure. The resulting residue
was purified by column chromatography (CH2Cl2-MeOH, 90:10) affording 9 (1.00 g, 89%)
as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.78 (3 H, d, 5-CH3), 2.13 (2H, m, H-2’),
2.51 (1H, m, H-3’), 3.51 (2H, app d, H-6’), 3.55-3.61 (1H, m, H-4'), 3.69-3.74 (2H, m,
H-5’), 5.13 (1H, app t, 5’-OH), 6.02 (1H, dd, J = 5.0 and 6.3 Hz, H-1’), 7.82 (1H, d,
J = 1.1 Hz, H-6); 13C NMR (125 MHz, DMSO-d6): d 12.96 (5-CH3), 36.36 (C-2’), 38.07
(C-3’), 52.71 (C-6’), 61.90 (C-5’), 84.45 and 84.13 (C-1’ and C-4’), 109.56 (C-5), 136.97
(C-6), 151.05 (C-2), 164.51 (C-4); HRMS (ESI-MS) for C11H15N5O4Na [M + Na]+: found,
304.1033; calcd, 304.1021. Anal. (C11H15N5O4) C, H, N.
1-[3-(Aminomethyl)-2,3-dideoxy-b -D-erythro-pentofuranosyl]thymine (10)
Compound 9 (169 mg, 0.60 mmol) and triphenylphosphine (252 mg, 0.96 mmol) were
dissolved in pyridine (7 mL) and stirred at room temperature. After 1h, concentrated NH4OH
(6 mL) was added and the solution was allowed to stir for an additional 2h. Pyridine was
removed under reduced pressure, water (8 mL) was added and the unreacted triphenylphos-
phine and triphenylphosphine oxide were removed by filtration. The filtrate was extracted
with toluene and the water layer was evaporated under reduced pressure to give a syrup. The
syrup was purified by column chromatography (0.175 N NH3 in CH2Cl2-MeOH, 80:20) to
yield amine 10 (112 mg, 73%) as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.78 (3 H,
s, 5-CH3), 2.3-2.14 (2H, m, H-2’), 2.24 (1H, m, H-3’), 2.55-2.65 (2H, m, H-6’), 3.55-3.71
(3H, m, H-5’ and H-4’), 5.95 (1H, dd, J = 3.9 and 6.9 Hz, H-1’), 7.8 (1H, d, J = 1.1 Hz, H-6);
13C NMR (75 MHz, DMSO-d6): d 12.98 (5-CH3), 43.38, 41.60 and 37.05 (C-6’, C-3’ and
C-2’), 62.27 (C-5’), 85.49 (C-4’), 85.24 (C-1’), 109.37 (C-5), 136.95 (C-6), 151.04 (C-2),
164.51 (C-4); HRMS (ESI-MS) for C11H18N3O4 [M + H]+: found, 256.1293; calcd, 256,1296.
Anal. (C11H17N3O4) C, H, N.
1-[3-(Azidomethyl)-2,3-dideoxy-5-O-phosphoryl-b -D-erythro-pentofuranosyl]thymine (3)
9 was phosphorylated as described in the general procedure to yield 53% of the title
compound. 1H NMR (300 MHz, D2O): d 1.91 (3 H, s, 5-CH3), 2.33 (2H, app dd, H-2’), 2.68
(1H, m, H-3’), 3.54 (2H, app d, J6’, 3’ = 6.3 Hz, H-6’), 4.00-4.19 (3H, m, H-5’ and H-4’), 6.16
(1H, app t, J = 5.8 Hz, H-1’), 7.80 (1H, d, J = 1.1 Hz, 6-H); 13C NMR (75 MHz, D2O):
d 11.75 (5-CH3), 35.36 (C-2’), 37.71 (C-3’), 52.15 (C-6’), 65.13 (C-5’), 82.62 (C-4’), 85.36
(C-1’), 111.36 (C-5), 137.71 (C-6), 151.79 (C-2), 166.79 (C-4); 31P NMR (500 MHz, D2O):
d 1.14; HRMS (ESI-MS) for C11H16N5O7P [M + H]+: found, 362.0889; calcd, 362.0865.
1-[3-(Aminomethyl)-2,3-dideoxy-5-O-phosphoryl-b -D-erythro-pentofuranosyl]thymine
(4)
Compound 3 (476 mg, 1.26 mmol) and triphenylphosphine (528 mg, 2.01 mmol) were
dissolved in pyridine (15 mL) and stirred at room temperature. After 1h, concentrated NH4OH
(12.6 mL) was added and the solution was allowed to stir for an additional 6.5 h. Pyridine was
removed at reduced pressure, water (200 mL) was added and the unreacted triphenylphosphi-
ne and triphenylphosphine oxide were removed by filtration. The filtrate was extracted with
toluene and the water layer was evaporated under reduced pressure to give a syrup. The syrup
was purified by column chromatography (iPrOH-NH4OH-H2O, 77.5:15:2.5®60:30:5). The
resulting white powder was further purified by HPLC (C-18, CH3CN-MeOH-0.05%
HCOOH in H2O, 45:45:10, 3 mL/min) and the fractions containing the title compound were
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lyophilised to yield 4 (306 mg, 69%) as a white powder. 1H NMR (300 MHz, D2O): d 1.92
(3 H, s, 5-CH3), 2.32-2.50 (2H, m, H-2’), 2.74-2.82 (1H, m, H-3’), 3.12-3.26 (2H, 2dd,
H-6’), 4.05-4.12 (3H, m, H-4’ and H-5’), 6.17 (1H, dd, J = 3.7 and 7.3 Hz, H-1’), 7.78 (1H,
d, J = 1.2 Hz, H-6); 13C NMR (75 MHz, D2O): d 11.76 (5-CH3), 166.79 (C-2), 151.74 (C-4),
137.70 (C-5), 111.40 (C-6), 85.29 (C-1’), 82.72 (C-4’), 63.94 (C-5’), 40.80 (C-6’), 36.88
(C-3’), 35.95 (C-2’); 31P NMR (500 MHz, D2O): d 2.82; HRMS (ESI-MS) for
C11H19N3O7PNa [M + Na]+: found, 336.0980; calcd, 336.0960.
1-[5-O-Benzyl-3-deoxy-3-(hydroxymethyl)-b -D-ribofuranosyl]thymine (31)
This compound was synthesised from 23 (346 mg, 0.74 mmol) using the procedure described
for 28 to yield 130 mg (49%) of the title compound as a foam. 1H NMR (300 MHz,
DMSO-d6): d 1.42 (3 H, s, 5-CH3), 2.31 (1H, m, J3’, 6’ = 6.6 Hz, H-3’), 3.49 and 3.68 (2H, 2m,
6’-H), 3.64 (1H, m, H-5’A), 3.98 (1H, m, J5’A, 5’B = -11.1 Hz, H-5’B), 4.13 (1H, m, H-4’),
4.19 (1H, m, H-2’), 4.58 (3H, m, CH2Ph and 6’-OH), 5.60 (1H, d, J = 5.0 Hz, 2’-OH), 5.67
(1H, d, J = 1.9, H-1’), 7.37 (5H, m, CH2Ph), 7.70 (1H, br s, 6-H); HRMS (ESI-MS) for
C18H22N2O6Na [M + Na]+: found, 385.1386; calcd, 385.1375.
1-[3-Azidomethyl-5-O-benzyl-3-deoxy-b -D-ribofuranosyl]thymine (32)
This compound was synthesised from 31 (130 mg, 0.36 mmol) using the same procedure as
described for the synthesis of 30 to yield 123 mg (89%, 2 steps) of the title compound as a
foam. 1H NMR (300 MHz, DMSO-d6): d 1.42 (3 H, s, 5-CH3), 2.46 (1H, m, H-3’), 3.35-3.90
(4H, m, H-5’ and H-6’), 4.10 (1H, m, H-4’), 4.22 (1H, m, H-2’), 4.59 (2H, s, CH2Ph), 5.67
(1H, d, J = 1.6 Hz, H-1’), 5.93 (1H, d, J = 5.1 Hz, 2’-OH), 7.37 (CH2Ph), 7.67 (1H, br s,
H-6); HRMS (ESI-MS) for C18H21N5O5Na [M + Na]+: found, 410.1504; calcd, 410.144.
1-[3-Azidomethyl-3-deoxy-b -D-ribofuranosyl]thymine (13)
Debenzylation of 32 (346 mg, 0.89 mmol) was performed as described for the synthesis of 9
to yield 210 mg (79%) of the title compound as a foam. 1H NMR (300 MHz, DMSO-d6):
d 1.76 (3 H, s, 5-CH3), 2.37 (1H, m, H-3’), 3.35-3.78 4H, m, H-5’ and H-6’), 3.91 (1H, m,
H-4’), 4.20 (1H, app d, H-2’), 5.24 (1H, br s, 5’-OH), 5.66 (1H, d, J1’, 2’ = 1.9 Hz, H-1’), 5.94
(1H, br s, 2’-OH), 7.95 (1H, br s, H-6). The assignment, done by a cosy-experiment, differs
from that reported in ref. 8. 13C NMR (75 MHz, DMSO-d6): d 12.95 (5-CH3), 41.35 (C-3’),
47.90 (C-6’), 61.14 (C-5’), 75.36 (C-2’), 82.90 (C-4’), 91.26 (C-1’), 109.10 (C-5), 136.93
(C-6), 151.11 (C-2), 164.53 (C-4); HRMS (ESI-MS) for C11H15N5O5Na [M + Na]+: found,
320.0975; calcd, 320.0971. Anal. (C11H15N5O5) C, H, N.
1-[3-Aminomethyl-3-deoxy-b -D-ribofuranosyl]thymine (14)
Reduction of azide 13 (173 mg, 0.58 mmol) was accomplished using the procedure described
for the synthesis of 11 to yield 123 mg (73%) of amine 14 as a foam. 1H NMR (300 MHz,
DMSO-d6): d 1.76 (3 H, d, 5-CH3), 2.16 (1H, m, H-3’), 2.63-2.89 (2H, 2dd, H-6’), 3.59 (1H,
dd, H-5’A), 3.76 (1H, dd, , J5’A, 5’B = -12.3 Hz, H-5’B), 3.92 (1H, m, H-4’), 4.21 (1H, app d,
H-2’), 5.63 (1H, d, J = 1.4 Hz, H-1’), 7.94 (1H, d, J = 1.1 Hz, H-6); HRMS (ESI-MS) for
C11H18N3O5 [M + H]+: found, 272.1245; calcd, 272.1246. Anal. (C11H17N3O5) C, H, N.
1-[3-Azidomethyl-3-deoxy-5-O-phosphoryl-b -D-ribofuranosyl]thymine (7)
13 was phosphorylated as described in the general procedure to yield 51% of nucleotide 7.
1H NMR (300 MHz, D2O): d 1.92 (3 H, d, 5-CH3), 2.59 (1H, m, H-3’), 3.56 and 3.66 (2H,
2dd, J6’, 3’ = 5.8 and 8.1 Hz, H-6’), 4.04 (1H, m, H-5’A), 4.26 (1H, m, H-5’B), 4.32 (1H, app
d, H-4’), 4.52 (1H, dd, H-2’), 5.86 (1H, d, J = 2.0 Hz, H-1’), 7.89 (1H, d, J = 1.0 Hz, H-6);
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13C NMR (125 MHz, D2O): d 14.28 (5-CH3), 43.40 (C-3’), 49.71 (C-6’), 66.68 (C-5’,
2JC, P = 36.0 Hz), 77.95 (C-2’), 84.52 (C-4’, 3JC, P = 8.9 Hz), 93.83 (C-1’), 113.62 (C-5),
139.84 (C-6), 154.25 (C-2), 169.33 (C-4); 31P NMR (500 MHz, D2O): d 1.27; HRMS
(ESI-MS) for C11H17N5O8P [M + H]+: found, 378.0813; calcd, 378.0814.
1-[3-Aminomethyl-3-deoxy-5-O-phosphoryl-b -D-ribofuranosyl]thymine (8)
Azide 7 (346 mg, 0.74 mmol) was reduced to the corresponding amine following the
procedure described for the preparation of 4 to yield 110 mg (65%) of the amino-nucleotide 8
as a foam. 1H NMR (300 MHz, D2O): d 1.92 (3 H, s, 5-CH3), 2.69 (1H, m, H-3’), 3.17 and
3.38 (2H, 2dd, J = 5.2 and 10.2 Hz, H-6’), 4.07 and 4.17 (2H, 2m, H-5’), 4.30 (1H, app d,
H-4’), 4.56 (1H, dd, H-2’), 5.84 (1H, d, J = 1.8 Hz, H-1’), 7.86 (1H, d, J = 1.1 Hz, H-6);
13C NMR (125 MHz, D2O): d 14.30 (5-CH3), 38.26 (C-6’), 42.22 (C-3’), 65.74 (C-5’,
2JC, P = 4.9 Hz), 77.88 (C-2’), 84.43 (C-4’, 3JC, P  = 7.8 Hz), 94.17 (C-1’), 113.72 (C-5), 139.95
(C-6), 155.51 (C-2), 169.32 (C-4); 31P NMR (500 MHz, D2O): d 3.45; HRMS (ESI-MS) for
C11H19N3O8P [M + H]+: found, 352.0902; calcd, 352.0909.
3'-Deoxy-3'-C-(2-hydroxyethyl)thymine (15)
To a mixture of 5'-O-tert-butyldiphenylsilyl-3'-C-allyl-2',3'-dideoxy-thymidine (33)14 (0.80 g,
1.58 mmol) and 4-methylmorpholine N-oxide (0,26 g, 1.91 mmol) in dioxane (10 mL) was
added an aqueous solution of OsO4 (0.09 mmol, 1% in water). After stirring 3 h at room
temperature under light protection, the reaction mixture was complete (TLC), then sodium
periodate (0.53 g, 2.49 mmol) was added in small portions. After completion of the reaction
(2 h), the mixture was diluted with ethyl acetate, filtered through celite and solids washed
with ethyl acetate. The combined filtrates were washed with saturated aqueous NaCl, dried
and evaporated under vacuum. To the crude aldehyde 34 in ethanol/water (6/2 mL) was added
dropwise NaBH4 (0.18 g, 4.90 mmol) in ethanol (30 mL). After 2 h at room temperature, the
reaction was complete. The mixture was diluted in ethyl acetate and washed with water, the
organic layer was dried and concentrated to dryness. After purification by column chroma-
tography (CH2Cl2/MeOH), compound 35 (0.24 g, 0.48 mmol) was isolated in 30% yield from
33 as a white foam. Compound 35 (50 mg, 0.098 mmol) was treated with a 1M solution of
TBAF in THF (0.5 mL). After stirring 1 h at room temperature, solvent was evaporated and
the residue was purified by HPLC on a C18 reverse phase column (5-25 % linear gradient of
acetonitrile in 10 mM TEAA) to give compound 15 (22 mg, 81%). Rt = 8.98 min. 1H NMR
(400 MHz, D2O): d 1.50 (1H, m, H-6'A), 1.75 (1H, m, H-6'B), 1.81 (3 H, d, J6, 5-CH3 = 1.1 Hz,
5-CH3), 2.15 (1H, m, H-2'A), 2.25 (2H, m, H-2B and H-3’), 3.58 (2H, m, H-7'A and H-7'B),
3.70 (1H, dd, J = 8.6 and 4.4, H-5’A), 3.79 (1H, m, H-4’), 3.86 (1H, dd, J = -12.7 Hz,
J = 2.5 Hz, H-5’B), 6.06 (1H, dd, J = 7.2 and 2.1 Hz, H-1’), 7.71 (1H, d, J6, 5-CH3 = 1.1 Hz,
H-6). 13C NMR (100 MHz, D2O) d: 11.92 (CH3), 33.83 (C6’), 34.46 (C3’), 37.90 (C2’), 60.51
(C7’), 61.34 (C5’), 86.96 (C1’), 85.61 (C4’), 111.19 (C5), 138.17 (C6), 152.09 (C2), 167.00
(C4); HRMS (ESI-MS) for C12H19N2O5 [M + H]+: found, 271.1288; calcd, 271.1283.
Supporting Information Available
HPLC retention times of all target compounds. This material is available free of charge via
the Internet at http://pubs.acs.org.
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Abstract
The affinity of a series of 2’, 3’-and 5-modified thymidine analogues for Mycobacterium
tuberculosis thymidine monophosphate kinase (TMPKmt) was evaluated. The affinities of
several non-phosphorylated analogues are in the same order of magnitude as those of their
phosphorylated congeners. In view of drug delivery problems associated with phosphorylated
compounds, these “free” nucleosides seem more promising leads in the search of TMPKmt
inhibitors as novel anti-tuberculosis agents.
Recently, Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) was put
forward as an attractive target for the design of a novel class of anti-tuberculosis agents.1,2,3
Figure 1: Schematic representation of the most important amino acid residues of TMPKmt interacting
with TMP (in black).
TMPK accounts for the phosphorylation of thymidine monophosphate (dTMP) to thymidine
diphosphate (dTDP), using ATP as a preferred phosphoryl donor.4 Because TMPK lies at the
junction of the de novo and salvage pathways of thymidine triphosphate (dTTP) synthesis and
in view of its low (22%) sequence identity with the human isozyme,5 it represents an
attractive target for selectively blocking mycobacterial DNA synthesis. Recently, the X-ray
structure of TMPKmt was solved at 1.95 Å as a complex with dTMP,6 allowing structure-
based design of TMPKmt ligands (Figure 1).
In order to establish initial structure-activity relationships, a series of sugar- and base-
modified nucleoside-5'-O-monophosphates were examined for TMPKmt affinity. The aim of
conserving the 5'-O-monophosphate moiety was to preserve its hydrogen bonding and ionic
interactions with Tyr39, Arg95 and Mg2+. These bindings, together with the stacking
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interaction between the pyrimidine ring and Phe70 should account for a dTMP-like
orientation of the substrate analogues under investigation, thereby rendering prediction and
modeling of the interactions of the various dTMP substituents with the enzyme more
straightforward. Next, alternative substitution patterns at the 5'-position would be explored
and combined with optimal sugar and base modifications. These sugar- and base-modified
nucleotides were examined on their affinity for the enzyme using a reported
spectrophotometric assay, 7 unless mentioned otherwise.
First, systematic substitution of the 5-methyl group for various halogen atoms was explored.
5F-dUMP, 5Br-dUMP and 5I-dUMP turned out to be substrates for TMPKmt.5 5Br-dUMP
(Km = 33 mM) showed the highest affinity, probably because a bromine occupies about the
same steric space as a methyl group. The presence of the guanidinium group of Arg74 in the
otherwise hydrophobic pocket around the 5-position could explain the measured affinity of
the halogenated substrates. It is believed that the difference in the kinetic parameters of these
compounds essentially reflects a size effect, with the halogen atoms serving as cavity filling
atoms.5 A co-crystal of 5I-dUMP with TMPKmt6 showed that it, indeed, binds the phosphate
acceptor binding site in a very similar fashion to dTMP.2
Since these findings confirmed the assumption that TMPKmt can accommodate sterically
larger substituents at the 5-position, 1 was synthesised to accomplish a favourable interaction
with a water molecule (W12), detected in the crystal structure. In contrast to the 5-halogeno-
substituted substrates, this compound behaves as a (relatively weak) inhibitor of TMPKmt.
Co-crystallisation with TMPKmt proved the predicted interaction with W12.2 Other dTMP
analogues with sterically more demanding substituents that maintain one polar atom (2 and 3)
were found less active inhibitors than 1, indicating that the volume of the cavity cannot be
stretched too much. It is inferred that these three compounds are inhibitors because any
modification, significantly perturbing the volume at the 5-position, changes the orientation of
the sugar moiety as well as that of the a-phosphate.2 Surprisingly, removal of the 5-methyl-
group of dTMP (dUMP) caused a drastic decrease in affinity (Km = 2100 mM compared to
4.5 mM for dTMP) (Table 1).5
OH
O
--OPO3
N NH
O
O
R
Compounds R Km (µM) Vm
a Ki (µM)
dTMP5 CH3 4.5 10.6
dUMP5 H 2100 3.5
5F-dUMP6 F 420 4.7
5Br-dUMP6 Br 33 9.8
5I-dUMP6 I 140 7.5
12 CH2OH 110
b
22 furan-2-yl 140b
32 thien-2-yl 270b
42 benzyl 28
Table 1: Kinetic parameters of TMPKmt with base-modified nucleoside monophosphates.
a Vm in mmole/min.mg of protein
b The TMP kinase activity of these compounds was not determined using the spectrometric test
described by Blondin et al.7 but using HPLC chromatography. The Km for dTMP obtained with this test
is 40 mM.2
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The observation that TMPKmt, as opposed to all TMPKs of other species examined so far,5 is
strongly inhibited by AZTMP (Ki = 10 mM) offered good prospects for finding selective
inhibitors of TMPKmt through altering the sugar part of the dTMP scaffold. At the
3'-position, the crystal structure reveals a hydrogen bonding network (denoted by the dotted
lines, Figure 1): the 3'-OH of dTMP interacts with the terminal carboxyl of Asp9, which, in its
turn, is linked to the Mg2+-ion that is responsible for positioning a phosphate oxygen of TMP.
Through its interaction with Asp9, the 3'-azido function of AZTMP is believed to perturb the
aforementioned hydrogen bonding interplay that is essential for catalysis, hence completely
impeding the phosphoryl transfer.6 Although an analogous interaction was expected upon
reduction of the 3'-azido group of AZTMP to a 3'-amine (5), this drastically increased the
Ki-value to 235 mM. Replacing the 3'-OH of dTMP by a 3'-F (8), on the other hand, afforded
an analogue that behaves as a substrate with a Km of 30 mM.
The presence of Tyr103 close to the 2'-position is believed to render the enzyme catalytically
selective for 2'-deoxynucleotides versus ribonucleotides. The ribo analogue (6) of 5, however,
unexpectedly showed a much higher affinity for the enzyme (45 mM versus 235 mM), this
compound being the first example of a ribonucleotide with good affinity for TMPKmt.
Modeling indicates that, in this case, Tyr103 stays somewhat further away from the
2'-position and is, therefore, unable to clash with the 2'-hydroxyl.1 Introduction of halogens at
the 2'-position (9 and 10) is better tolerated than a hydroxyl group at that position. Modeling
showed that the halogen affects the relative position of the sugar ring. As a result, the
2'-chlorine occupies the pocket, in which the 3'-hydroxyl usually resides. As previously
demonstrated with AZTMP, this particular domain can, indeed, accommodate more
voluminous substituents.1
Replacing the 5-membered sugar ring of dTMP by a 1,5-anhydrohexitol yielded a moderately
active inhibitor. This effect is probably due to the inability of 11 to position both the
phosphate and the 3'-hydroxyl groups in a favourable arrangement for catalysis.2 With a Ki of
30 mM, the bisubstrate analogue Ap5T, emerged as a good inhibitor of TMPKmt. The crystal
structure of the complex of TMPKmt with Ap5T, which has been established at 2.45 Å
resolution,2 revealed an unexpected binding mode for the adenine moiety of this compound.
While the thymidine residue of this bisubstrate analogue occupies the binding pocket of
dTMP, its ADP unit, surprisingly, fits a cavity on the surface of TMPKmt. This finding opens
avenues to the design of branched molecules at the a-phosphate of Ap5T, with an additional
group reaching out to this cavity present only in TMPKmt (Table 2).2
Obviously, monophosphate derivatives are unable to enter cells and, as a consequence, can
not be delivered in such a way. Generally, nucleosides cross the cell membrane barrier in a
non-phosphorylated form and are then converted by intracellular kinases to the corresponding
nucleotides. In this particular case where TMPK is the drug target, a thymidine analogue
could be activated by thymidine kinase (TK), which converts the analogue into the
corresponding monophosphorylated compound. However, a search of the M. tuberculosis
genome8 did not identify any gene coding for a TK. This result aligns with other biochemical
studies indicating a lack of TK activity in mycobacteria.9 At first sight, the absence of TK
seems to be a severe limitation on the use of thymidine analogues or related compounds as
anti-tuberculosis drugs. However, the finding that dT behaves as a competitive inhibitor of
TMPKmt (with Ki in the same order of magnitude as Km of dTMP3), raises the possibility of
discovering non-phosphorylated nucleosidic inhibitors of TMPKmt. Enhancing the specific
delivery of such inhibitors to bacteria within macrophages by modifying the 5'-position of
dTMP is another option. Such modifications may also decrease toxicity by reducing
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interaction with the host cellular TK. Replacement of the 5'-hydroxyl by an azido or amino an
group (13 and 14) yielded two high-affinity inhibitors of TMPKmt (Ki values of 7 and 12 mM,
respectively).3
R2
O
R3
N NH
O
O
R1
O
N NH
O
O--OPO3
OH
15
Compounds R1 R2 R3 Ki (µM)
dTMP H H OPO3
2- 4.5a
AZTMP5 H N3 OPO3
2- 10
D4T-MP5 dehydro dehydro OPO3
2- 140a
51 H NH2 OPO3
2- 235
61 OH NH2 OPO3
2- 45
71 NH2 OH OPO3
2- 120
81 H F OPO3
2- 30a
91 Cl OH OPO3
2- 19
101 F OH OPO3
2- 43
112 150b
Ap5T
2 30b
Table 2: Kinetic parameters of TMPKmt with sugar-modified nucleoside monophosphates.
a Km-value
b The TMP kinase activity of these compounds was not determined using the spectrophotometric assay
by Blondin et al.7, but using HPLC chromatography. Km for dTMP is 40 mM.
2
We investigated whether the negligible effect on TMPKmt affinity, observed upon deletion of
the phosphate moiety of dTMP, is parallelled in other series. AZT, 5-BrdU and 221 exhibited
similar affinities as their nucleotide congeners. In the case of 23,1 the affinity decreased only
2.8 times upon removal of the 5'-O-phosphoryl. With regard to these observed similar
affinities of nucleosides and nucleotides and in view of the drug delivery problems of phos-
phorylated compounds, nucleosides seem more useful leads for further drug design.
To further explore other substitution patterns at the 5'-position, the 5'-hydroxymethyl was
substituted for a 5'-methyl. In 25,10 this caused a 42-fold decrease in affinity compared to 6.
The affinities of 2011 and 1911, on the contrary, were similar, making assumptions about the
removal of the 5'-hydroxyl group unreliable. Compound 24,10 with a 5'-iodo group, showed a
low affinity (Ki = 490 mM), but it's not clear if the 5'-iodo group or the 2'-hydroxyl function
accounts for this effect.
Because 6 conveyed the impression that ribo analogues are well tolerated by TMPKmt, two
other ribonucleosides (1512 and 19) were examined. The affinity of 15 was 26 times lower
than the affinity of dT and 19 showed to be a poor inhibitor as well. These results indicate that
the affinity improvement resulting from the introduction of a 2'-hydroxyl function in 5 (6) is
exceptional. 1613 even indicates that a 2'-b-OH is better tolerated.
Because AZTMP is one of the best known inhibitors, another nitrogen-containing substituent,
a guanidine group (26),10 was introduced at the 3'-position. Although one would expect the
delocalised positive charge of the guanidine moiety to strengthen the interaction with Asp9,
the Ki value of 140 mM was not affirmative.
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Since the efficient affinity of 1 proved that the 5-position can accommodate intermediately
sized substituents, 1711 (which has a 5-CF3 mimicking the size of the 5-methyl) and 1811 were
investigated as well. However, with Ki-values of 97 and 1140 mM, they proved to be poor
inhibitors of TMPKmt (Table 3).
In our search for high-affinity TMPKmt ligands as anti-tuberculosis agents, most of the base-
and sugar-modified dTMP-analogues (with the 5-halogeno dUMP derivatives, dUMP,
3'-F-dTMP and D4T-MP as exceptions) proved to be inhibitors of the enzyme. However,
conversion to prodrugs is the only way to deliver phosphorylated compounds into cells. Since
this recent work indicates that in many cases (AZT, 5-BrdU, 22 and 23) nucleoside analogues
show affinities that approach those of their phosphorylated counterparts, this problem could
be easily circumvented by focusing on nucleosides instead of nucleotides. Concerning the
5'-modifications we can conclude that a 5'-amino and a 5'-azidofunction are a good alternative
for a 5'-hydroxyl and that further study is required to probe the effect of the deletion of the
5'-hydroxyl. At the 2'-position, a 2'-hydroxyl has proven to reduce the affinity for TMPKmt,
with compounds 5 and 6 as the only exception known so far.
Future research will be directed towards finding other high-affinity 5'-substituents that are
unable to be phosphorylated by cellular kinases, thereby diminishing the risk for toxicity and
further exploration of the 3'-position to improve the current inhibitors. Also, analogues
exhibiting interesting inhibitory activity towards TMPKmt will be examined for selectivity
vis-à-vis the human enzyme.
R3
O
R4
N NH
O
O
R1
R2
Compounds R1 R2 R3 R4 Ki (µM)
dTMP CH3 H OH OPO3
-- 4.5a
dT CH3 H OH OH 27
AZT CH3 H N3 OH 28
5Br-dU3 Br H H H 5
123 CH3 H OH NHCOCH3 90
133 CH3 H OH N3 7
143 CH3 H OH NH2 12
15 CH3 OH OH OH 715
16 CH3 OH
b OH OH 238
17 CF3 H OH OH 97
18 CH2CH3 H OH OH 1140
19 F OH OH OH 521
20 F OH OH H 560
21 CH3 H NH2 OH 230
22 CH3 H F OH 28
23 CH3 F OH OH 122
24 CH3 OH N3 I 490
25 CH3 OH NH2 H 1900
26 CH3 OH NHC(NH)NH2 OH 140
Table 3: Kinetic parameters of TMPKmt with sugar- and base-modified thymidine analogues.
a Km-value; 
b This hydroxyl lies at the b-side of the sugar ring.
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Abstract
Thymidine monophosphate kinase of Mycobacterium tuberculosis represents an attractive
target for selectively blocking the bacterial DNA synthesis. Hereby, we report on the
discovery of a novel class of bicyclic nucleosides (10 and 11) and one dinucleoside (12),
belonging to the most selective inhibitors of TMPKmt discovered so far.
Introduction
The appearance of multiple drug-resistant strains of Mycobacterium tuberculosis and the
synergism between HIV and M. tuberculosis infection has caused a steeply rising incidence of
tuberculosis during the last decades. This has made the development of new anti-tuberculosis
agents, preferably acting on novel targets, a research priority for many health organisations.1
M. tuberculosis thymidine monophosphate kinase (TMPKmt) recently emerged as a potential-
ly attractive target for the design of a novel class of anti-tuberculosis agents.2
TMPK catalyses the g-phosphate transfer from ATP to thymidine monophosphate (dTMP) in
the presence of Mg2+, yielding thymidine diphosphate (dTDP) and ADP.3 Because TMPK is
essential for thymidine triphosphate (dTTP) synthesis and in view of its low (22%) sequence
identity with the human isozyme (TMPKh),2 it represents an attractive target for selectively
inhibiting mycobacterial DNA synthesis. Recently, the X-ray structure of TMPKmt was
solved at 1.95Å as a complex with dTMP,4 allowing structure-based design of TMPKmt
ligands.
A series of 2'-, 3'- and 5-modified nucleosides and nucleotides was tested for their affinities
with respect to TMPKmt.5,6,7,8 The results showed that, in general, nucleosides and their
corresponding 5'-O-monophosphate esters were nearly equivalent inhibitors of TMPKmt. The
low permeability of the cell wall for phosphorylated compounds (i.e. nucleotides) prompted
us to focus on nucleosides as new drug leads. Recently, we reported a series of 3'-C-branched
chain nucleosides and nucleotides that exhibit micromolar inhibitory activity against
TMPKmt.9 The introduction of 3'-CH2OH, 3'-CH2NH2, 3'-CH2N3 and 3'-CH2F substituents
was aimed at occupying a cavity in the enzyme near the 3'-position. Biological results and
modeling confirmed this hypothesis. Modeling also indicated that these nucleosides bind to
TMPKmt in the (N) (northern, 2'-exo-3'-endo) conformation [dTMP, in contrast, binds to
TMPKmt in the (S) (southern, 2'-endo, 3'-exo) conformation]. This N-type sugar pucker
enables interactions between the 6'-substituent and Asp9.9 From this, 1-[3-C-(azidomethyl)-
2,3-dideoxy-b-D-erythro-pentofuranosyl]thymine (1) emerged as a promising lead for further
research, since it combines a low Ki-value with a favourable selectivity profile for TMPKmt
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versus TMPKh (Table 1). Moreover, conformational analysis of a series of 2'- and 3'-modified
nucleosides showed that the presence of a halogen at the a-face of the 2'-position, especially a
2'-fluorine, biases the sugar pucker of thymidine analogues strongly towards the (N)
conformation. 10 Based on these results and the high affinities of 2'-halogeno substituted
nucleotides for TMPKmt5 (3 and 4, Table 1), it was considered interesting to combine a
2'-chlorine or a 2'-fluorine substituent with a 3'-aminomethyl or a 3'-azidomethyl group (5-8).9
In an attempt to supersede the good affinities of the 3'-C-branched-chain nucleosides, we also
further explored the enzyme cavity near the 3'-position with alternative nitrogen containing
substituents.
Results and Discussion
Chemistry
The synthesis of 5-9 started from 14 (obtained from 1,2-O-isopropylidene-a-D-xylofuranose
in 11 steps11) (Scheme 1). After protection of the 5'-hydroxyl group, 15 was converted into
anhydronucleoside 16 upon treatment with trifluoromethanesulfonyl chloride and DMAP.12
Opening of the anhydro ring with HCl in dioxane yielded 5, the 2'-a-chloro analogue of 1.13
The corresponding 2'-fluoro derivative 7 was obtained via formation of ara-nucleoside 17
from 16 with NaOH,14 followed by fluorination with DAST15 and removal of the trityl
protective group. Reduction of 5 and 7 with Ph3P and NH3 yielded the corresponding
3'-amino analogues 6 and 8, respectively.11 Due to unwanted intramolecular attack of the
2-carbonyl of thymine on the 5'-O-diethylaminosulphur difluoride intermediate, reaction of 7
with DAST afforded 9 in low yield.
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Scheme 1: Reagents: (a) trityl chloride, DMAP, pyridine; (b) trifluoromethanesulfonyl chloride,
DMAP, CH2Cl2; (c) HCl, dioxane; (d) Ph3P, NH4OH, pyridine; (e) NaOH, EtOH, H2O; (f) DAST,
toluene, pyridine; (g) 80% HOAc in H2O.
128
In an attempt to prepare intermediate 20 for further derivatisation, the 5'-hydroxyl group of 14
was first protected as t-butyldimethylsilyl ether 18 (Scheme 2). After esterification of the
2'-hydroxyl with phenylchlorothionocarbonate (®19),11 however, attempted simultaneous
reduction of the azido function and Barton deoxygenation at the 2’-position to give 20 failed.
Instead three peculiar nucleoside analogues 21, 22 and 23 were formed. In a similar attempt,
Robins et al. found that, apart from a low yield of the desired aminonucleoside, Barton
deoxygenation of an azide in the presence of a phenoxythiocarbonyl ester led to some
uncharacterised byproducts.16 Compounds 21 and 22 represent a novel class of bicyclic
nucleoside analogues.
O
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12 R = Hd
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25 R = Tr
d
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Scheme 2: Reagents: (a) t-butyldimethylsilyl chloride, imidazole, DMF; (b) phenyl
chlorothionocarbonate, DMAP, CH3CN; (c) AIBN, Bu3SnH, toluene; (d) n-Bu4NF, THF; (e) Ph3P,
NH4OH, pyridine; (f) 1,1-thiocarbonyldiimidazole, DMF; (g) 80% HOAc in H2O.
The formation of carbamates through reaction of thioacids with azides has recently been
studied by Shangguan et al.17 A mechanism is proposed in which the three nitrogens of the
azide take part in formation of the carbamate. However, since access to the thiocarbamate
cannot be explained this way, it is suggested that a radical intermediate of the reduction of the
azide interacts with a radical resulting from attack of a tributyltin radical on the thioester.
Another surprising byproduct of this radical-mediated reduction is dinucleoside 23. Most
probably, the ureum moiety of this dimer is formed through attack of the 6'-amines (resulting
from reduction of the 6'-azide of 19) on the carbonoxysulfide, arising from decomposition of
the 2'-phenylthionocarbonate ester.18
The TBDMS-protective groups of 21, 22 and 23 were removed with TBAF in THF and the
free nucleosides (10, 11 and 12) were tested for their affinity for TMPKmt.
In view of the interesting biological properties of 10 (see below), a more efficient way for its
synthesis was desirable. Tritylation of the 5'-hydroxyl of 14, followed by reduction of the
6'-azido group (®24), treatment with thiocarbonyldiimidazole, and subsequent acidic removal
of the 5'-trityl group afforded 10 in 62 % overall yield. Likewise, 11 can be obtained by using
carbonyldiimidazole.
Binding Assay
All nucleosides were tested for their affinity for TMPKmt (Table 1) via a reported
spectrometric assay. 19 The affinities of most 2'-halo substitued nucleosides were not as
expected. In 5-8, the introduction of the 2'-halogen led to a drastic decrease in affinity
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compared to the corresponding 2'-deoxynucleosides. Due to the presence of the 2'-fluorine, 8
even didn' show inhibition at 1 mM for the enzyme. Instead of enhancing the (N)
conformation, necessary for optimal interaction between Asp9 and the 3'-substituent, the
2'-halogens probably compete with the 3'-substituents for the same binding pocket,5 thereby
abolishing the affinity for the enzyme. Remarkably, introduction of a 5'-fluorine slightly
increases the affinity of 7 (Ki of 9 = 80 mM).
R2
O
R3
N NH
O
O
R1
Compound R1 R2 R3 Ki (mM) TMPKmt Ki (mM) TMPKh
dTMP H OH OPO3
2- 4.5a 5.0a
thymidine H OH OH 277 1808
1 H CH2N3 OH 40
9 10409
2 H CH2NH2 OH 57
9 2209
3 F OH OPO3
2- 435 n.d.d
4 Cl OH OPO3
2- 195 n.d.d
5 Cl CH2N3 OH 180 n.d.
d
6 Cl CH2NH2 OH 390 n.d.
d
7 F CH2N3 OH 165 n.d.
d
8 F CH2NH2 OH n.i.
c at 1 mM n.d.d
9 F CH2N3 F 80 n.d.
d
10 2'-OC(S)NHCH2-3' OH 3.5 700
11 2'-OC(O)NHCH2-3' OH 13.5 1100
12 Scheme 2 OH 37 n.i.c at 1 mM
13b H CH2N3 OH 29 n.i.
c at 2 mM
Table 1:. Kinetic parameters of TMPKmt and TMPKh with compounds 1-13.
a Km-value
b Thymine is oriented at the a-side of the sugar ring.
c n.i.: no inhibition
d n.d.: not determined
Compounds 10, 11 and 12 were, likewise, assayed for their affinity for TMPKmt.
Unexpectedly, these compounds are among the highest affinity inhibitors for TMPKmt found
so far. Due to the lack of a binding site for a second nucleoside at the 3’-position, the Ki-value
of 12 (37 mM) was most unexpected. A modeling experiment in GOLD showed that the sugar
ring of the first monomer I binds the TMP-pocket upside down, which enables hydrogen
bonding of its 5'-hydroxyl with Asp9 (Figure 1). This binding mode permits the sugar ring of
the second monomer (II) to be directed towards the outside of the enzyme, where normally
the phosphoryl donor binds. This orientation is the only feasible conformer to have 12
accommodated by the enzyme. The thymine base of II undergoes only few hydrophobic
interactions with Phe36, Ala35 and Tyr39. Comparison with the binding positions of ATP4
and bisubstrate inhibitor Ap5T20 showed that nucleoside II does not bind to the pocket where
adenosine normally resides. Instead, it is buried deeper in the enzyme. The fact that these two
nucleosides in 12 are bound via their 3'-positions makes it a unique example of a bisubstrate
inhibitor, thereby paving the way for the design of much larger molecules as inhibitors for
TMPKmt than explored thus far.
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Figure 1: Predicted binding mode of 12 with TMPKmt. A ribbon follows the backbone atoms of the
enzyme. Hydrogen bonds are drawn as dashed lines. dTMP, as observed in the X-ray structure with
TMPKmt,4 is shown in black sticks.Residues of which atoms make contact with 12, based on the
Ligplot analysis, are Lys13, Ala35, Tyr39, Phe36, Phe70, Arg95, Asn100, Tyr103 and Tyr 165.
Figure 2: Predicted binding mode of 13 with TMPKmt. A ribbon follows the backbone atoms of the
enzyme. Hydrogen bonds are drawn as dashed lines. dTMP, as observed in the X-ray structure with
TMPKmt,4 is shown in black sticks.Residues of which atoms make contact with 13, based on a Ligplot
analysis, are Asp9, Leu52, Phe70, Arg95, Tyr103 and Tyr165.
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The observed affinity of a-nucleoside 13 (an undesired anomer formed during the synthesis
of 19) could confirm the postulated binding mode of monomer I. A similar sugar orientation
would position the thymine base ideally for stacking with Phe70. Indeed, with a Ki-value of
29 mM, this compound proves to be a good inhibitor of TMPKmt. Docking in GOLD showed
a similar binding mode of the sugar ring, rendering stacking interaction with Phe70 possible
(Figure 2). The 5'-hydroxyl interacts through hydrogen bonding with Asp9 and the azido
group, lying in the cavity where normally the 5'-phosphoryl of dTMP resides, is engaged in a
polar interaction with Arg95 and Asp9. This exceptional flexibility of TMPKmt towards the
orientation of the sugar ring is of great interest for further inhibitor design.
Bicyclic nucleosides 10 and 11 showed excellent binding affinities. With a Ki-value of
3.5 mM, 10 exceeds the Km-value of the natural substrate (4.5 mM). Compound 10 was
modelled into the crystal structure of TMPKmt (Figure 3).4 The six-membered ring, fused to
the the C-2', C-3'-bond of the sugar, apparently forces the 6'-nitrogen into the most
appropriate position for interaction with the Asp9 residue in the enzyme cavity. The sulphur
atom, in its turn, undergoes hydrophobic interactions with Tyr103 and Tyr165 residues. When
the sulphur atom in 10 is replaced by a smaller oxygen in 11, the cavity near the 3'-position is
filled less efficiently, which is reflected in the somewhat lower affinity of 11. The
functionalities of the extra ring convincingly contribute to the high affinity interactions with
the biological target.
Figure 3: Predicted binding mode of 10 with TMPKmt. A ribbon follows the backbone atoms of the
enzyme. Hydrogen bonds are drawn as dashed lines. dTMP, as observed in the X-ray structure with
TMPKmt,4 is shown in black sticks. Residues of which atoms make  contact with 10, based on a Ligplot
analysis, are Phe36, Pro37, Leu52, Phe70, Arg95, Tyr103 and Tyr165.
The highest affinity inhibitors of this series were tested for their affinity for TMPKh. The low
affinities of 12 and 13 for the human enzyme indicate that the flexibility towards the
orientation of the sugar ring is unique for TMPKmt. Most interesting, however, is compound
10, with a selectivity index (Ki TMPKh/ Ki TMPKmt) of 200, superseding 1 not only in
affinity, but also in selectivity.
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Conclusions
In inhibitor design the binding pocket of the nucleoside in nucleoside and nucleotide
metabolising enzymes is generally explored by introducing small modifications to the
substrate. In the present example, however, a variety of sugar modified thymidine analogues
have been discovered with apparently different binding modes to TMPKmt involving Asp9,
Tyr103 and Phe70 as common amino acids to anchor the inhibitors. These molecules may
function as leads for further drug design, increasing considerably the variety of nucleoside
analogues that may be considered for further synthesis. Of particular importance is the
bicyclic nucleoside 10 with a Ki for TMPKmt of 3.5 mM and a SI of 200, which will be used
as starting compound to increase further affinity forTMPKmt.
Experimental Section
Spectrophotometric binding assay
TMPKmt and TMPKh activities were determined using the coupled spectrophotometric assay
described by Blondin et al.19 at 334 nm in an Eppendorf ECOM 6122 photometer. The
reaction medium (0.5 mL final volume) contained 50 mM Tris-HCl pH 7.4, 50 mM KCl,
2 mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol pyruvate and 2 units each of lactate
dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase. The concentrations of
ATP and dTMP were kept constant at 0.5 mM and 0.05 mM respectively, whereas the
concentrations of analogues varied between 0.1 and 2.5 mM.
Modeling: docking experiments using GOLD
The X-ray structure published by Li de la Sierra et al.4 (pdb entry 1G3U) was used in all
docking experiments. Water molecules and sulphate counter ions were removed. The Mg2+
was considered as being part of the enzyme. Explicit hydrogen atoms were added to the
enzyme and inhibitor structures using Reduce.21 The inhibitor structures 10, 12 and 13 were
created using Macromodel 5.0,22 based on the dTMP substrate from pdb entry 1G3U. Their
geometry was optimised in the AM1 force field using Mopac6.0.23 PDB files were then
converted to mol2 files using Babel. 24 The position of atom C1' in the dTMP ligand in the pdb
file 1G3U was used as the center of a 20 Å docking sphere. Default settings were used in
Gold for all dockings.25,26 The structures in the top 50 of the docking scores were retained for
visual inspection and comparison with published X-ray structures 1G3U 4 and 1MRN.20
Criteria for selection were the same position (but not necessarily same orientation) of the
base, the nonbonded interactions as calculated by Ligplot27 and HBPLUS.28 Figures 1-3 were
generated using Molscript.29
Synthesis
General
NMR spectra were obtained with a Varian Mercury 300 spectrometer. Chemical shifts are
given in ppm (d) relative to residual solvent peakof DMSO-d6 (2.5 ppm). All signals assigned
to amino and hydroxyl groups were exchangeable with D2O. Mass spectra and exact mass
measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight
(Q/oaTOF) tandem mass spectrometer (qTof 2, Micromass, Manchester, UK) equipped with a
standard electrospray ionisation (ESI) interface. Samples were infused in a 2-propanol:water
(1:1) mixture at 3 µL/min. Precoated Merck silica gel F254 plates were used for TLC and spots
were examined under UV light at 254 nm and revealed by sulfuric acid-anisaldehyde spray.
Column chromatography was performed on Uetikon silica (0.2-0.06 mm).
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Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone;
pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane,
dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF
was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure.
1-[3-Azidomethyl-3-deoxy-5-O-trityl-b -D-ribofuranosyl]thymine (15)
To a solution of 1411 (700 mg, 2.35 mmol) in pyridine (6 mL) containing DMAP (345 mg,
2.82 mmol) trityl chloride (786 mg, 2.82 mmol) was added in different portions. The mixture
was heated to 65 °C and stirred overnight. Then it was diluted with CH2Cl2 (50 mL), washed
with saturated aqueous NaHCO3 (50 mL), and dried over anhydrous MgSO4. The solvent was
removed under diminished pressure and the resulting residue was purified by column
chromatography (CH2Cl2-MeOH, 98:2) affording 15 (1.15 g, 92%) as a white foam. 1H NMR
(300 MHz, DMSO-d6): d 1.42 (3H, d, J = 1.2 Hz, 5-CH3), 2.50 (1H, m, H-3'), 3.13-3.22 (2H,
m, H-5'A and H-6'A), 3.37 (1H, dd, J = 1.8 Hz and 10.8 Hz, H-5'B), 3.60 (1H, dd, J = 6.9 and
12.6 Hz, H-6'B), 4.03 (1H, ddd, J = 2.1, 3.9 and 9.0 Hz, H-4'), 4.32 (1H, dd, J = 2.1 and
6.0 Hz, H-2'), 5.68 (1H, d, J = 2.4 Hz, 2'-OH), 5.86 (1H, d, J = 5.4 Hz, H-1'), 7.35 (15H, m,
arom H), 7.55 (1H, d, H-6); HRMS (ESI-MS) for C30H29N5O5Na [M + Na]+: found,
562.2067; calcd, 562.2066.
2,2'-Anhydro-1-(3-azidomethyl-3-deoxy-5-O-trityl-b -D-arabinofuranosyl)thymine (16)
A solution of 15 (940 mg, 1.74 mmol) and DMAP (854 mg, 7.00 mmol) in CH2Cl2 (17 mL)
was stirred at room temperature. After stirring for 30 minutes trifluoromethanesulfonyl
chloride (0.37 mL, 3.50 mmol) was added to the cooled (4 °C) solution. After further stirring
for 3h at the same temperature, the reaction was quenched with water (20 mL) and extracted
with CH2Cl2 (20 mL). The organic layer was successively washed with an aqueous saturated
solution of Na2CO3 (20 mL), dried over anhydrous MgSO4 and evaporated under reduced
pressure. The obtained residue was purified by column chromatography (CH2Cl2-MeOH,
97:3) to yield 16 (743 mg, 82 %) as a white foam.1H NMR (300 MHz, DMSO-d6): d 1.76
(3H, d, 5-CH3), 2.66 (1H, m, H-3'), 2.82 (1H, dd, J = 6.6 and 10.2 Hz, H-5'A), 3.01 (1H, dd,
J = 3.9 and -10.5 Hz, H-5'B), 5.57 (2H, m, H-6'A and H-6'B), 5.21 (1H, m, H-4'), 5.27 (1H,
dd, J = 2.1 and 5.4 Hz, H-2'), 6.20 (1H, d, J = 6.0 Hz, H-1'), 7.22 (15H, m, arom H), 7.80 (1H,
d, J = 1.5 Hz, H-6); HRMS (ESI-MS) for C30H28N5O4 [M + H]+: found, 522.2138; calcd,
522.2141.
1-(3-Azidomethyl-2-chloro-2,3-dideoxy-b -D-ribofuranosyl)thymine (5)
An ice-cooled suspension of 16 (220 mg, 0.42 mmol) in dry dioxane (50 mL) was saturated
with anhydrous hydrogen chloride. The mixture was heated in a sealed tube at 75-80 °C for
24 h. After cooling, the solution was concentrated and the obtained residue purified by co-
lumn chromatography (CH2Cl2-MeOH, 97:3), yielding 5 (90 mg, 71%) as a white foam.
1H NMR (300 MHz, DMSO-d6): d 1.74 (3H, s, 5-CH3), 2.72 (1H, m, H-3'), 3.57 (3H, m,
H-5'A and H-6'A and H-6'B), 3.84 (1H, m, H-5'B), 4.01 (1H, app d, J3', 4' = 9.9 Hz, H-4'), 4.81
(1H, app d, J2', 3' = 5.4 Hz, H-2'), 5.36 (1H, t, J = 4.8 Hz, 5'-OH), 5.89 (1H, d, J = 1.5 Hz,
H-1'), 8.01 (1H, d, H-6), 11.30 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): d 12.96 (5-CH3),
C-3’hidden by DMSO signal, 48.73 (C-6'), 60.15 (C-5'), 65.32 (C-2'), 83.57 (C-4'), 91.36
(C-1'), 109.07 (C-5), 136.06 (C-6), 151.04 (C-2), 162.12 (C-4); HRMS (ESI-MS) for
C11H14ClN5O4Na [M+Na]+: found, 338.0615; calcd, 338.0632. Anal. (C11H14ClN5O4) C,H,N.
1-[3-Aminomethyl-2-chloro-2,3-dideoxy-b -D-ribofuranosyl]thymine (6)
Compound 5 (60 mg, 0.20 mmol) and triphenylphosphine (87 mg, 0.33 mmol) were dissolved
in pyridine (3 mL) and stirred at room temperature. After 1h, concentrated NH4OH (2 mL)
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was added and the solution was allowed to stir for an additional 6.5 h. Pyridine was removed
at reduced pressure, water (50 mL) was added and the unreacted triphenylphosphine and
triphenylphosphine oxide were removed by filtration. The filtrate was extracted with toluene
and the water layer was evaporated under reduced pressure to give a syrup, which was
purified by column chromatography (0.175 N NH3 in CH2Cl2-MeOH, 90:10) to yield 6
(42 mg, 72 %) as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.73 (3H, s, 5-CH3), 2.52
(1H, m, H-3'), 2.77 (2H, m, H-6'A and H-6'B), 3.65 (1H, d, H-5'A), 3.87 (1H, dd, J = 2.7 and
12.9 Hz, H-5'B), 3.97 (1H, app d, J3', 4' = 10.5 Hz, H-4'), 4.79 (1H, d, J2', 3' = 4.8 Hz, H-2'),
5.85 (1H, s, H-1'), 8.04 (1H, s, H-6); 13C NMR (75 MHz, DMSO-d6): d 12.93 (5-CH3), 38.06
(C-3'), 42.90 (C-6'), 60.04 (C-5'), 66.39 (C-2', 84.06 (C-4'), 91.53 (C-1'), 108.90 (C-5), 136.06
(C-6), 150.89 (C-2), 164.47 (C-4); HRMS (ESI-MS) for C11H17ClN3O4 [M + H]+: found,
290.0911; calcd, 290.0907. Anal. (C11H16ClN3O4.2H2O) C,H,N; N:calcd, 12.90; found: 11.81.
1-(3-Azidomethyl-3-deoxy-5-O-trityl-b -D-arabinofuranosyl)thymine (17)
A mixture of 16 (590 mg, 1.13 mmol), 1N NaOH (3.2 mL), dioxane (45 mL) and EtOH-H2O
(1:1, 45 mL) was stirred at room temperature for 2h. The solution was neutralised with
HOAc/EtOH (1:1, v/v) to pH 7. The resulting mixture was extracted with CH2Cl2 (100 mL)
and the organic layer was dried over anhydrous MgSO4, evaporated under reduced pressure
and purified by column chromatography (CH2Cl2-MeOH, 90:10), yielding 17 (530 mg, 87 %)
as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.53 (3H, s, 5-CH3), 2.32 (1H, m, H-3'),
3.21-3.43 (3H, m, H-5'A and H-5'B, H-6'A), 3.56 (1H, dd, J = 5.7 and -12.6 Hz, H-6'B), 3.80
(1H, m, H-4'), 4.11 (1H, t, J = 5.4 Hz, H-2'), 5.60 (1H, d, J = 5.1 Hz, 2'-OH), 5.97 (1H, d,
J = 5.7 Hz, H-1'), 7.32 (15H, m, arom H).
1-(3-Azidomethyl-2,3-dideoxy-2-fluoro-b -D-ribofuranosyl)thymine (7)
To a solution of 17 (640 mg, 1.19 mmol) in toluene (12 mL) containing pyridine (1.2 mL),
DAST (0.59 mL, 4.42 mmol) was added and the mixture was stirred for 2 h at room
temperature and then for 3 h at 50 °C. The reaction was quenched with ice-water (50 mL) and
extracted with CH2Cl2 (50 mL). The organic layer was dried over anhydrous MgSO4,
evaporated under reduced pressure and purified by column chromatography (CH2Cl2-MeOH,
97:3), yielding 1-[3-azidomethyl-2,3-dideoxy-2-fluoro-5-O-trityl-b-D-ribofuranosyl]thymine
(460 mg, 72 %) as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.45 (3H, s, 5-CH3), 2.85
(1H, m, J3', F = 33.0 Hz, H-3'), 3.20 (4H, m, H-5'A, H-5'B, H-6'A and H-6'B), 4.11 (1H, app d,
J4', F = 9.6 Hz, H-4'), 5.40 (1H, dd, J2', 3' = 3.9 Hz, J2', F = 52.2 Hz, H-2'), 5.87 (1H, d,
J1', F = 21.6 Hz, H-1'), 7.32 (15H, m, arom H), 7.55 (1H, s, H-6); HRMS (ESI-MS) for
C30H28FN5O4Na [M + Na]+: found, 564.2020; calcd, 564.2023.
The obtained foam was dissolved in 80% HOAc in H2O (7 mL). The mixture was heated to
90°C during 1h. The solvent was removed under reduced pressure and the residue purified by
column chromatography (CH2Cl2-MeOH, 90:10), yielding 10 (221 mg, 62% from 17) as a
white foam. 1H NMR (300 MHz, DMSO-d6): d 1.75 (3H, s, 5-CH3), 2.62 (1H, m,
J3', F = 32.7 Hz, H-3'), 3.46-3.62 (3H, m, H-5'A, H-6'A and H-6'B), 3.83 (1H, d, J = -12.0 Hz,
H-5'B), 3.99 (1H, dt, J3', 4' = 2.7, J4', F = 10.5 Hz, H-4'), 5.27 (1H, br s, 5'-OH), 5.31 (1H, dd,
J2', 3' = 4.2 Hz, J2', F = 52.5 Hz, H-2'), 5.87 (1H, d, J1', F = 19.5 Hz), 7.84 (1H, s, H-6); 13C NMR
(75 MHz, DMSO-d6): d 12.90 (5-CH3), C-3’ hidden by DMSO signal, 47.79 (C-6',
J6', F = 8.6 Hz), 60.42 (C-5'), 83.44 (C-4'), 89.46 (C-1', J1', F = 37.0 Hz), 97.46 (C-2',
J2', F = 180.8 Hz), 109.38 (C-5), 136.67 (C-6), 150.91 (C-2), 164.54 (C-4); 19F NMR
(300 MHz, D2O): d -195.046; HRMS (ESI-MS) for C11H14FN5O4Na [M + Na]+: found,
322.0908; calcd, 322.092. Anal. (C11H14FN5O4) C, H, N.
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1-(3-Aminomethyl-2,3-dideoxy-2-fluoro-b -D-ribofuranosyl)thymine (8)
This compound was synthesised from 7 (80 mg, 0.26 mmol) using the procedure described for
the synthesis of 6, yielding 54 mg (77 %) of amine 8 as a foam. 1H NMR (300 MHz, DMSO-
d6): d 1.73 (3H, s, 5-CH3), 2.30 (1H, m, J3', F = 34.2 Hz, H-3'), 2.57 (1H, m, H-6'A), 2.76 (1H,
m, H-6'B), 3.62 (1H, d, J = -12.0 Hz, H-5'A), 3.79 (1H, d, H-5'B), 3.89 (1H, app d, J4',
F = 10.2 Hz, H-4'), 5.03 (1H, br s, 5'-OH), 5.22 (1H, d, J2', F = 51.9 Hz, H-2'), 5.82 (1H, d, J1',
F = 18.3 Hz, H-1'), 7.85 (1H, s, H-6); 13C NMR (75 MHz, DMSO-d6): d 12.95 (5-CH3), 36.95
(J = 7.7 Hz) and 44.76 (J = 18 Hz) (C-3' and C-6'), 60.63 (C-5'), 84.41 (C-4'), 89.07 (C-1', J1',
F = 36.3 Hz), 97.89 (C-2', J2', F = 179.4 Hz), 109.21 (C-5), 136.43 (C-6), 150.79 (C-2), 164.51
(C-4); 19F NMR (300 MHz, D2O): d -195.70; HRMS (ESI-MS) for C11H17FN3O4 [M + H]+:
found, 274.1191; calcd, 274.1202. Anal. (C11H16FN3O4.1/2H2O) C, H, N; N: calcd, 14.89;
found, 13.61.
1-(3-Azidomethyl-2,5-difluoro-2,3,5-trideoxy-b -D-ribofuranosyl)thymine (9)
This compound was synthesised from 7 (66 mg, 0.22 mmol) using the procedure described for
the synthesis of 7, to yield 12 mg (18 %) of 9. 1H NMR (300 MHz, DMSO-d6): d 1.75 (3H, s,
5-CH3), 2.67 (1H, m, J3', F = 24.0 Hz, H-3'), 3.60 (2H, m, H-6'A and H-6'B), 4.61 (1H, ddd, J5',
4' = 4.2 Hz, J5', 5'' = -10.8 Hz, J5', F = 49.5 Hz, H-5'A), 4.80 (1H, dd, H-5'B), 5.41 (1H, dd, J2',
3' = 4.8 Hz, J2', F = 52.5 Hz, H-2'), 5.88 (1H, d, J1', F = 21.3 Hz, H-1'), 7.40 (1H, s, H-6); 13C
NMR (75 MHz, DMSO-d6): d 12.87 (5-CH3), under DMSO signal (C-3'), 46.68 (C-6'), 81.10
(C-4', J4', F = 18.1 Hz), 83.02 (C-5', J5 ' ,  F = 170.0 Hz), 90.60 (C-1', J1 ' ,  F = 38.0 Hz), 96.90
(C-2', J2', F = 181.2 Hz), 110.01 (C-5), 136.81 (C-6), 150.87 (C-2), 164.52 (C-4); 19F NMR
(300 MHz, D2O): d -194.04 and -228.74; HRMS (ESI-MS) for C11H13F2N5O3Na [M + Na]+:
found, 324.0881; calcd, 324.0884. Anal. (C11H13F2N5O3) C, H, N.
1-[3-Aminomethyl-3-deoxy-5-O-(tert-butyldimethyl)silyl-2-O,6-N-(thiocarbonyl)-b -D-ri-
bofuranosyl]thymine (21), 1-(3-aminomethyl-2-O,6-N-carbonyl-3-deoxy-5-O-(tert-butyl-
dimethyl)silyl-b -D-ribofuranosyl)thymine (22) and 1,3-bis[(3R)-(3'-deoxy-5’-O-(tert-bu-
tyldimethyl)silyl-thymidin-3'-yl)methyl]urea (23)
To a solution of 1911 (460 mg, 0.84 mmol) in toluene was added 2,2'-azobis(2-methyl-
propionitrile) (354 mg, 2.1 mmol) and tri-n-butyltinhydride (0.48 g, 1.65 mmol) at 50-60° C
under N2. The reaction mixture was stirred at 95-100 °C for 5h. The solvent was removed in
vacuo and the residue was purified by silica gel column chromatography (CH2Cl2-MeOH,
99:1 ® 95:5), affording produce 21 (0.16 mmol, 20 %), 22 (17 %) and 23 (19 %) as white
solids. 21: 1H NMR (300 MHz, DMSO-d6): d 0.00 (6H, s, (CH3)2Si), 0.80 (9H, s, C(CH3)3),
1.70 (3H, s, 5-CH3), 2.76 (1H, m, H-3'), 3.11 (1H, d, H-6'A), 3.39 (1H, dd, J = 5.70 and
-13.5 Hz, H-6'B), 3.86 (3H, m, H-4' and H-5'A and H-5'B), 4.95 (1H, d, J2', 3' = 5.1 Hz, H-2'),
5.75 (1H, s, H-1'), 7.45 (1H, s, H-6), 9.81 (1H, s, 6’-NH), 11.36 (1H, s, N(3)H); HRMS
(ESI-MS) for C18H30N3O5SSi [M + H+]: found, 428.1675; calcd, 428.1675.
22: 1H NMR (300 MHz, DMSO-d6): d 0.00 (6H, s, (CH3)2Si), 0.81 (9H, s, C(CH3)3), 1.70
(3H, s, 5-CH3), 2.61 (1H, m, H-3'), 3.07 (1H, br d, H-6'A), 3.37 (1H, dd, J = 5.7 Hz and
-12.3 Hz, H-6'B), 3.78 (1H, dd, J = 3.6 and -12.0 Hz, H-5'A), 3.91 (1H, dd, H-5'B), 3.98 (1H,
dt, J = 2.7 and 9.6 Hz, H-4'), 4.90 (1H, br d, J2', 3' = 5.7 Hz, H-2'), 5.70 (1H, d, J = 1.2 Hz,
H-1'), 7.37 (1H, br s, 6'-NH), 7.44 (1H, d, = 1.2 Hz, H-6); HRMS (ESI-MS) for C18H30N3O6Si
[M + H]+: found, 412.1897; calcd, 412.1903.
23: 1H NMR (300 MHz, DMSO-d6): d 0.15 (12H, s, (CH3)2Si), 0.83 (18H, s, (CH3)3C), 1.73
(6H, s, 5-CH3), 2.03 (4H, m, H-2'), 2.30 (2H, m, H-3'), 3.05 (4H, m, H-6'A and H-6'B), 3.71
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(6H, m, H-4' and H-5'A and H-5'B), 5.94 (2H, t, J = 5.4 Hz, H-1'), 6.01 (2H, t, 6'-NH), 7.46
(2H, d, J = 1.2 Hz, H-6); HRMS (ESI-MS) for C35H60N6O9Si2Na [M + Na]+: found,
787.3970; calcd, 787.3858.
1-[3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)-b -D-ribofuranosyl]thymine (10),
1-(3-aminomethyl-2-O,6-N-carbonyl-3-deoxy-b -D-ribofuranosyl)thymine (11) and
1,3-bis[(3R)-(3'-deoxythymidin-3'-yl)methyl]urea (12)
Solutions of 21, 22 and 23 were treated with 5 equivalents TBAF in THF. After 1 hour the
mixtures were evaporated to dryness and purified by column chromatography (CH2Cl2-
MeOH, 95:5), yielding 10, 11 and 12 as white powders. 10: 1H NMR (300 MHz, DMSO-d6):
d 1.73 (3H, s, 5-CH3), 2.80 (1H, m, H-3'), 3.45 (1H, d, H-6'A), 3.42 (1H, dd, J = 6.0 and
-14.1 Hz, H-6'B), 3.66 (1H, br d, H-5'A), 3.85 (1H, br d, J = -12.6 Hz, H-5'B), 3.92 (1H, m,
H-4'), 4.95 (1H, d, J2', 3' = 5.0 Hz, H-2'), 5.34 (1H, t, 5'-OH), 5.82 (1H, s, H-1'), 7.97 (1H, s,
H-6), 9.83 (1H, br s, 6’-NH), 11.35 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6):
d 12.89 (5 CH3), 31.54 (C-3'), 37.18 (C-6'), 59.65 (C-5'), 82.57 (C-4'), 83.98 (C-2'), 89.28
(C-1'), 109.30 (C-5), 136.84 (C-6), 150.84 (C-2), 164.43 (C-4), 184.48 (C=S); HRMS
(ESI-MS) for C12H15N3O5SNa [M + Na]+: found, 336.0636; calcd, 336.0630. Anal.
(C12H15N3O5S) C, H, N.
11: 1H NMR (300 MHz, DMSO-d6): d 1.74 (3H, s, 5-CH3), 2.66 (1H, m, H-3'), 3.13 (1H, m,
H-6'), 3.42 (1H, dd, J6'', 3' = 5.4 Hz, J6”, 6’' = -12.9 Hz, H-6''), 3.64 (1H, m, H-5'), 3.82 (1H, m,
H-5''), 4.02 (1H, dt, J = 2.7 and 10.2 Hz, H-4'), 4.90 (1H, d, J2', 3' = 5.4 Hz, H-2'), 5.31 (1H, t,
J = 5.1 Hz, 5'-OH), 5.72 (1H, s, H-1'), 7.39 (1H, d, J = 3.0 Hz, H-6), 7.97 (1H, s, 6'-NH),
11.29 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6): d 12.88 (5-CH3), 32.44 (C-3'), 36.73
(C-6'), 59.94 (C-5'), 82.50 (C-4'), 83.31 (C-2'), 89.83 (C-1'), 109.28 (C-5), 136.62 (C-6),
150.86 (C=O), 151.84 (C-4), 164.44 (C-2); HRMS (ESI-MS) for C12H15N3O6Na [M + Na]+:
found, 320.0856; calcd, 320.0858. Anal. (C12H15N3O6) C, H, N.
12: 1H NMR (300 MHz, DMSO-d6): d 1.75 (6H, s, 5-CH3), 2.04 (4H, m, H-2'), 2.33 (2H, m,
H-3'), 3.08 (4H, m, H-6'A and H-6'B), 3.52 (2H, dd, J = 4.5 and -12.6 Hz, H-5'A), 3.66 (4H,
m, H-4' and H-5'B), 5.03 (2H, t, J = 5.1 Hz, 5'-OH), 5.94 (2H, t, J = 6.6 Hz, H-1'), 6.00 (2H, t,
J = 6.0 Hz, 6'-NH), 7.84 (2H, s, H-6); 13C NMR (75 MHz, DMSO-d6): d 12.96 (5-CH3), 36.74
(C-2'), 38.97 and hidden by DMSO-signal (C-3' and C-6'), 61.78 (C-5'), 84.58 (C-1' and C-4'),
109.30 (C-5), 137.05 (C-6), 150.97 (C-2), 158.82 (NHCONH), 164.47 (C-4); HRMS
(ESI-MS) for C23H32N6O9Na [M+Na]+: found, 559.2121; calcd, 559.2128. Anal.
(C23H32N6O9) C, H, N.
1-(3-Aminomethyl-3-deoxy-5-O-trityl-b -D-ribofuranosyl)thymine (24)
Compound 15 (450 mg, 0.83 mmol) and triphenylphosphine (356 mg, 1.36 mmol) were
dissolved in pyridine (10 mL) and stirred at room temperature. After 1h concentrated NH4OH
(8.5 mL) was added, and the solution was allowed to stir for an additional 2h. Pyridine was
removed under reduced pressure, water (5 mL) was added, and the unreacted triphenylphos-
phine and triphenylphosphine oxide were removed by filtration. The filtrate was extracted
with toluene, and the water layer was evaporated under reduced pressure to give a syrup. The
syrup was purified by column chromatography (0.175 N NH3 in CH2Cl2-MeOH, 90:10) to
yield the title compound (415 mg, 97 %) as a white foam. 1H NMR (300 MHz, DMSO-d6):
d 1.37 (3H, s, 5-CH3), 2.25 (1H, m, H-3'), under DMSO signal (1H, H-5'A), 2.67 (1H, dd,
J = 7.8 and -12.6 Hz, H-5'B), 3.18 (1H, dd, J = 4.5 and -10.5 Hz, H-6'A), under H2O signal
(1H, H-6'B), 4.04 (1H, d, J = 7.8 Hz, H-4'), 4.30 (1H, d, J = 5.4 Hz, H-2'), 5.64 (1H, s, H-1'),
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7.33 (15H, m, arom H), 7.54 (1H, s, H-6); HRMS (ESI-MS) for C30H31N3O5Na [M + Na]+:
found, 536.2162; calcd, 536.2161.
1-[3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)-5-O-trityl-b -D-ribofuranosyl]thymi-
ne (25)
A solution of amine 24 (200 mg, 0.39 mmol) and thiocarbonyldiimidazole (78 mg, 0.43 mg)
in THF (6 mL) was stirred overnight. The solvent was removed under reduced pressure and
the obtained residue was purified by column chromatography (CH2Cl2-MeOH, 95:5) to yield
25 as a white powder (162 mg, 75 %). 1H NMR (300 MHz, DMSO-d6): d 1.44 (3H, d,
J = 1.2 Hz, 5-CH3), 2.90 (1H, d, J = 13.8 Hz, H-6'A), 3.02 (1H, m, H-3'), H-5’A hidden by
residual H2O signal, 3.38 (1H, dd, J = 3.0 and -11.7 Hz, H-5'B), 3.46 (1H, dd, J = 5.4 and
-13.8 Hz, H-6'B), 3.99 (1H, dt, J = 4.2 and 10.5 Hz, H-4'), 5.07 (1H, d, J = 5.7 Hz, H-2'), 5.80
(1H, d, J = 0.9 Hz, H-1'), 7.33 (15H, m, arom H), 7.53 (1H, s, H-6), 9.83 (1H, s, 6’-NH),
11.48 (1H, s, N(3)H); HRMS (ESI-MS) for C31H29N3O5SNa [M + Na]+: found, 578.1825;
calcd, 578.1725.
1-[3-Aminomethyl-3-deoxy-2-O,N-(thiocarbonyl)-b -D-ribofuranosyl]thymine (10) from
25
Compound 24 (148 mg, 0.26 mmol) was dissolved in 80% HOAc in H2O (6mL). The mixture
was heated to 90 °C during 1h. The solvent was removed under reduced pressure and the
residue purified by column chromatography (CH2Cl2-MeOH, 90:10) yielding 10 (69 mg,
85%) as a white powder. For characterisation data: see above.
1-[3-(Azidomethyl)-2,3-dideoxy-a -D-erythro-pentofuranosyl]thymine (13)
a-Anomer 13 was a minor unreported byproduct from the synthesis of 1.9 1H NMR
(300 MHz, DMSO-d6): d 1.76 (3H, d, 5-CH3), 1.80 (1H, m, H-2'A), 2.25 (1H, ddd, J = 5.6,
7.0 and 12.3 Hz, H-2'B), 2.73 (1H, m, H-3'), 3.50-3.67 (4H, m, H-5'A and H-5'B and H-6'A
and H-6'B), 4.02 (1H, dt, J = 3.9 and 8.1 Hz, H-4'), 5.06 (1H, t, 5'-OH), 5.99 (1H, dd, J = 5.7
and 8.7 Hz, H-1'), 7.83 (1H, d, H-6), 13C NMR (75 MHz, DMSO-d6): d 12.95 (5-CH3), 35.46
(C-2'), 39.43 (C-3'), 51.03 (C-6'), 61.68 (C-5'), 80.00 and 84.23 (C-1' and C-4'), 109.98 (C-5),
136.77 (C-6), 151.17 (C-2), 164.39 (C-4); HRMS (ESI-MS) for C11H16N5O4 [M + H]+: found,
282.1205; calcd, 282.1202. Anal. (C11H15N5O4) C, H, N.
Appendix: Elemental analysis
C H N C H N
5 41.85 4.47 22.18 41.78 4.81 21.74
6 + 2 H2O 40.56 6.19 12.90 41.04 5.96 11.81
7 44.15 4.72 23.40 44.14 4.96 23.04
8 + 1/2 H2O 46.81 6.07 14.89 46.58 6.00 13.61
9 46.00 4.83 13.41 45.67 4.84 13.21
10 43.86 4.35 23.25 43.74 4.32 23.16
11 48.49 5.09 14.14 48.61 5.31 13.92
12 51.49 6.01 15.66 51.48 5.78 15.34
13 46.97 5.38 24.90 46.95 5.24 24.63
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Abstract
Due to the assumed equatorial orientation of its base moiety, 1-[2,4-dideoxy-4-C-hydroxy-
methyl-a-L-lyxopyranosyl]thymine (2) was put forward as an interesting thymidine mimic and
inhibitor of Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt). The
key to the synthesis of 2 involves the stereoselective introduction of the hydroxymethyl group
onto the C-4 carbon of the pyranose sugar. Attempts to achieve this via hydroboration/oxi-
dation of a C-4'-exocyclic vinylic intermediate selectively yielded the undesired a-directed
hydroxymethyl group. Therefore, we envisaged another approach in which the C-4 substituent
was introduced upon treatment of 2,3-O-isopropylidene-1-O-methyl-4-O-phenoxythiocarbo-
nyl-a-L-lyxopyranose with b-tributylstannyl styrene. This allowed stereoselective b-directed
introduction of a 2-phenylethenyl group at C-4, which was converted via oxidation/reduction
(OsO4, NaIO4/NaBH4) into the desired 4-hydroxymethyl group (17). The resulting 1-O-me-
thyl-2,3,6-tri-O-acetyl protected sugar was coupled with silylated thymine, using SnCl2 as
Lewis acid (19). After suitable protection, Barton deoxygenation of the 2'-hydroxyl function of
the obtained ribo-nucleoside yielded the desired 2'-deoxynucleoside 2, indeed showing the
aimed equatorial orientation of the thymine ring (4C1).
Introduction
Recently Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) emerged
as an interesting target for the design of new anti-tuberculosis agents.1,2 A series of 1,5-anhy-
drohexitol nucleosides was tested for its affinity for the enzyme to probe the effect of a six-
membered sugar ring. 1',5'-Anhydro-2',3'-dideoxy-6'-O-phosphoryl-2'-(thymin-1-yl)-D-ara-
bino-hexitol and its nucleoside analogue 1 proved to be inhibitors of TMPKmt (Ki-values of
30 and 103 mM), indicating that nucleosides with six-membered sugar rings can be accomo-
dated by the target enzyme. In these two nucleoside analogues the base is preferentially in an
axial (1C4) conformation, 3 in contrast to dTMP, where thymine prefers an equatorial-like
position. 4
When co-crystallised with a similar enzyme, herpes simplex virus-1 thymidine kinase, the
5-iodouracil-analogue of 1, was forced in the 4C1 (base oriented equatorially) conformation. 5
Because this conformational change upon binding of the kinase occurs at the expense of ener-
gy, a six-membered ring nucleoside analogue of 1, in which thymine preferably adopts an
equatorial position, was expected to be a better inhibitor of TMPKmt. Since modeling
suggested that the thymine moiety in 1-[2,4-dideoxy-4-C-hydroxymethyl-a-L-lyxopyrano-
syl]thymine (2), a structural isomer of 1, prefers an equatorial position,5 this nucleoside seems
a very promising thymidine mimic (Figure 1).
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Furthermore, due to their difficult synthetic availability, pyranose nucleosides with a 1,4-sub-
stitution pattern have not been studied yet for their antiviral and antibiotic properties and as
building blocks in nucleic acid synthesis. For those purposes synthesis of 2 is also considered
interesting.
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Figure 1: Strucures of nucleosides 1 and 2
Results and Discussion
Chemistry
Two strategies towards the synthesis of 20, a precursor of the target nucleoside, were already
attempted.6 Both reaction schemes are not useful for the synthesis of significant amounts of
the target molecule due low yields and separation problems at different stages. In these
attempts, the key to the synthesis of 2, i.e. the introduction of the hydroxymethyl moiety
precursor onto C-4 of the pyranose sugar, was achieved by displacement of a 4-O-triflate
group by the sodium salt of diethyl malonate or via the formation of a C-4-exocyclic vinylic
intermediate by Wittig reaction at the C-4-ketone of an oxidised pentopyranose.6 The first
procedure starting from b-D-ribopyranose, required an extensive purification to isolate the
desired 2,3-O-isopropylidene protected sugar from the unavoidably formed 3,4-O-isopropyli-
dene protected isomer.7 The hydroxyl group at carbon atom 4 (R-configuration) was efficient-
ly substituted for a b-directed diethyl malonyl group.6 However, problems of ring opening
during acetolytic deprotection of the obtained 4-hydroxymethyl-1-O-methylglycoside, prior to
sugar-base coupling, were the reason that 20 could be obtained in a low yield only. On the
other hand, Doboszewski and Herdewijn6 experienced that treatment of 4-deoxy-2,3-O-iso-
propylidene-1-O-methyl-4-C-methylene-b-D-erythro-pentopyranose (3) with borane in THF,
followed by oxidation with H2O2 yielded mainly the undesired 4-a-hydroxymethyl sugar,
probably caused by sterical hindrance of the 2,3-O-isopropylidene protective group during
borane addition.
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Figure 2: Image of the sterical hindrance caused by the 2',3'-O-isopropylidene in the 1C4 and 
4C1
conformation.
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In other studies, we observed that preferential attack of borane on an exo double bond is not
always predictable and may be governed by complexation of the reagent and steric effects.8
By carrying out the hydroboration/oxidation of the 4-methylene function after sugar-base
coupling, we postulated that the presence of the thymine moiety would favor a 4C1
conformation of the pyranose, which reduces the steric hindrance caused by the
isopropylidene protective group (Figure 2). We hoped this would influence the stereochemical
outcome of this reaction towards the formation of the 4-b-hydroxymethylcompound (20).
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Scheme 1: Reagents: (a) CF3COOH, H2O; (b) (CH3CO)2O, pyridine; (c) 5-methyl-2,4-
bis[(trimethylsilyl)oxy]pyrimidine, CH3CN, SnCl2; (d) NH3, MeOH; (e) 2,2-dimethoxypropane,
acetone, p-toluenesulphonic acid; (f) (i) 9-BBN, THF, (ii) H2O2, NaOH; (g) (PhO)2CO, NaHCO3,
DMF; (h) HOAc, H2O.
Synthesis was started from 4-deoxy-2,3-O-isopropylidene-1-O-methyl-4-C-methylene-b-D-
erythro-pentopyranose (3), obtained in 4 steps from L-lyxose.6 Because acid catalysed
exchange of the 1-O-methyl group of 3 by an 1-O-acetylgroup with HOAc, Ac2O and H2SO4,
is known to cause partial ring opening,6 it was decided to maintain the methyl protective
group at the 1-O-position. The 2,3-O-isopropylidene protective group of 3 was selectively
removed upon short treatment with CF3COOH6 and the 2- and 3-hydroxyl groups were
reprotected by acetylation. Coupling of the resulting sugar 5 with silylated thymine in the
presence of trimethylsilyl triflate or SnCl4 as catalysts proceeded slowly and yielded an
uncharacterised side product with a similar polarity as 6, rendering purification of the desired
nucleoside difficult. This problem could be overcome by performing the coupling reaction
under reflux conditions in CH3CN using SnCl2 as a Lewis acid, which selectively yielded the
desired 1-b-nucleoside in 48% yield.9 The remaining starting material 5, could be recuperated
(37 %). To avoid possible side reactions during hydroboration, 10 the 2'- and 3'-hydroxyl-
groups were deprotected and reprotected with an isopropylidene protective group to yield 8.
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However, reaction of 8 with 9-BBN exclusively yielded 9, the undesired epimer. The
selectivity of the formation of 9 was most unexpected. Analysis of its 1H-NMR spectrum
reveals an axial-axial coupling between H-1' and H-2' and another one between H-4' and H-5'.
The former is indicative for an equatorial orientation of the thymine ring, while the latter and
the narrow H-3' signal (half band width of 7.8 Hz), suggest a 4C1 chair conformation with an
a-directed 4'-hydroxymethyl. This assumption was supported by a NOEDIF experiment,
showing a weak increase (0.53 %) of the H-2' signal upon irradiation of the H-4' signal. After
deprotection of 9 with acetic acid to give 10, the a-orientation of the 4'-CH2OH was
confirmed via protection of the 6'- and 3'-hydroxyls with an isopropylidene protective group
(11), which would be less likely for 20. Apparently, sterical hindrance of the 2',3'-O-isopropy-
lidene and formation of the thermodynamically most stable product (both the 4'-hydroxy-
methyl and the base are oriented equatorially) govern the stereochemical outcome of the
hydroboration.6 Attempts to increase the sterical hindrance at the b-side of the sugar ring
before hydroboration, through the formation of a 2,2'-anhydronucleoside (12), failed. Upon
treatment of 7 with diphenylcarbonate and NaHCO3, elimination of the base occurred,
yielding an uncharacterised highly volatile sugar analogue.
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Scheme 2: Reagents: (a) PhOC(S)Cl, DMAP, CH3CN; (b) b-tributylstannyl styrene, AIBN, benzene;
(c) NMMO, OsO4, dioxane; (d) NaIO4,  H2O; (e) NaBH4, EtOH, H2O; (f) CF3COOH, H2O; (g)
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Because synthesis of 2 from 7 failed, it was decided to exploit the steric space at the b-side of
the sugar ring through radical-mediated introduction of a carbon group. Thus 2,3-O-isopropy-
lidene-1-O-methyl-4-O-phenoxythiocarbonyl-a-L-lyxopyranose (14), obtained through reac-
tion of 13 with phenyl chlorothionocarbonate,11 was reacted with b-tributylstannylstyrene.12
This led to stereoselective introduction of a 2-phenylethenyl group at the b-side of the sugar
ring (15) as indicated by its 1C4 conformation and the positive NOEDIF effect between H-3'
and H-b  of the styrene moiety (3.9 % enhancement) (Scheme 2).13 Via oxidative cleavage of
the double bond and in situ reduction (OsO4, NaIO4/ NaBH4) the phenylethenyl group of 15
was converted into a 4-hydroxymethyl group (17) in a 55% overall yield.13 A similar reaction
sequence as described for the synthesis of 7, was employed for the conversion of 17 to ribo-
analogue 20. The yield of the sugar-base condensation reaction was only 38%. The presence
of the acetoxymethyl moiety in the 4'-position (instead of the 5'-position in natural sugars) has
an important effect on the reaction. The 4'-acetoxymethyl group would favor a-attack of the
base moiety, 14 while the neighbouring group effect of the 2'-acetoxygroup would favor
b-attack of the thymine base. To allow selective deoxygenation of the 2'-hydroxyl of 20, we
envisaged a simultaneous protection of the 3'- and 6'-hydroxyl groups as 1,1,3,3-tetraiso-
propyldisiloxane-1,3-diyl. At room temperature this reaction was unsuccessful due to the axial
position of the 4'-hydroxylmethyl- and 3'-hydroxyl functions. Heating to 30°C allowed the
sugar moiety to change its conformation from 4C1 to 1C4, positioning both groups equatorially
what resulted in a successful protection. 15 Esterification of the 2'-hydroxyl as a phenyl
thionocarbonate ester, followed by Barton deoxygenation and removal of the TIPDS group
with TBAF, yielded the desired six-membered ring nucleoside 2. Upon removal of the
TIPDS-protective group, the chair conformation of the sugar ring was restored to the 4C1
conformation (J1',2' = 11.4 Hz), indicating that the thymine ring of 2 indeed adopts an
equatorial orientation.
Conformational analysis
The conformations of nucleosides 10, 20, 21, 23 and 2 were studied by NMR spectroscopy.
The data are given for each compound in the experimental section. A standard numbering
system is used for carbon atoms as exemplified for 2 in Figure 3. All 13C resonances were
consistently assigned by gHMQC experiments. The 1H-NMR results for 10, 20, 21, 23 and 2
are summarised in Table 1. Due to occasional overlapping of 1H-NMR spectra, full spectral
analysis was difficult in the case of 10 and 20. Coupling constants in the pentopyranosyl parts
of 2 and 20 are essentially the same; hence the conformational analysis for compound 2
applies to compound 20 as well. This is also the case for the 21-23 couple.
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Figure 3: Structure of 2 and 10.
According to the Karplus equation, the coupling between H-1' and H-2' (J1',2' = 9.6 Hz) in
compound 10 indicates, that the dihedral angle between these protons is close to 180°C,
consistent with an axial-axial arrangement of these bonds in a chair conformation. This points
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to an equatorially oriented base. The J4', 5'A (11.7 Hz) and the small coupling for H-3' indicate
that H-4' and H-5'A are in axial and H-3' in an equatorial arrangement and thus leads to the
chair conformation as shown in Figure 3. Herein the 4'-hydroxymethyl is necessarily directed
equatorially.
In 2, proton H-1' shows also a large coupling (11.4 Hz) with H-2'A, indicating an axial
position of both protons. The 3' proton is in an equatorial conformation because its half band
width (n½) is about 7.2 Hz for three couplings. This cannot contain an axial-axial coupling.
Also the absence of a large coupling between H-4'-H-5'A or H-4'-H-5'B points to an equato-
rial H-4' proton and further proves that 2 is in a chair conformation with the base in an equato-
rial position and the 4'-hydroxymethyl axially oriented as depicted in Figure 3.
In 21, a J1',2'-value of 2.7 Hz indicates an equatorial orientation of both protons and thus an
axially directed thymine ring. From J3',4' (10.2 Hz) and J4',5'A (11.4 Hz) it can be concluded that
H3', H4' and H5'A are all three in an axial orientation, hereby confirming the flipping of the
chair conformation from 4C1 to 1C4 upon introduction of a TIPDS protective group on 20
(Figure 4).
O
T
Heq
Heq
OH
Hax
RO
Hax
RO
Hax
Heq 1
'
2'3'
4'
6'
5'
21
Figure 4: Structure of 21.
Summarising, the values of the vicinal H,H-coupling constants lead to the conclusion that 10,
20 and 2 are in chair conformations with the base in an equatorial position, contrary to 21 and
23 where the base is in an axial orientation.
The data for 20 and 2 indicate that the conformational preference of 4-deoxy-4-hydroxy-
methyl-a-L-lyxopyranosyl nucleosides is opposite to that of the anhydro-hexitol nucleosides.3
When 2 is considered, an axially oriented heterocycle would lead to an unfavorable 1,3-di-
axial interaction between the nucleoside base and the 3'- and 5'-positions. With an equatorially
oriented heterocycle, this unfavorable interaction is present between the 4'-hydroxymethyl
function and the hydrogen atom in the 2'-positon and also between the 3'-OH and the H-5' and
H-1'. These latter interactions may be less unfavorable than the ones with the thymine ring.
Considering the anhydro-hexitol nucleosides, on the contrary, only one sterically unfavorable
1,3-diaxial interaction is present when the nucleoside base is oriented axially. Apart from this,
a hydrogen bond between the 6'-CH2OH and the ring oxygen may also stabilise the 4C1
conformation in 20 and 2.
Binding Assay
Nucleosides 20 and 2 were tested for their affinities for TMPKmt. Unfortunately 2 showed to
be a lower affinity inhibitor of TMPKmt (Ki-value of 320 mM) compared to its anhydro-hexi-
tol congener 1. 20 even didn't show any inhibition at a final concentration of 3 mM.
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10 20 21 23 2
proton coupling d J d J d J d J d J
1' -
1'-2'A
1'-2'B
5.60
9.6
-
5.59
9.6
-
5.36
2.7
-
5.93
4.8
0
5.82
11.4
0
2'A -
2'A-2'B
2'A-3'
2'A-2'OH
3.63
-
3.6
n.d.
3.66
-
n.d.
n.d.
4.49
-
2.7
5.1
2.18
-14.7
10.4
-
1.51
-11.4
n. d.
-
2'B -
2'B-3'
-
-
-
-
-
-
2.54
3.3
1.96
<1
3' -
3'-4'
3'-3'OH
3.95
n.d.
n.d.
3.97
n.d.
n.d.
3.99
10.2
-
4.26
10.4
-
4.02
n.d.
2.7
4' -
4'-5'A
4'-5'B
4'-6'A
4'-6'B
1.91
11.7
4.8
n.d.
6.3
1.77
0
2.4
n.d.
n.d.
2.22
11.4
5.7
0
2.1
1.79
11.7
4.8
0
2.7
1.51
0
2.1
7.2
8.4
5'A -
5'A-5'B
3.52
-11.7
3.66
-11.7
3.75
-11.4
3.72
-11.7
3.77
-11.4
5'B - 3.68 3.83 3.87 3.86 3.92
6'A -
6'A-6'B
6'A-6'OH
H2O
-10.8
n.d.
3.50
-11.7
n.d.
3.55
-11.1
-
3.57
-11.7
-
3.50
-10.1
5.1
6'B -
6'B-6'OH
3.41
n.d.
3.59
n.d.
3.92
-
4.14
-
3.60
5.1
Table 1: 1H NMR Chemical shifts (d in ppm) and Coupling Constants (J in Hz) in sugar parts of 10,
20, 21, 23 and 2. Chemical shifts indicated in the first column are d-values relative to the residual
solvent peak in DMSO-d6 (2.48 ppm) in the case of 10, 20, 21, and 2 and in CDCl3 (7.26 ppm) in the
case of 23. Coupling constants between the protons indicated in the second column are values in Hz.
Protons are labeled by the number of the carbon atom to which they are bonded; if two protons are
bonded to the same carbon atom, the one resonating at a higher field is denoted by A and the other by
B. Geminal coupling constants are assumed to be negative. Abbreviation n.d.: not determined.
Conclusions
We have successfully developed a stereoselective approach for the synthesis of 1-[2,4-
dideoxy-4-C-hydroxymethyl-a-L-lyxopyranosyl]thymine (2) from 2,3-O-isopropylidene-1-O-
methyl-a-L-lyxopyranose (13) in 13 steps. The key steps of this synthesis route involve the
stereoselective introduction of the 6'-carbon on the b-side of the sugar ring, via the radical
mediated substitution of the 4'-OH by a phenylethenylgroup (14 ® 15) followed by the intro-
duction of the base via a SnCl2-mediated coupling. Conformational analysis proves that 2
indeed shows the expected 4C1 conformation with an equatorially orientated thymine ring.
Experimental Section
Spectrophotometric binding assay.
TMPKmt activities were determined using the coupled spectrophotometric assay described by
Blondin et al.16 at 334 nm in an Eppendorf ECOM 6122 photometer. The reaction medium
(0.5 mL final volume) contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl2,
0.2 mM NADH, 1 mM phosphoenol pyruvate and 2 units each of lactate dehydrogenase,
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pyruvate kinase and nucleoside diphosphate kinase. The concentrations of ATP and dTMP
were kept constant at 0.5 mM and 0.05 mM respectively, whereas the concentrations of the
analogues varied between 0.1 and 2.5 mM.
Synthesis
General
NMR spectra were obtained with a Varian Mercury 300 spectrometer. Chemical shifts are
given in ppm (d) relative to residual solvent peak, in the case of DMSO-d6 2.54 ppm for 1H
and 40.5 ppm for 13C, in the case of CDCl3 7.26 ppm for 1H and 77.4 ppm for 13C. All signals
assigned to hydroxyl groups were exchangeable with D2O. Mass spectra and exact mass
measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight
(Q/oaTOF) tandem mass spectrometer (qTof 2, Micromass, Manchester, UK) equipped with a
standard electrospray ionisation (ESI) interface. Samples were infused in a 2-propanol:water
(1:1) mixture at 3 µL/min. Precoated Merck silica gel F254 plates were used for TLC and spots
were examined under UV light at 254 nm and revealed by sulfuric acid-anisaldehyde spray.
Column chromatography was performed on Uetikon silica (0.2-0.06 mm).
Anhydrous solvents were purchased from Sigma-Aldrich.
2,3-Di-O-acetyl-4-deoxy-1-O-methyl-4-methylene-b -D-erythro-pentopyranose (5)
Compound 36 (1.02 g, 5.08 mmol) was treated with 90 % trifluoroacetic acid (9 mL) during 5
minutes. After evaporation, water was added, followed by Dowex 1x2 (OH- form) to neutrali-
se residual acid. The resin was removed by filtration and washed with water. The combined
water filtrates were evaporated and the residue was thoroughly dried under high vacuum. The
resulting 4-deoxy-1-O-methyl-4-methylene-b-D-erythro-pentopyranose (4) was dissolved in
pyridine. Ac2O was added and the mixture was stirred at room temperature for 2 h.
Evaporation and coevaporation with toluene yielded crude 5 (980 mg, 79 %). 1H-NMR
(300 MHz, CDCl3): d 2.10 (6H, s, OCOCH3), 3.43 (3H, s, OCH3), 4.09 (1H, d, J = -12.3 Hz,
H-5A), 4.34 (1H, ddd, J = -12.3, 1.5 and 0.6 Hz, H-5B), 4.72 (1H, d, J = 2.4 Hz, H-1), 5.02
and 5.10 (2H, 2m, methylene), 5.14 (1H, m, H-2), 5.78 (1H, m, H-3); 13C NMR (75 MHz,
CDCl3): d 20.09 (OCOCH3), 21.04 (OCOCH3), 55.57 (OCH3), 64.21 (C-5), 68.77 (C-3),
70.68 (C-2), 99.53 (C-1), 110.63 (C-6), 138.19 (C-4), 169.76 (CO), 170.39 (CO); HRMS
(ESI-MS) for C11H16O6 [M+Na]+: found, 267.0849; calcd, 267.0844.
1-[2,3-Di-O-acetyl-4-deoxy-4-methylene-b -D-erythro-pentopyranosyl]thymine  (6)
Thymine (991 mg, 7.86 mmol) was suspended in hexamethyldisilazane (87.8 mL, 416 mmol),
containing trimethylsilylchloride (0.71 mL, 5.6 mmol) and pyridine (7 mL). The mixture was
heated to 125° C and stirred overnight. The reaction mixture was evaporated and co-
evaporated with toluene. The resulting residue and 5 (980 mg, 4.01 mmol) were dissolved in
CH3CN (27 mL), SnCl2 (anhydrous, 1.98 g, 10.5 mmol) was added and the mixture was
refluxed under nitrogen during 39 h. After cooling, the mixture was poured in 10 % Na2CO3
(500 mL) and extracted with CH2Cl2 (3 times 300 mL). After drying and evaporation of the
organic layer, the obtained residue was purified by column chromatography (CH2Cl2-MeOH,
100:0 ® 98:2) yielding pure 6 (640 mg, 48%) and recuperated starting material 5 (355 mg,
37 %). 1H-NMR (300 MHz, DMSO-d6): d 1.73 (3 H, s, 5-CH3), 1.90 (3H, s, OCOCH3), 2.11
(3H, s, OCOCH3), 4.28 (1H, d, J = -12.6 Hz, H-5'A), 4.35 (1H, d, J = -12.1 Hz, H-5'B), 5.16
(1H, dd, J = 3.3 and 9.9 Hz, H-2'), 5.34 and 5.36 (2H, 2s, methylene), 5.78 (1H, d, J = 3.0 Hz,
H-3'), 5.93 (1H, d, J = 9.9 Hz, H-1'), 7.67 (1H, s, H-6); HRMS (ESI-MS) for C15H18N2O7
[M+Na]+: found, 361.1011; calcd, 361.1011.
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1-[4-Deoxy-4-methylene-b -D-erythro-pentopyranosyl]thymine (7)
A solution of 6 (30 mg, 0.089 mmol) in methanolic ammonia solution 7 N (5 mL) was stirred
2h at room temperature and was evaporated under reduced pressure. The resulting residue was
purified by column chromatography (CH2Cl2-MeOH, 90:10) yielding 7 (20 mg, 89%) as a
white foam. 1H-NMR (300 MHz, DMSO-d6): d 1.75 (3 H, d, J = 1.2 Hz, 5-CH3), 3.68 (1H,
m, H-2'), 4.02 and 4.28 (3H, d and m, H-3' and H-5'), 5.00 (1H, br s, methylene), 5.07 (1H, d,
J = 1.8 Hz, methylene), 5.74 (1H, d, J = 9.3 Hz, H-1'), 7.52 (1H, q, H-6); 13C NMR (75 MHz,
DMSO-d6): d 12.48 (5-CH3), 67.38, 69.90 and 73.01 (C-2', C-3' and C-5'), 80.28 (C-1'),
110.27 (C-5), 114.53 (C-6'), 137.51 (C-6), 143.98 (C-4'), 151.74 (C-2), 164.55 (C-4); HRMS
(ESI-MS) for C11H14N2O5Na [M+Na]+: found, 277.0812; calcd, 277.0800.
1-[4-Deoxy-2,3-O-isopropylidene-4-methylene-b -D-erythro-pentopyranosyl]thymine (8)
To a stirred suspension of 7 (129 mg, 0.51 mmol) in anhydrous acetone (3 mL) and 2,2-di-
methoxypropane (0.31 mL, 2.52 mmol) was added p-toluenesulphonic acid monohydrate
(97 mg, 0.51 mmol). After 4 h the resulting solution was poured slowly into stirred aqueous
0.5 M NaHCO3 (2 mL). The solution was concentrated in vacuo to ca 1.5 mL, diluted with
water (100 mL) and extracted with CH2Cl2 (3 times 75 mL). The combined organic layers
were dried, evaporated under reduced pressure and quickly chromatographed
(CH2Cl2-MeOH, 97:3) yielding 8 (124 mg, 83%) as a white foam. HRMS (ESI-MS) for
C14H18N2O5Na [M + Na]+: found, 317.1109; calcd, 317.1113.
1-[4-Deoxy-4-(hydroxymethyl)-2,3-O-isopropylidene-b -D-ribopyranosyl]thymine (9)17
To an ice cooled solution of 8 (102 mg, 0.40 mmol) in anhydrous THF (1 mL), under
nitrogen, was added dropwise 9-BBN (2.0 mL of a 0.5 M solution in THF, 1.0 mmol). The
mixture was slowly warmed to room temperature and stirred for 24h. The reaction mixture
was cooled to 0°C, treated sequentially with EtOH (1.6 mL), a 2 N solution of NaOH
(0.78 mL, 1.56 mmol) and 30% aqueous H2O2 solution (0.78 mL, 6.8 mmol). The resulting
mixture was stirred 24 h and then poured into a mixture of EtOAc (10mL) and water (10mL).
The layers were separated and the aqueous layer was extracted with EtOAc (3 times). The
combined organic layers were dried over MgSO4 and evaporated under reduced pressure. The
obtained residue was purified by column chromatography (CH2Cl2-MeOH, 95:5®98:2)
yielding pure 9 (77 mg, 62%). 1H-NMR (300 MHz, DMSO-d6): d 1.09 (3 H, s, C(CH3)2), 1.26
(3H, s, C(CH3)2), 1.76 (3H, s, 5-CH3), 2.23 (1H, m, H-4'), 3.20 (1H, dd, J = -11.2 and 5.4 Hz,
H-6'A), 3.37 (1H, dd, J = 8.31 and -10.8 Hz, H-5'A), 3.43 (1H, t, J = -11.72, H-6'B), 3.53
(1H, dd, J = -10.8 and 6.35 Hz, H-5'B), 4.33 (1H, m, H-2'), 4.42 (1H, m, H-3'), 4.71 (1H, t,
6'-OH), 5.41 (1H, d, J = 9.0 Hz, H-1'), 7.63 (1H, q, J = 0.9 Hz, 6-H); 13C NMR (75 MHz,
DMSO-d6): d 12.53 (5-CH3), 28.38 and 26.95 (C(CH3)2), under DMSO signal (C-4'), 59.52
(C-6'), 66.55 (C-5'), 72.70 and 74.06 (C-2' and C-3'), 82.02 (C-1'), 110.05 (C-5), 110.77
(C(CH3)2), 137.27 (C-6), 151.38 (C-2), 164.18 (C-4); HRMS (ESI-MS) for C14H20N2O6Na
[M+H]+: found, 335.1232; calcd, 335.1219.
1-[4-Deoxy-4-(hydroxymethyl)-b -D-ribopyranosyl]thymine  (10)
Compound 9 (70 mg, 0.21 mmol) was refluxed for 3 hours in a 1:1 mixture of HOAc-H2O
(5 mL). The mixture was evaporated under reduced pressure, co-evaporated with EtOH and
the resulting residue was purified by column chromatography (CH2Cl2-MeOH, 95:5),
yielding 10 (51 mg, 98%) as a white foam. 1H-NMR (300 MHz, DMSO-d6): d 1.76 (1H, d,
J = 0.9 Hz, 5-CH3), 1.91 (1H, m, H-4'), under H2O-signal (1H, H-6'A), 3.41 (1H, dd, J = 6.3
and -10.8 Hz, H-6'B), 3.52 (1H, t, J = -11.7 Hz, H-5'A), 3.63 (1H, dd, J = 3.6 and 9.3 Hz,
H-2'), 3.68 (1H, dd, J = 4.8 and -10.8 Hz, H-5'B), 3.95 (1H, br s, H-3'), 4.49 (1H, br s, 6'-OH),
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4.92 (1H, br s, 3'-OH, 5.11 (1H, br s, 2'-OH), 5.60 (1H, d, J = 9.6 Hz, H-1'), 7.57 (1H, q,
J = 1.2 Hz, 6-H); 13C NMR (75 MHz, DMSO-d6): d 12.66 (5-CH3), 43.86 (C-4'), 59.83 (C-6'),
64.92 (C-5'), 68.81 and 69.40 (C-2' and C-3'), 80.74 (C-1'), 109.85 (C-5), 137.71 (C-6),
151.83 (C-2), 164.46 (C-4); HRMS (ESI-MS) for C11H16N2O6Na [M + Na]+: found,
295.9010; calcd, 295.0906.
1-[4-Deoxy-4-(hydroxymethyl)-3,6-O-isopropylidene-b -D-ribopyranosyl]thymine (11)
To a stirred suspension of 10 (13 mg, 0.048 mmol) in anhydrous acetone (0.1 mL) and 2,2-di-
methoxypropane (0.03 mL, 0.24 mmol) was added p-toluenesulphonic acid monohydrate
(0.15 mg, 0.8 mmol). After 1 h the resulting solution was poured slowly into stirred aqueous
0.5 M NaHCO3 (2 mL). The solution was concentrated in vacuo, diluted with water (10 mL)
and extracted with CH2Cl2 (3 times 10 mL). The combined organic layers were dried,
evaporated under reduced pressure and purified by column chromatography (CH2Cl2-MeOH,
98:2 ® 97:3) yielding pure 11. 1H-NMR (300 MHz, DMSO-d6): d 1.33 (3 H, s, C(CH3)2),
1.41 (3H, s, C(CH3)2), 1.76 (4H, m, 5-CH3 and H-4'), 3.45-4.05 (5H, m, H-5', H-6' and H-2'),
4.38 (1H, m, n1/2 = 6.6 Hz, H-3'), 5.09 (1H, br s, 2-OH), 5.59 (1H, d, J = 9.9 Hz, H-1'), 7.58
(1H, s, 6-H); 13C NMR (75 MHz, DMSO-d6): d 12.63 (5-CH3), 19.28 and 30.30 (C(CH3)2),
34.02 (C-4'), 60.07 (C-6'), 64.84, 67.44 and 69.28 (C-2', C-3' and C-5'), 80.15 (C-1'), 99.15
(C(CH3)2), 110.13 (C-5), 137.40 (C-6), 151.70 (C-2), 164.43 (C-4); HRMS (ESI-MS) for
C14H20N2O6 [M+Na]+: found, 335.1207; calcd, 335.1219.
2,3-O-Isopropylidene-1-O-methyl-4-O-phenoxythiocarbonyl-a -L-lyxopyranose (14)
To an ice-cold solution of 13 (2.50 g, 12.2 mmol) and DMAP (3.00 g, 24.5 mmol) in CH3CN
(100 mL) was gradually added phenyl chlorothionocarbonate (2.3 mL, 16.4 mmol). The
mixture was stirred at 0 °C for 5 h. The solvent was removed in vacuo, and the residue was
dissolved in CH2Cl2 (500 mL). The solution was washed with water (2 x 500 mL), dried over
anhydrous MgSO4, filtered, and evaporated in vacuo. The obtained residue was purified by
column chromatography (CH2Cl2-MeOH, 95:5) to give 14 (3.6 g, 87 %) as a syrup. 1H NMR
(300 MHz, CDCl3): d 1.39 (3H, s, C(CH3)2), 1.58 (3H, s, C(CH3)2), 3.46 (3H, s, OCH3), 3.83
(1H, dd, J = 7.5 and -12.0 Hz, H-5A), 3.92 (1H, dd, J = 4.2 and -12.1 Hz, H-5B), 4.16 (1H,
dd, J = 5.4 and 3.2 Hz, H-2), 4.45 (1H, m, H-3), 4.71 (1H, d, J = 3.0 Hz, H-1), 5.49 (1H, m,
H-4), 7.10-7.44 (5H, m, arom H); 13C NMR (75 MHz, CDCl3): d 26.49 and 28.09 (C(CH3)2),
56.07 (OCH3), 58.67 (C-5), 74.48 (C-3), 75.39 (C-2), 78.89 (C-4), 100.31 (C-1), 110.21
(C(CH3)2), 122.07 (arom Co), 126.89 (arom Cp), 129.78 (arom Cm), 153.63 (arom Ci), 194.73
(O(CS)O); HRMS (ESI-MS) for C16H20O6SNa [M + Na]+: found, 363.0865; calcd, 363.0878.
2,3-O-Isopropylidene-1-O-methyl-4-C-(2-phenylethenyl)-a -L-lyxopyranose (E-isomer)
(15)
To a solution of 14 (1.47 g, 4.3 mmol) in benzene (34 mL) was added b-tributylstannylstyrene
(4.02 g, 10.22 mmol). The resulted solution was degassed three times with nitrogen at room
temperature and 45°C. After 2,2'-azobisisobutyronitrile (AIBN) (230 mg, 1.4 mmol) was
added, the solution was refluxed for 2h. Another part of AIBN (230 mg, 1.4 mmol) was added
after cooling the reaction mixture to 40° C. The reaction mixture was then refluxed again for
2h. This procedure was repeated until the starting material disappeared (6 times). The solvent
was evaporated, and the residue was purified by column chromatography (CH2Cl2-MeOH,
98:2) to give 15 (773 mg, 62 %) as an oil. 1H NMR (300 MHz, CDCl3): d 1.26 (3H, s, CCH3),
1.44 (3H, s, CCH3), 2.55 (1H, m, H-4), 3.46 (3H, s, OCH3), 3.50 (2H, app d, H-5), 3.92 (1H,
dd, J = 2.1 and 5.1 Hz, H-2), 4.11 (1H, dd, J = 5.1 and 7.2 Hz, H-3), 4.78 (1H, d, J = 2.1 Hz,
H-1), 6.15 (1H, dd, J = 16.2 and 7.8 Hz, H-b  styrene), 6.52 (1H, d, J = 16.1 Hz, H-a styrene),
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7.11-7.40 (5H, m, arom H); 13C NMR (75 MHz, CDCl3): d 26.58 (CCH3), 28.53 (CCH3),
42.83 (C-4), 55.72 (OCH3), 61.31 (C-5), 73.90 (C-3), 76.05 (C-2), 99.94 (C-1), 109.29
(CCH3), 126.47 (arom Co), 127.20 and 127.74 (arom Cp and Ca styryl), 128.72 (arom Cm),
132.78 (Cb  styryl), 137.10 (arom Ci); HRMS (ESI-MS) for C17H22O4Na [M + Na]+: found,
313.1412; calcd, 313.1415.
4-Deoxy-4-C-hydroxymethyl-2,3-O-isopropylidene-1-O-methyl-a -L-lyxopyranose (17)
To a solution of styrene 15 (330 mg, 1.1 mmol) and N-methylmorpholine-N-oxide (NMMO)
(200 mg, 1.7 mmol) in dioxane (20 mL), was added a catalytic amount of osmium tetraoxide
4% in H2O (0.3 mL, 0.04 mmol). The flask was covered by aluminium foil, and the reaction
mixture was stirred at room temperature overnight. A solution of NaIO4 (731 mg, 3.4 mmol)
in water (1 mL) was added to the stirred reaction mixture. It was stirred for 1 h at 0° C and 2h
at room temperature, followed by addition of EtOAc (20 mL). The mixture was filtered
through a celite pad and washed with EtOAc. The filtrate was washed three times with 10 %
aqueous Na2S2O3 solution until the color of the aqueous phase disappeared. The organic phase
was further washed with water, dried (MgSO4) and concentrated. The obtained aldehyde was
dissolved in EtOH-H2O (4:1 v/v, 16 mL). NaBH4 (190 mg, 5.0 mmol) was added in portions
at 0° C. The resulting reaction mixture was stirred at room temperature for 2 h and then
treated with ice water. The mixture was extracted with EtOAc. The organic phase was washed
with water and brine, dried (MgSO4) and concentrated. The obtained residue was purified by
column chromatography (CH2Cl2-MeOH, 9:1) to give 17 (127 mg, 53 % over three steps).
1H NMR (300 MHz, DMSO-d6): d 1.24 (3H, s, CCH3), 1.38 (3H, s, CCH3), 1.78 (1H, m,
H-4), 3.28 (3H, s, OCH3), 3.30-3.55 (4H, m, H-5 and H-6), 3.79 (1H, dd, J = 3.0 and 5.4 Hz,
H-2), 4.03 (1H, dd, J = 5.1 and 6.6 Hz, H-3), 4.60 (1H, d, J = 3.0 Hz, H-1), 4.66 (1H, t,
J = 5.7 Hz, 6-OH); 13C NMR (75 MHz, DMSO-d6): d 26.93 (CCH3), 22.77 (CCH3), under
DMSO signal (C-4), 55.51 (OCH3), 59.94 and 60.10 (C-5 and C-6), 72.49 (C-3), 73.81 (C-2),
100.50 (C-1), 108.57 (CCH3); HRMS (ESI-MS) for C10H18O5Na [M + Na]+: found, 241.1050;
calcd, 241.1052.
2,3,6-Tri-O-acetyl-4-deoxy-4-C-hydroxymethyl-1-O-methyl-a -L-lyxopyranose (18)
A solution of 17 (72 mg, 0.3 mmol) in trifluoroacetic acid-H2O (9:1 v/v, 1 mL) was stirred
for 5 minutes. The solution was neutralised with Dowex 1x2 (OH-). The resin was removed
by filtration and washed with MeOH-H2O (3:1). The filtrate was evaporated under
diminished pressure and purified by column chromatography (CH2Cl2-MeOH, 90:10),
yielding 4-deoxy-4-C-hydroxymethyl-1-O-methyl-a-L-lyxopyranose6 (45 mg, 77 %) as a
glassy solid. 1H NMR (300 MHz, DMSO-d6): d 1.91 (1H, m, H-4), 3.20 (3H, s, OCH3),
3.30-3.61 (6H, m, H-6, H-2, H-3 and H-5), 4.35 (2H, t, 6- and 3-OH), 4.45 (1H, d, J = 4.5 Hz,
H-1), 4.47 (1H, app d, J = 2.1 Hz, 2-OH); 13C NMR (75 MHz, DMSO-d6): d under DMSO
signal (C-4), 54.90 (OCH3), 60.06, 61.78, 66.65 and 69.35 (C-6, C-2, C-3 and C-5), 102.54
(C-1); HRMS (ESI-MS) for C7H14O5Na [M + Na]+: found, 201.0750; calcd, 201.0739. The
above mentionned glassy solid (40 mg, 0.2 mmol) was dissolved in pyridine (2.5 mL) and
acetic anhydride (2.5 mL) was added. The solution was stirred at room temperature for 3 h.
The solvent was removed under vacuum and the resulting residue was purified by column
chromatography (CH2Cl2-MeOH, 99:1) to yield 18 (60 mg, 89 %) as a foam. 1H NMR
(300 MHz, CD3OD): d 1.97, 2.02 and 2.10 (OCOCH3), 2.47 (1H, m, H-4), 3.38 (3H, s, OMe),
3.70 (1H, t, J = -11.4 Hz, H-5A), 3.77 (1H, dd, J = -11.4 and 5.4 Hz, H-5B), 4.01 (1H, dd,
J = -11.4 and 2.7 Hz, H-6A), 4.11 (1H, dd, J = 6.0 and -11.7 Hz, H-6B), 4.65 (1H, d,
J = 5.1 Hz, H-1), 5.09 (1H, dd, J = 5.1 and 3.0 Hz, H-2), 5.13 (1H, dd, J = 3.0 and 11.0 Hz,
H-3); 13C NMR (75 MHz, CD3OD): d 19.29, 19.40 and 19.51 (OCOCH3), 35.70 (C-4),
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54.028 (OCH3), 60.34 (C-5), 61.04 (C-6), 67.31 (C-3), 68.10 (C-2), 99.32 (C-1), 170.58,
170.88 and 170.25 (OCOCH3); HRMS (ESI-MS) for C13H20O8Na [M + Na]+: found,
327.1058; calcd, 327.1056.
1-[2,3,6-Tri-O-acetyl-4-deoxy-4-C-hydroxymethyl-a -L-lyxopyranosyl]thymine (19)6
Thymine (615 mg, 4.9 mmol) was suspended in hexamethyldisilazane (55 mL, 260 mmol),
containing trimethylsilylchloride (0.48 mL, 3.8 mmol) and pyridine (4 mL). The mixture was
heated to 125° C and stirred overnight. The reaction mixture was evaporated and co-evapora-
ted with toluene. The resulting residue and 18 (744 mg, 2.44 mmol) were dissolved in CH3CN
(17 mL), SnCl2 (anhydrous, 1.23 g, 6.5 mmol) was added and the mixture was refluxed under
nitrogen during 39 h. After cooling it was poured in 10 % Na2CO3 (500 mL) and extracted
with CH2Cl2 (3 times 300 mL). After drying and evaporation of the organic layer, the obtained
residue was purified by column chromatography (CH2Cl2-MeOH 99:1 ® 97:3) yielding pure
19 (367 mg, 38%) as a white foam and residual starting product 18 (315 mg, 42 %). 1H NMR
(300 MHz, DMSO-d6): d 1.75 (3H, s, 5-CH3), 1.88, 2.04 and 2.11 (OCOCH3), 2.18 (1H, m,
H-4'), 3.86 (1H, d, J = -12.3 Hz, H-5'A), 3.97 (1H, d, J = -12.3 Hz, H-5'B), 4.36 (2H, m,
H-6'A and H6'B), 5.30 (1H, dd, J = 2.7 Hz and 9.9 Hz, H-2'), 5.45 (1H, br s, H-3'), 5.80 (1H,
d, J = 9.9 Hz, H-1'), 7.82 (1H, s, 6-H), 11.40 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6):
d 12.50 (5-CH3), 21.02, 21.34 and 21.45 (OCOCH3), 55.60 (C-4'), 62.47 and 64.86 (C-5' and
C-6'), 66.23 and 68.40 (C-2' and C-3'), 79.22 (C-1'), 110.70 (C-5), 137.05 (C-6), 151.36 (C-2),
164.19 (C-4), 169.80, 170.27 and 170.91 (OCOCH3); HRMS (ESI-MS) for C17H22N2O9Na
[M + Na]+: found, 421.1253; calcd, 421.1223.
1-[4-Deoxy-4-C-hydroxymethyl-a -L-lyxopyranosyl]thymine (20)6
Compund 19 (410 mg, 1.03 mmol) was treated with a 7N methanolic ammonia solution
(30 mL) at room temperature for 7 h. Evaporation yielded a residue which was purified by
column chromatography (CH2Cl2-MeOH, 90:10) to afford 20 (218 mg, 78%) as a white
foam. 1H NMR (300 MHz, DMSO-d6): d 1.77 (4H, br s, 5-CH3 and H-4'), 3.50 (1H, m,
H-6'A), 3.59 (1H, m, H-6'B), 3.66 (2H, m, H-5'A and H-2'), 3.83 (1H, dd, J = 2.4 and
-11.1 Hz, H-5'B), 3.97 (1H, br s, H-3'), 4.65 (1H, t, J = 5.1 Hz, 6'-OH), 4.97 (2H, br s, 2'-OH
and 3'-OH), 5.59 (1H, d, J = 9.6 Hz, H-1'), 7.56 (1H, s, 6-H), 11.25 (1H, s, NH); 13C NMR
(75 MHz, DMSO-d6): d 12.56 (5-CH3), 45.95 (C-4'), 60.00 (C-6'), 63.92 (C-2') and 66.17
(C-5'), 68.83 (C-3'), 81.18 (C-1'), 109.93 (C-5), 137.74 (C-6), 151.71 (C-2), 164.40 (C-4);
HRMS (ESI-MS) for C11H16N2O6Na [M + Na]+: found, 295.0902; calcd, 295.0906; Anal.
(C11H16N2O6) C, H, N.
1-[4-Deoxy-4-C-hydroxymethyl-3,6-O-(1,1,3,3,-tetraisopropyldisiloxan-1,3-diyl)-a -L-
lyxopyranosyl]thymine (21)
Compound 20 (46 mg, 0.17 mmol) and imidazole (60 mg, 0.88 mmol) were dissolved in
DMF (1 mL) at 0°C. 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (58 mL, 0.19 mmol) was
added dropwise. The mixture was stirred 3h at room temperature and overnight at 30°C.
Water (10 ml) was added and the mixture was extracted with CH2Cl2 (10 mL). The organic
layer was dried over MgSO4 and evaporated under reduced pressure. The obtained residue
was purified by column chromatography (CH2Cl2-MeOH, 99:1) to afford 21 (78 mg, 89%) as
a white foam. 1H NMR (300 MHz, DMSO-d6): d 0.95 (28H, m, CH(CH3)2), 1.75 (3H, s,
5-CH3), 2.22 (1H, m, H-4'), 3.55 (1H, d, J = -11.1 Hz, H-6'A), 3.75 (1H, t, J = -11.4 Hz,
H-5'A), 3.87 (1H, dd, J = 5.7 and -11.4 Hz, H-5'B), 3.92 (1H, dd, J = 2.1 and -11.1 Hz,
H-6'B), 3.99 (1H, dd, J = 2.7 and 10.2 Hz, H-3'), 4.49 (1H, br, H-2'), 5.30 (1H, d, J = 5.1 Hz,
2'-OH), 5.36 (1H, d, J = 2.7 Hz, H-1'), 7.41 (1H, s, 6-H), 11.31 (1H, s, NH); 13C NMR (75
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MHz, DMSO-d6): d 12.63, 12.66, 12.77, 13.44, 13.47 (CH(CH3)2 and 5-CH3), 17.12, 17.79,
17.84, 17.87, 17.90 (CH(CH3)2), 38.83 (C-4'), 59.41 (C-6'), 65.23(C-5'), 66.48 (C-3'), 68.21
(C-2'), 88.47 (C-1'), 109.83 (C-5), 137.59 (C-6), 151.33 (C-2), 164.40 (C-4); HRMS
(ESI-MS) for C23H43N2O7Si2 [M + H]+: found, 515.2619; calcd, 515.2608.
1-[4-Deoxy-4-C-hydroxymethyl-3,6-O-(1,1,3,3,-tetraisopropyldisiloxan-1,3-diyl)-2-O-
phenoxythiocarbonyl-a -L-lyxopyranosyl]thymine (22)
Compound 21 (126 mg, 0.24 mmol) was dissolved in anhydrous CH3CN (4 mL). DMAP (58
mg, 0.48 mmol) was added at 0°C. The mixture was stirred 15 min at 0°C, then phenylchloro-
thionocarbonate (46 mL, 0.33 mmol) was added dropwise and the resulting solution was
stirred overnight at room temperature. After adding 7% NaHCO3 solution (7mL), the mixture
was evaporated to dryness, the obtained residue was dissolved in EtOAc, washed with water,
dried over MgSO4, evaporated under reduced pressure and purified by column chromato-
graphy (CH2Cl2-MeOH, 99.5:0.5) to afford 22 (140 mg, 89%) as a white foam. 1H NMR
(300 MHz, CDCl3): d 1.03 (28H, m, CH(CH3)2), 1.94 (3H, s, 5-CH3), 2.25 (1H, m, H-4'), 3.60
(1H, d, J = -11.7 Hz, H-6'A), 3.82-3.99 (2H, m, H-5'A and H-5'B), 4.10 (1H, dd, J = -11.7 and
2.4 Hz, H-6'B), 4.52 (1H, dd, J = 2.8 and 11.1 Hz, H-3'), 5.61 (1H, d, J = 2.6 Hz, H-1'), 6.58
(1H, t, J = 2.7 Hz, H-2'), 7.09-7.44 (5H, m, arom H), 8.06 (1H, s, 6-H); 13C NMR (75 MHz,
CDCl3): d 12.61 (5-CH3), 12.82, 13.04, 13.45, 13.73 (CH(CH3)2), 17.43, 17.51, 17.55, 17.66,
17.74 (CH(CH3)2), 39.73 (C-4'), 58.68 (C-6'), 64.97 and 65.02 (C-3' and C-5'), 80.78 (C-2'),
85.84 (C-1'), 112.03 (C-5), 122.00 (arom Co), 126.88 (arom Cp), 129.77 (arom Cm), 136.71
(C-6), 150.03 (arom Ci), 153.58 (C-2), 163.35 (C-4), 194.84 (OC(S)O); HRMS (ESI-MS) for
C30H46N2O8SSi2Na [M + Na]+: found, 673.2409; calcd, 673.2411.
1-[2,4-Dideoxy-4-C-hydroxymethyl-3,6-O-(1,1,3,3,-tetraisopropyldisiloxan-1,3-diyl)-a -L-
lyxopyranosyl]thymine (23)
Compound 22 (134 mg, 0.20 mmol) was co-evaporated three times with anhydrous toluene,
dissolved in toluene (32 mL) and degassed with nitrogen for 30 minutes. In a second flask,
AIBN (17 mg, 0.10 mmol) and Bu3SnH (166 mL, 0.62 mmol) in toluene (2 mL) were
degassed with nitrogen for 30 minutes. The first flask was heated to 80°C, the second solution
was added dropwise via a syringe. The mixture was heated to 90°C for 2h. After cooling to
room temperature, the mixture was evaporated, and the residue was purified by column
chromatography (CH2Cl2-MeOH, 99.5:0.5) to afford 23 (81 mg, 79%) as a white foam.
1H NMR (300 MHz, CDCl3): d 1.05 (28H, m, CH(CH3)2), 1.79 (1H, m, H-4'), 1.90 (3H, s,
5-CH3), 2.18 (1H, m, H-2'A), 2.54 (1H, dd, J = 3.3 and -14.1 Hz, H-2'B), 3.57 (1H, d,
J = -11.7 Hz, H-6'A), 3.72 (1H, t, J = -11.7 Hz, H-5'A), 3.86 (1H, dd, J = 4.8 and -11.7 Hz,
H-5'B), 4.14 (1H, dd, J = 2.7 and -12.0 Hz, H-6'B), 4.26 (1H, m, H-3'), 5.93 (1H, d,
J = 4.8 Hz, H-1'), 8.04 (1H, s, 6-H); 13C NMR (75 MHz, CDCl3): d 12.71 (5-CH3), 12.78,
13.46, 13.77 (CH(CH3)2), 17.37, 17.40, 17.50, 17.53, 17.57, 17.63 (CH(CH3)2, 36.36 (C-2'),
45.69 (C-4'), 58.94 (C-6'), 64.77 and 63.29 (C-3' and C-5'), 82.31 (C-1'), 110.51 (C-5), 136.64
(C-6), 150.52 (C-2), 163.47 (C-4); HRMS (ESI-MS) for C23H43N2O6Si2 [M + H]+: found,
499.2571; calcd, 499.2659.
1-[2,4-Dideoxy-4-C-hydroxymethyl-a -L-lyxopyranosyl]thymine (2)
Compound 23 (76 mg, 0.15 mmol) was dissolved in THF (8 mL) and Bu4NF (1M in THF,
0.76 mL, 0.76 mmol) was added. The mixture was stirred for 1h at room temperature,
evaporated to dryness and purified by column chromatography (CH2Cl2-MeOH, 93:7) to
afford 2 (38 mg, 97%) as a white foam. 1H NMR (300 MHz, DMSO-d6): d 1.51 (2H, m,
H-2'A and H-4'), 1.76 (3H, s, 5-CH3), 1.96 (1H, app t, J = -11.4 Hz, H-2'B), 3.50 (1H, m,
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J = 8.4 and -10.2 Hz, H-6'A), 3.60 (1H, m, J = 7.2 and -10.2 Hz, H-6'B), 3.77 (1H, d,
J = -11.4 Hz, H-5'A), 3.92 (1H, dd, J = 2.1 and -11.4 Hz, H-5'B), 4.02 (1H, m, H-3'), 4.58
(1H, t, J = 5.1 Hz, 6'-OH), 4.98 (1H, d, J = 2.7 Hz, 3'-OH), 5.82 (1H, d, J = 11.4 Hz, H-1'),
7.57 (1H, s, 6-H), 11.25 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): d 12.57 (5-CH3), 33.79
(C-2'), 43.43 (C-4'), 60.53 (C-6'), 64.66 (C-5'), 64.75 (C-3'), 78.07 (C-1'), 110.08 (C-5),
137.27 (C-6), 150.91 (C-2), 164.36 (C-4); HRMS (ESI-MS) for C11H16N2O5Na [M + Na]+:
found, 279.0952; calcd, 279.0957; Anal. (C11H16N2O5) C, H, N.
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GENERAL DISCUSSION, CONCLUSIONS AND PERSPECTIVES
The incidence of tuberculosis has drastically increased during the last 20 years. Especially the
appearance of multi-drug resistant strains of Mycobacterium tuberculosis is a major concern.
Therefore, more potent anti-tuberculosis drugs, preferably acting on novel targets, are eagerly
awaited.1 Thymidine monophosphate kinase (TMPK) catalyses the conversion of dTMP to
dTDP. Because M. tuberculosis thymidine monophosphate kinase (TMPKmt) plays a crucial
role in the thymidine triphosphate synthesis and in view of its low (22%) sequence identity
with the human isozyme, it emerged as an attractive target for new drug design.2 Recently the
structure of TMPKmt was elucidated,3 enabling the structure based design of TMPKmt
inhibitors.
Chapters 2, 3 and 5
In order to establish a first structure-activity relationship, modifications were carried out at the
2'-, 3'- and 5-positions of the dTMP scaffold. From these results, the following general
tendencies could be observed:
§ At the 2'-position the only well-tolerated modifications are a 2'-chlorine and a 2'-fluorine
substituent (2.12 and 2.13). Modeling suggested that the introduction of the chlorine
affects the position of the sugar ring in the active pocket. As a result the 2'-chlorine
occupies the pocket where normally the 3'-hydroxyl group resides. Apparently Tyr103,
believed to be responsible for the discrimination between ribo- and deoxy-nucleotides,
hampered the introduction of other substituents like a 2'-amine or a 2'-hydroxyl group
(2.9, 5.15, 5.16, 5.22).
§ Introduction of a fluorine at the 3'-position of the dTMP scaffold yielded a substrate with
a Km-value of 30 mM (2.20). Introduction of a 3'-amine (2.1), on the other hand yielded a
weak inhibitor, not able to establish a similar interaction with Asp9 as the one observed
for AZTMP. However, when a 2'-hydroxyl was combined with a 3'-amine (2.8), the
affinity increased (Ki = 45 mM). Modeling showed an interaction between the amine and
Asp9 and a larger distance between Tyr103 and the 2'-position than the one present in the
crystal structure. So far, this compound remains the only example of a ribo-nucleotide
showing higher affinity than its corresponding 2'-deoxy-analogue.
§ At the 5-position, introduction of a CH2OH (3.1) yielded a moderately active inhibitor as
compared to AZTMP. This nucleotide was co-crystallised with TMPKmt, showing
hydrogen bonding interactions between the 5-CH2OH, Ser99 and a water molecule, which
is held in place by Asp73 and Arg74. Compounds bearing larger substituents at the
5-position (a furanyl-, a benzyloxymethyl- or a thienyl group) were less active, indicating
that the cavity near the 5-position cannot be stretched too much. However, introduction of
smaller 5-substituents (a 5-ethyl, 5-fluorine and 5-trifluoromethyl) also proved
unsuccessful.
§ The affinities of a series of nucleosides and their corresponding nucleotides were
compared. The deletion of the phosphate moiety typically resulted in a modest, in many
cases negligible affinity loss. In view of the drug delivery problems of phosphorylated
compounds, nucleosides seem more useful leads for further drug design. Exploration of
other substitution patterns at the 5'-position (e. g. a 5'-H and a 5'-iodine) only yielded poor
affinity inhibitors.
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Chapter 4
Because TMPKmt represents the first TMPK that does not phosphorylate AZTMP
(Ki = 10 mM), modifications of the 3'-position were considered attractive to find good and
selective inhibitors. Most probably, an interaction between the 3'-azido group and Asp9
abolishes the catalysis. Since the X-ray structure3 showed a cavity near the 3'-position, a series
3'-C-substituted branched-chain nucleosides and nucleotides was synthesised. Although an
efficient synthetic route for the synthesis of 3’-C-branched-chain substituted nucleosides
4.9-4.14 has been reported,4 we developed a route that gives access to both 2’-deoxy- and
ribo-analogues and allows easier conversion to the corresponding monophosphates. In the
procedure of Lin et al.,5 all 3’-C-modifications are introduced on the sugar moiety before
coupling with thymine. In our approach, the 3’-C-modifications are effected after sugar-base
coupling, which allows synthesising all derivatives from a single key intermediate. A
judicious choice of 5’- and 6’-O-protective groups permitted conversion of the key compound
to the phosphorylated 3’-hydroxymethylanalogues, on one hand and to the 3’-azidomethyl-,
3’-aminomethyl- and 3’-fluoromethyl-derivatives, on the other hand.
The 3’-aminomethyl, 3’-azidomethyl- and 3’-fluoromethyl dTMP analogues 4.3, 4.4 and 4.5
indeed showed to be potent inhibitors of TMPKmt with Ki-values in the 10-15 mM respective-
ly. Modeling indicated that 4.4 adopts a 2’-exo-3’-endo conformation (dTMP, in contrast, is
in the 2’-endo-3’-exo conformation). Consequently, the amino group occupies the same space
as the 3’-hydroxyl group of dTMP; hence, it is in an appropriate position to interact with
Asp9. However, the 3'-fluoromethylnucleotide indicated that an ionic interaction with Asp9 is
not a prerequisite for good affinity. Interestingly, deletion of the phosphate moiety typically
resulted in a modest (at most 6-fold) affinity loss. The affinities of the ribo-analogues of these
compounds were disappointing, indicating that 2.8 was an exceptional example of  a ribo-
nucleotide exhibiting better affinity than its 2'-deoxy-analogue. The modest affinity of 4.15
indicated that the ideal length of the spacer between the 3'-position and the introduced
functionality is one carbon atom. The selectivity of all target compounds for TMPKmt versus
TMPKh was evaluated. All, except 4.6, are inhibitors of TMPKh. Most nucleotides (4.3-4.8)
showed affinities for the human enzyme in the same order of magnitude as for the M. tubercu-
losis enzyme. The corresponding nucleosides (4.9, 4.11 and 4.12), however, exhibit very low
affinities for the human enzyme, resulting in selectivity indices between 10 and 26. Therefore,
these nucleosides, combining a low Ki-value with a favorable selectivity index are put
forward as the most promising leads for further research.
Chapter 6
Encouraged by the promising affinities of the 3'-C-branched-chain nucleosides, attempts were
made to combine these favourable 3'-substitution patterns with 2'-halogen substituents
(6.5-6.9). However, introduction of the 2'-halogen led to a drastic decrease in affinity
compared to the corresponding 2'-deoxy-nucleosides. Probably, the 2'-halogens compete with
the 3'-substituents for the same binding pocket.
In an attempt to supersede the good affinities of the 3'-C-branched-chain nucleosides, we
wanted to further explore the enzyme cavity near the 3'-position with alternative nitrogen
containing substituents. However, attempted simultaneous reduction of the 6'-azido function
and the 2'-hydroxyl of compound 19 (chapter 6) failed, yielding three peculiar nucleoside
analogues (6.10, 6.11 and 6.12).
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Bicyclic nucleosides 6.10 and 6.11 showed excellent binding affinities. With a Ki-value of
3.5 mM, 6.10 exceeds the Km-value of the natural substrate (4.5 mM), making it the best
TMPKmt inhibitor found so far. Compound 6.10 was modelled into the crystal structure of
TMPKmt. The six-membered ring, fused to the C-2', C-3'-bond of the sugar, apparently forces
the 6'-nitrogen into the most appropriate position for interaction with the Asp9 residue in the
enzyme cavity. The sulphur atom undergoes hydrophobic interactions with the Tyr103 and
Tyr165 residues. When the sulphur atom in 6.10 is replaced by a smaller oxygen in 6.11, the
cavity near the 3'-position is filled less efficiently, which is reflected in the somewhat lower
affinity of 6.11 (Ki = 13.5 mM).
Due to the lack of a binding site for a second nucleoside at the 3’-position, the Ki-value of
6.12 (37 mM) was most unexpected. A modeling experiment in GOLD showed that the sugar
ring of the first monomer I binds the dTMP-pocket upside down, which enables hydrogen
bonding of its 5'-hydroxyl with Asp9. This binding mode permits the sugar ring of the second
monomer (II) to be directed towards the outside of the enzyme, where normally the
phosphoryl donor binds. With a-nucleoside 6.13 the postulated binding mode of monomer I
was confirmed. The observed exceptional flexibility of TMPKmt towards the orientation of
the sugar ring is of great interest for further inhibitor design.
The low affinities of 6.12 and 6.13 for the human enzyme indicate that the flexibility towards
the orientation of the sugar ring is unique for TMPKmt. Most interesting, however, is
compound 6.10, with a selectivity index (Ki TMPKh/ Ki TMPKmt) of 200, superseding 4.9
not only in affinity, but also in selectivity.
These three inhibitors are very interesting leads for further drug design, considerably
increasing the variety of nucleoside analogues that may be considered for future synthesis.
Especially 6.12 forms an interesting challenge for finding other bisubstrate inhibitors with an
improved fit in the enzyme cavity.
Chapter 7
1',5'-Anhydro-2',3'-dideoxy-5'-O-phosphoryl-2'-(thymin-1-yl)-D-arabino-hexitol (7.1) proved
to be a good inhibitor of TMPKmt (Ki-value of 30 mM), indicating that six-membered sugar
rings can be accomodated by the target enzyme. In 7.1, the base is preferentially in an axial
(1C4) conformation, in contrast to dTMP, were thymine prefers an equatorial-like position.
Because modeling showed that the thymine moiety in 1-[2,4-dideoxy-4-C-hydroxymethyl-a-
L-lyxopyranosyl]thymine (7.2) would prefer an equatorial position, 6 this nucleoside was
considered a promising inhibitor of TMPKmt.
The key to the synthesis of 7.2, involves the introduction of the hydroxymethyl moiety onto
the 4'-carbon of the pyranose sugar. This was first attempted through hydroboration/oxidation
of an exocyclic 4'-methylene bond. Preferential attack of the hydroboration reagent at the
b-side of the sugar ring due to steric hindrance caused by the 2'-3'-O-isopropylidene
protective group, however, led to the undesired a-directed 4'-hydroxymethyl nucleoside. The
preferential attack at the b-side of the sugar ring was then exploited through radical mediated
introduction of a carbon nucleophile. Treatment 2,3-O-isopropylidene-1-O-methyl-4-O-
phenoxythiocarbonyl-a-L-lyxopyranoside with b-tributylstannylstyrene allowed stereoselec-
tive introduction of a 2-phenylethenyl group at C-4, that via oxidation/reduction (OsO4,
NaIO4/NaBH4) was converted to the desired 4-hydroxymethyl group. In conclusion, a high
yield method was developed for the synthesis of 7.2 in 13 steps from 2,3-O-isopropylidene-1-
163
O-methyl-a-L-lyxopyranose. NMR analysis showed that the obtained nucleoside is indeed
characterised by the intended equatorial orientation of the thymine ring (4C1). However,
affinity results of this nucleoside for TMPKmt were disappointing.
In conclusion, this work yielded some high affinity and selective inhibitors for TMPKmt that
open interesting perspectives in the search for new anti-tuberculosis agents. Based on their
high selectivity indices, especially dinucleoside 6.12 and bicyclic nucleosides 6.10 and 6.11
will be used as the starting point for the search of inhibitors with an even better fitting in the
active pocket of TMPKmt.
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OVERVIEW OF THE EVALUATED COMPOUNDS
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4.9 R1= H, R2= N3
4.10 R1= H, R2= NH2
4.11 R1= H, R2= F
4.12 R1= H, R2= OH
4.13 R1= OH, R2= N 3
4.14 R1= OH, R2= NH2
4.15 R1= H, R2= CH2OH
4.3 R1= H, R2= N 3
4.4 R1= H, R2= NH2
4.5 R1= H, R2= F
4.6 R1= H, R2= OH
4.7 R1= OH, R2= N3
4.8 R1= OH, R2= NH2
2.1 R1= H, R2= NH2
2.8 R1= OH, R2= NH2
2.9 R1= NH2, R2= OH
2.12 R1= Cl, R2= OH
2.13 R1= F, R2= OH
2.20 R1= H, R2= F
5.15 R1= OH, R2= OH, R3=OH
5.16 R1= OHb , R2= OH, R3=OH
5.21 R1= H, R2= NH2, R3= OH
5.22 R1= OH, R2= F, R3=OH
5.23 R1= F, R2= OH, R3=OH
5.24 R1= OH, R2= N 3, R3=I
5.25 R1= OH, R2= NH2, R3= H
5.26 R1= OH, R2= NHC(NH)NH2, R3= OH
3.1 R= CH2OH
3.2 R= CH2OBn
3.3a R= CH2OH
3.4 R= furan-2-yl
3.5 R= thien-2-yl
5.17 R1= CF3, R2= H, R3=OH, R4= OH
5.18 R1= CH2CH3, R2= H, R3= OH, R4= OH
5.19 R1= F, R2= OH, R3= OH, R4= OH
5.20 R1= F, R2= OH, R3= OH, R4= H
6.5 R1= Cl, R2= N3, R3= OH
6.6 R1= Cl, R2= NH2, R3= OH
6.7 R1= F, R2= N3, R3= OH
6.8 R1= F, R2= NH2, R3= OH
6.9 R1= F, R2= N3, R3= F
6.13a R1= OH, R2= N3, R3= OH 
6.12
T= thymin-1-yl
6.10 R= S
6.11 R= O
7.1 7.20 R= OH
7.2   R= H
a the thymine ring lies at the a side
of the sugar ring
b the 2'-OH lies at the b side of the 
sugarring
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